[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 209
1. Saffin JM, Venoux M, Prigent C, Espeut J, Poulat F, Giorgi D, Abrieu A, Rouquier S: ASAP, a human microtubule-associated protein required for bipolar spindle assembly and cytokinesis. Proc Natl Acad Sci U S A; 2005 Aug 9;102(32):11302-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ASAP, a human microtubule-associated protein required for bipolar spindle assembly and cytokinesis.
  • We have identified a unique human microtubule-associated protein (MAP) named ASAP for ASter-Associated Protein.
  • ASAP localizes to microtubules in interphase, associates with the mitotic spindle during mitosis, localizes to the central body during cytokinesis and directly binds to purified microtubules by its COOH-terminal domain.
  • Overexpression of ASAP induces profound bundling of cytoplasmic microtubules in interphase cells and aberrant monopolar spindles in mitosis.
  • Depletion of ASAP by RNA interference results in severe mitotic defects: it provokes aberrant mitotic spindle, delays mitotic progression, and leads to defective cytokinesis or cell death.
  • These results suggest a crucial role for ASAP in the organization of the bipolar mitotic spindle, mitosis progression, and cytokinesis and define ASAP as a key factor for proper spindle assembly.
  • [MeSH-minor] Base Sequence. Blotting, Western. Cells, Cultured. Cloning, Molecular. Glutathione Transferase. Humans. Microscopy, Fluorescence. Molecular Sequence Data. Oligonucleotides. RNA Interference. Sequence Analysis, DNA

  • SciCrunch. HGNC: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 2001 Oct 19;294(5542):543-7 [11641489.001]
  • [Cites] Nat Cell Biol. 2001 Jan;3(1):E28-34 [11146647.001]
  • [Cites] J Cell Biol. 2002 Nov 25;159(4):549-55 [12438418.001]
  • [Cites] Mol Biol Cell. 2003 Jul;14(7):2876-89 [12857871.001]
  • [Cites] Nat Cell Biol. 2003 Sep;5(9):773-6 [12951607.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 Jun;5(6):429-40 [15173822.001]
  • [Cites] J Cell Biol. 2004 Jun 21;165(6):813-22 [15197175.001]
  • [Cites] J Cell Biol. 2004 Jul 19;166(2):179-91 [15249581.001]
  • [Cites] J Cell Biol. 1990 Nov;111(5 Pt 1):1905-11 [2229180.001]
  • [Cites] Mol Cell Biol. 1995 Dec;15(12):7143-51 [8524282.001]
  • [Cites] Scanning Microsc. 1995 Sep;9(3):843-57; discussion 858-60 [7501997.001]
  • [Cites] J Cell Biol. 1998 Mar 9;140(5):991-1002 [9490714.001]
  • [Cites] Cell Motil Cytoskeleton. 1998;39(3):223-32 [9519903.001]
  • [Cites] Trends Biochem Sci. 1998 Aug;23(8):307-11 [9757832.001]
  • [Cites] Chromosoma. 1998 Dec;107(6-7):461-70 [9914378.001]
  • [Cites] Dev Cell. 2004 Nov;7(5):637-51 [15525526.001]
  • [Cites] Nat Rev Cancer. 2005 Jan;5(1):42-50 [15630414.001]
  • [Cites] Science. 1999 Oct 29;286(5441):971-4 [10542155.001]
  • [Cites] EMBO J. 1999 Dec 1;18(23):6786-92 [10581251.001]
  • [Cites] Trends Cell Biol. 2000 Jun;10(6):228-37 [10802538.001]
  • [Cites] Annu Rev Biochem. 2000;69:95-114 [10966454.001]
  • [Cites] Nat Cell Biol. 2000 Nov;2(11):767-75 [11056530.001]
  • [Cites] EMBO J. 2000 Nov 1;19(21):5711-9 [11060022.001]
  • [Cites] J Cell Biol. 2000 Dec 25;151(7):1575-82 [11134084.001]
  • [Cites] J Cell Biol. 2002 Jun 24;157(7):1175-86 [12082078.001]
  • (PMID = 16049101.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ AY690636
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MAP9 protein, human; 0 / Microtubule-Associated Proteins; 0 / Oligonucleotides; EC 2.5.1.18 / Glutathione Transferase
  • [Other-IDs] NLM/ PMC1183541
  •  go-up   go-down


2. Lloyd JA, Harron AF, McEwen CN: Combination atmospheric pressure solids analysis probe and desorption electrospray ionization mass spectrometry ion source. Anal Chem; 2009 Nov 1;81(21):9158-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination atmospheric pressure solids analysis probe and desorption electrospray ionization mass spectrometry ion source.
  • The atmospheric solids probe analysis (ASAP) probe was investigated as a means for conducting desorption electrospray ionization (DESI) using a commercially available ion source.
  • Solid and liquid samples as well as a raw urine sample were placed on individual melting point tubes and were inserted into either a heated gas stream for ASAP analysis or a charged solvent spray for DESI-like experiments.
  • The configuration of the ion source also allowed rapid switching (approximately 1 min) between ASAP, electrospray ionization (ESI), and DESI.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19807111.001).
  • [ISSN] 1520-6882
  • [Journal-full-title] Analytical chemistry
  • [ISO-abbreviation] Anal. Chem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. Kable JW, Glimcher PW: An "as soon as possible" effect in human intertemporal decision making: behavioral evidence and neural mechanisms. J Neurophysiol; 2010 May;103(5):2513-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These data support an alternative behavioral-neural model (which we call "ASAP"), in which subjective value declines hyperbolically relative to the soonest currently available reward and a small number of valuation areas serve as a final common pathway through which these subjective values guide choice.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. OXYGEN .
  • SciCrunch. NeuroSynth: Data: Activation Foci .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Addiction. 2001 Jan;96(1):73-86 [11177521.001]
  • [Cites] Neuron. 2004 Oct 14;44(2):365-78 [15473973.001]
  • [Cites] J Neurophysiol. 2001 Oct;86(4):1916-36 [11600651.001]
  • [Cites] Neuron. 2002 Oct 10;36(2):285-98 [12383782.001]
  • [Cites] Science. 2004 Jun 18;304(5678):1782-7 [15205529.001]
  • [Cites] Nat Neurosci. 2004 Aug;7(8):887-93 [15235607.001]
  • [Cites] Psychol Bull. 2004 Sep;130(5):769-92 [15367080.001]
  • [Cites] Neuron. 2004 Oct 14;44(2):379-87 [15473974.001]
  • [Cites] Science. 2004 Oct 15;306(5695):503-7 [15486304.001]
  • [Cites] Nature. 1999 Jul 15;400(6741):233-8 [10421364.001]
  • [Cites] Neuroimage. 2005 May 1;25(4):1302-9 [15945130.001]
  • [Cites] Nat Neurosci. 2005 Sep;8(9):1220-7 [16116449.001]
  • [Cites] J Exp Psychol Learn Mem Cogn. 2005 Sep;31(5):1121-33 [16248754.001]
  • [Cites] Nat Neurosci. 2005 Dec;8(12):1704-11 [16286932.001]
  • [Cites] Science. 2005 Nov 25;310(5752):1337-40 [16311337.001]
  • [Cites] Nature. 2006 May 11;441(7090):223-6 [16633341.001]
  • [Cites] Nature. 2006 Jun 15;441(7095):876-9 [16778890.001]
  • [Cites] J Neurosci. 2006 Aug 9;26(32):8360-7 [16899731.001]
  • [Cites] Science. 2007 Jan 26;315(5811):515-8 [17255512.001]
  • [Cites] J Neurosci. 2007 May 23;27(21):5796-804 [17522323.001]
  • [Cites] J Neurosci. 2007 Sep 12;27(37):9984-8 [17855612.001]
  • [Cites] Nat Neurosci. 2007 Dec;10(12):1625-33 [17982449.001]
  • [Cites] Nat Neurosci. 2008 Jan;11(1):95-102 [18066060.001]
  • [Cites] Neuron. 2008 Apr 10;58(1):144-57 [18400170.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 May 6;105(18):6741-6 [18427116.001]
  • [Cites] Neuron. 2008 May 8;58(3):451-63 [18466754.001]
  • [Cites] J Neurosci. 2008 May 28;28(22):5623-30 [18509023.001]
  • [Cites] Nat Rev Neurosci. 2008 Jul;9(7):545-56 [18545266.001]
  • [Cites] Neuroimage. 2009 Mar 1;45(1):143-50 [19071223.001]
  • [Cites] Science. 2009 May 1;324(5927):646-8 [19407204.001]
  • [Cites] J Neurosci. 2009 Jul 29;29(30):9575-81 [19641120.001]
  • [Cites] Neuron. 2001 May;30(2):619-39 [11395019.001]
  • (PMID = 20181737.001).
  • [ISSN] 1522-1598
  • [Journal-full-title] Journal of neurophysiology
  • [ISO-abbreviation] J. Neurophysiol.
  • [Language] ENG
  • [Grant] United States / NIMH NIH HHS / MH / F32-MH-75544; United States / NINDS NIH HHS / NS / R01-NS-054775
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] S88TT14065 / Oxygen
  • [Other-IDs] NLM/ PMC2867580
  •  go-up   go-down


Advertisement
4. Bruns EA, Perraud V, Greaves J, Finlayson-Pitts BJ: Atmospheric solids analysis probe mass spectrometry: a new approach for airborne particle analysis. Anal Chem; 2010 Jul 15;82(14):5922-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atmospheric solids analysis probe mass spectrometry: a new approach for airborne particle analysis.
  • In this study, atmospheric solids analysis probe mass spectrometry (ASAP-MS) is applied for the first time to the identification of organics in particles from laboratory systems as well as from ambient air.
  • Particles were collected by impaction on ZnSe disks, analyzed by Fourier transform-infrared spectroscopy (FT-IR) and then transferred to an ASAP-MS probe for further analysis.
  • ASAP-MS data for the laboratory-generated samples show peaks from well-known products of these reactions, and higher molecular weight oligomers are present in both laboratory and ambient samples.
  • In addition, a dedicated instrument is not required for particle analysis.
  • This work establishes that ASAP-MS will be useful for identification of organic components of SOA in a variety of field and laboratory studies.
  • [MeSH-major] Aerosols / chemistry. Air Pollutants / analysis. Mass Spectrometry / methods. Particulate Matter / analysis

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. OZONE .
  • Hazardous Substances Data Bank. ISOPRENE .
  • Hazardous Substances Data Bank. ALPHA-PINENE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20568716.001).
  • [ISSN] 1520-6882
  • [Journal-full-title] Analytical chemistry
  • [ISO-abbreviation] Anal. Chem.
  • [Language] eng
  • [Publication-type] Letter; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aerosols; 0 / Air Pollutants; 0 / Butadienes; 0 / Hemiterpenes; 0 / Monoterpenes; 0 / Particulate Matter; 0 / Pentanes; 0A62964IBU / isoprene; 66H7ZZK23N / Ozone; JPF3YI7O34 / alpha-pinene
  •  go-up   go-down


5. Roobol MJ, Schröder FH, Crawford ED, Freedland SJ, Sartor AO, Fleshner N, Andriole GL: A framework for the identification of men at increased risk for prostate cancer. J Urol; 2009 Nov;182(5):2112-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A framework for the identification of men at increased risk for prostate cancer.
  • PURPOSE: We assessed the risk of prostate cancer over time, and the implications for screening strategies and potential risk reduction approaches to provide a framework for clinical use of this approach concordant with the use of prostate specific antigen as a marker of current prostate cancer risk.
  • In this article the phrase risk of/for prostate cancer refers to the risk of developing prostate cancer.
  • RESULTS: Prostate specific antigen is the single most significant predictive factor for identifying men at increased risk for prostate cancer.
  • A suspicious digital rectal examination, a family history of prostate cancer, the presence of high grade prostatic intraepithelial neoplasia or atypical small acinar proliferation and black ethnicity are also important predictive factors, while larger prostate volume and a previous negative biopsy are negative predictors.
  • For men of screening age (50 to 70 years) a prostate specific antigen of greater than 1.5 ng/ml is a marker for greater than average risk up to 8 years (7.5-times greater risk vs 1.5 ng/ml or less).
  • This prostate specific antigen threshold for a man at above average risk can be modified by the presence of other predictive factors.
  • It should be lower for men with a prostate volume less than 40 cc, black ethnicity or a family history of prostate cancer.
  • For younger men with longer followup a lower prostate specific antigen may be considered.
  • CONCLUSIONS: The risk of prostate cancer can be estimated in individual men primarily using prostate specific antigen, but also using prostate volume, previous biopsy status, family history and ethnicity.
  • [MeSH-major] Prostatic Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers / blood. Humans. Male. Predictive Value of Tests. Prostate-Specific Antigen / blood. Risk Assessment. Risk Factors

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Urol. 2009 Nov;182(5):2121; discussion 2122 [19758653.001]
  • [CommentIn] J Urol. 2009 Nov;182(5):2101-2 [19758645.001]
  • [CommentIn] J Urol. 2009 Nov;182(5):2120-1; discussion 2122 [19758612.001]
  • (PMID = 19758625.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; EC 3.4.21.77 / Prostate-Specific Antigen
  • [Number-of-references] 46
  •  go-up   go-down


6. Arista-Nasr J, Gómez-Bustamante D, Aguilar-Magaña FA, Saqui-Salces M, Martínez-Benítez B: [Histological findings in 100 needle prostatic biopsies and original diagnosis of benignity]. Rev Invest Clin; 2006 Mar-Apr;58(2):88-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Histological findings in 100 needle prostatic biopsies and original diagnosis of benignity].
  • INTRODUCTION: Detailed revision of prostate biopsies with benign alterations may show potentially malignant lesions limited to isolated fields, which may be overviewed in routine analysis.
  • AIM: To exam the morphological alterations in patients with suspicious of prostatic carcinoma and benign diagnosis in needle biopsies.
  • MATERIALS AND METHODS: During 2000-2001, one hundred consecutive patients with first prostate biopsy diagnosed as benign were included.
  • In this group, there were five biopsies with atypical small acinar proliferation, three with few isolated glands with xanthomatous cytoplasm, and one with scarce atypical cells in the prostatic stroma.
  • Some lesions that simulate carcinoma, as atypical basal cell hyperplasia, post-atrophic hyperplasia, and adenosis were diagnosed as benign, and there was none false positive result.
  • CONCLUSIONS: A small but significant group of the biopsies originally diagnosed as benign lesions, showed atypical lesions in isolated fields that were overlooked in the routine analysis.
  • It is necessary the urologist to ask for a directed review of the biopsies if clinical and laboratory data strongly suggest prostatic carcinoma.
  • [MeSH-major] Prostate / pathology. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16827260.001).
  • [ISSN] 0034-8376
  • [Journal-full-title] Revista de investigación clínica; organo del Hospital de Enfermedades de la Nutrición
  • [ISO-abbreviation] Rev. Invest. Clin.
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


7. Wolters T, van der Kwast TH, Vissers CJ, Bangma CH, Roobol M, Schröder FH, van Leenders GJ: False-negative prostate needle biopsies: frequency, histopathologic features, and follow-up. Am J Surg Pathol; 2010 Jan;34(1):35-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] False-negative prostate needle biopsies: frequency, histopathologic features, and follow-up.
  • Little is known about the frequency, histopathologic characteristics, and clinical consequences of false-negative prostate biopsies, that is, biopsies classified as benign but containing adenocarcinoma or atypical suspicious glands [atypical small acinar proliferations (ASAP)].
  • Objective of this study was to evaluate false-negative prostate biopsy in a prostate cancer screening setting.
  • Prostate biopsy sets of 196 participants of a screening trial, which had been reported as "benign" at initial diagnosis, followed by a diagnosis of adenocarcinoma in a subsequent screening round were reviewed by 2 urologic pathologists.
  • Adenocarcinoma was identified in 19 biopsy cores corresponding to 16 (8.2%) patients and ASAP in 24 cores, corresponding to 19 patients (9.7%).
  • All missed prostate cancers were Gleason score 6 (3+3).
  • After correction for patient selection, the overall false-negative biopsy rate was estimated to be 2.4%; 1.1% for prostate cancer; and 1.3% for ASAP.
  • Clinicopathologic features at the time of initial biopsy and of subsequent prostate cancer diagnosis did not differ between patients with a false-negative or true benign biopsy.
  • Relatively low number of atypical glands (<10 glands), intense intermingling with preexistent glands or lack of architectural disorganization were the most prominent risk factors for a false-negative diagnosis.
  • Another potential pitfall was the presence of prostate cancer variants, as 1 adenocarcinoma was of foamy gland type and 3 of pseudohyperplastic type.
  • Routine examination of at least 1 level of prostate biopsy sets at high magnification and awareness of histologic prostate cancer variants might reduce the risk of missing or misinterpreting a relevant lesion at prostate biopsy evaluation.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Biopsy, Needle. Diagnostic Errors. Prostatic Neoplasms / pathology. Prostatic Neoplasms / surgery
  • [MeSH-minor] Aged. False Negative Reactions. Humans. Male. Middle Aged. Prostate-Specific Antigen / blood

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19935058.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


8. Waterman KC, MacDonald BC: Package selection for moisture protection for solid, oral drug products. J Pharm Sci; 2010 Nov;99(11):4437-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This time-based RH is calculationally combined with a moisture-sensitive Arrhenius equation (determined using the accelerated stability assessment program, ASAP) to predict the drug product's chemical stability over time as a function of storage conditions and packaging options.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Wiley-Liss, Inc. and the American Pharmacists Association
  • (PMID = 20845442.001).
  • [ISSN] 1520-6017
  • [Journal-full-title] Journal of pharmaceutical sciences
  • [ISO-abbreviation] J Pharm Sci
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


9. Wesp W: Using STAT properly. Radiol Manage; 2006 Jan-Feb;28(1):26-30; quiz 31-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The diagnostic radiology department performed a 2-week analysis of orders in August 2004.
  • The manager, along with a staff radiologist, then created a list of clinical reasons that were appropriate for STAT, ASAP, or Routine orders.
  • These individuals then shared the list with their staff.
  • A second analysis conducted in November 2004 showed that an 11% decrease had been achieved.
  • With the success of this endeavor, the radiology department piloted a second program to further decrease the number of STAT orders.
  • The results showed that a STAT order could be completed and viewable on PACS in an average of 17 minutes, and an ASAP in 28 minutes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16570491.001).
  • [ISSN] 0198-7097
  • [Journal-full-title] Radiology management
  • [ISO-abbreviation] Radiol Manage
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Jiwa A, Kelly L, Pierre-Hansen N: Healing the community to heal the individual: literature review of aboriginal community-based alcohol and substance abuse programs. Can Fam Physician; 2008 Jul;54(7):1000-1000.e7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Healing the community to heal the individual: literature review of aboriginal community-based alcohol and substance abuse programs.
  • OBJECTIVE: To understand the development of culturally based and community-based alcohol and substance abuse treatment programs for aboriginal patients in an international context.
  • MeSH headings included the following: Indians, North American, Pacific ancestry group, aboriginal, substance-related disorders, alcoholism, addictive behaviour, community health service, and indigenous health.
  • The search produced 150 articles, 34 of which were relevant; most of the literature comprised opinion pieces and program descriptions (level III evidence).
  • MAIN MESSAGE: Substance abuse in some aboriginal communities is a complex problem requiring culturally appropriate, multidimensional approaches.
  • One promising perspective supports community-based programs or community mobile treatment.
  • These programs ideally cover prevention, harm reduction, treatment, and aftercare.
  • CONCLUSION: Community-based addictions programs are appropriate alternatives to treatment at distant residential addictions facilities.
  • The key components of success appear to be strong leadership in this area; strong community-member engagement; funding for programming and organizing; and the ability to develop infrastructure for longterm program sustainability.
  • Programs require increased documentation of their inroads in this developing field.
  • [MeSH-major] Alcoholism / ethnology. Alcoholism / rehabilitation. Substance-Related Disorders / ethnology. Substance-Related Disorders / rehabilitation

  • MedlinePlus Health Information. consumer health - Alcoholism and Alcohol Abuse.
  • MedlinePlus Health Information. consumer health - Drug Abuse.
  • MedlinePlus Health Information. consumer health - Opioid Abuse and Addiction.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Addiction. 2000 Jan;95(1):11-22 [10723822.001]
  • [Cites] Am J Med Qual. 2000 Jul-Aug;15(4):148-56 [10948787.001]
  • [Cites] Am Indian Alsk Native Ment Health Res. 2001;10(2):85-98 [11698985.001]
  • [Cites] J Psychoactive Drugs. 2003 Jan-Mar;35(1):15-25 [12733754.001]
  • [Cites] J Psychoactive Drugs. 2003 Jan-Mar;35(1):27-31 [12733755.001]
  • [Cites] J Psychoactive Drugs. 2003 Jan-Mar;35(1):71-7 [12733761.001]
  • [Cites] J Psychoactive Drugs. 2003 Jan-Mar;35(1):85-8 [12733763.001]
  • [Cites] J Psychoactive Drugs. 2003 Jan-Mar;35(1):89-96 [12733764.001]
  • [Cites] Alcohol Clin Exp Res. 2003 Aug;27(8):1356-60 [12966339.001]
  • [Cites] Am J Community Psychol. 2004 Jun;33(3-4):263-73 [15212184.001]
  • [Cites] Int J Addict. 1985 Nov-Dec;20(11-12):1707-26 [3833806.001]
  • [Cites] J Stud Alcohol. 1986 May;47(3):187-95 [3724152.001]
  • [Cites] Can J Public Health. 1988 Nov-Dec;79(6):424-9 [3233567.001]
  • [Cites] Community Health Stud. 1989;13(1):14-22 [2736901.001]
  • [Cites] R I Med J. 1991 Jun;74(6):281-6 [1887191.001]
  • [Cites] J Addict Dis. 1992;11(3):63-80 [1627667.001]
  • [Cites] Am Indian Alsk Native Ment Health Res. 1992;4(3):105-11; discussion 126-32 [1504169.001]
  • [Cites] Am Indian Alsk Native Ment Health Res. 1992;4(3):5-59; discussion 71-5, 95-100 [1504172.001]
  • [Cites] Int J Soc Psychiatry. 1992 Autumn;38(3):208-14 [1428664.001]
  • [Cites] Arctic Med Res. 1991;Suppl:271-5 [1365127.001]
  • [Cites] Aust J Public Health. 1995 Dec;19(6):567-72 [8616196.001]
  • [Cites] J Subst Abuse Treat. 1996 Jan-Feb;13(1):23-31 [8699539.001]
  • [Cites] J Subst Abuse Treat. 1996 May-Jun;13(3):265-71 [9017570.001]
  • [Cites] Subst Use Misuse. 1998 Nov;33(13):2605-46 [9818991.001]
  • [Cites] N Z Med J. 2006;119(1228):U1809 [16462919.001]
  • [CommentIn] Can Fam Physician. 2008 Jul;54(7):961, 963 [18625806.001]
  • (PMID = 18625824.001).
  • [ISSN] 1715-5258
  • [Journal-full-title] Canadian family physician Médecin de famille canadien
  • [ISO-abbreviation] Can Fam Physician
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Canada
  • [Number-of-references] 40
  • [Other-IDs] NLM/ PMC2464791
  •  go-up   go-down


11. Claassen G, Brin E, Crogan-Grundy C, Vaillancourt MT, Zhang HZ, Cai SX, Drewe J, Tseng B, Kasibhatla S: Selective activation of apoptosis by a novel set of 4-aryl-3-(3-aryl-1-oxo-2-propenyl)-2(1H)-quinolinones through a Myc-dependent pathway. Cancer Lett; 2009 Feb 18;274(2):243-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In order to identify pharmacological agents that cause selective apoptosis in tumors with deregulated Myc expression, we designed a cell-based screening assay based on our Anti-cancer Screening Apoptosis Program (ASAP) technology targeting increased activity in a "Myc-addicted" cancer cell panel.
  • [MeSH-minor] Caspases / metabolism. Cell Cycle. Cell Line, Tumor. Down-Regulation. Enzyme Activation. Humans. Magnetic Resonance Spectroscopy. Mass Spectrometry. Polymerase Chain Reaction. RNA Interference. RNA, Small Interfering. Ubiquitination

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19008038.001).
  • [ISSN] 1872-7980
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Quinolones; 0 / RNA, Small Interfering; EC 3.4.22.- / Caspases
  •  go-up   go-down


12. Karakiewicz PI, Perrotte P, McCormack M, Peloquin F, Perreault JP, Arjane P, Widmer H, Saad F: Early detection of prostate cancer with ultrasound-guided systematic needle biopsy. Can J Urol; 2005 Jun;12 Suppl 2:5-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early detection of prostate cancer with ultrasound-guided systematic needle biopsy.
  • INTRODUCTION: Prostate biopsy strategies have greatly evolved over the past 2 decades.
  • In the era of extended biopsy schemes, high-grade prostatic intraepithelial neoplasia no longer represents an independent predictor of prostate cancer on repeat biopsy.
  • Conversely, the risk is appreciably increased with atypical small acinar proliferation, and its presence warrants a repeat biopsy, which may be performed as soon as the pathologic findings of the previous biopsy become available.
  • CONCLUSION: Biopsy strategies and pathologic predictors of an increased risk of prostate cancer have appreciably changed over the past 2 decades.
  • [MeSH-major] Prostatic Neoplasms / pathology. Prostatic Neoplasms / ultrasonography

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16018825.001).
  • [ISSN] 1195-9479
  • [Journal-full-title] The Canadian journal of urology
  • [ISO-abbreviation] Can J Urol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Canada
  • [Number-of-references] 28
  •  go-up   go-down


13. Schlesinger C, Bostwick DG, Iczkowski KA: High-grade prostatic intraepithelial neoplasia and atypical small acinar proliferation: predictive value for cancer in current practice. Am J Surg Pathol; 2005 Sep;29(9):1201-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-grade prostatic intraepithelial neoplasia and atypical small acinar proliferation: predictive value for cancer in current practice.
  • In earlier studies, prostate cancer (PCa) has been reported to appear in 21% to 48% of subsequent biopsies for isolated high-grade prostatic intraepithelial neoplasia (PIN) and in 34% to 60% for isolated atypical small acinar proliferation suspicious for, but not diagnostic of, malignancy (ASAP).
  • The study group consisted of 336 men with initial diagnoses of PIN (n = 204), ASAP (n = 78), or both lesions (n = 54) who underwent at least one repeat biopsy.
  • Mean follow-up intervals in months were 6.0 for PIN, 3.8 for ASAP, and 4.9 for PIN/ASAP.
  • The predictive value of ASAP was significantly higher than that for PIN (P = 0.0188).
  • In 13 ASAP studies, mean PCa detection on follow-up was 45% until 1996 and 39% from 1997 to present.
  • PIN/ASAP predicted PCa in 33% of cases in our study, similar to ASAP alone (P = 0.65) and had a mean predictive value of 44% in the literature.
  • 1) extended biopsy techniques that yield higher rates of initial cancer detection, 2) lower detection rate for the remaining small cancers that may accompany PIN, and 3) remaining PIN cases may lack concomitant cancer.
  • [MeSH-major] Precancerous Conditions / diagnosis. Prostatic Intraepithelial Neoplasia / diagnosis. Prostatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Am J Surg Pathol. 2005 Nov;29(11):1548
  • (PMID = 16096410.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Flannery RB Jr: Crisis intervention services and empirical data: lessons learned from the Assaulted Staff Action Program (ASAP). Int J Emerg Ment Health; 2008;10(4):271-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Crisis intervention services and empirical data: lessons learned from the Assaulted Staff Action Program (ASAP).
  • This paper reviews the lessons learned from the Assaulted Staff Action Program (ASAP) data base to illustrate how empirical data can meet the national standard of evidence-based care and improve the quality of services provided.
  • The ASAP data have demonstrated the safety and efficacy of ASAP as well as providing insights for risk management strategies in the changing face of patient violence.
  • [MeSH-major] Crisis Intervention. Empirical Research. Program Development. Violence

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19278143.001).
  • [ISSN] 1522-4821
  • [Journal-full-title] International journal of emergency mental health
  • [ISO-abbreviation] Int J Emerg Ment Health
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Italian Panel on Prostate Biopsy: [Consensus-based guidelines on prostate biopsy]. Arch Ital Urol Androl; 2005 Sep;77(3 Suppl 1):1-2, preceding 1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Consensus-based guidelines on prostate biopsy].
  • OBJECTIVE: To develop evidence-based and consensus-based guidelines, helping physicians to take decisions about diagnostic procedures for men wishing to undergo examination for detection of prostate cancer.
  • MATERIAL AND METHODS: A panel of multidisciplinary Italian experts in urology, medical oncology, laboratory medicine, radiotherapy, pathology and methodologists for clinical trial (Mario Negri Institution) grouped together in 2002 to address specific questions relating to clinical controversies in prostate cancer diagnosis.
  • A practitioners feedback survey by means of a questionnaire of 49 items was also conducted in 2003 to assess the great variability in all the aspects relating a prostate biopsy (PB).
  • In the final document it has been reported as following: Prostatic biopsy (PB) is recommended in all patients with a PSA> = 4.0 ng/ml (2,5 ng/ml in patients with positive family history), abnormal DRE and %FPSA < 10%.
  • A PB should be repeated within 6-12 months in the following cases:1) First biopsy is inadequate (less than 6 cores, absence of prostatic cells on the cores), 2) in presence of HGPIN, ASAP or both on first PB, 3) in cases with persistently high levels of PSA (PSA > 10 ng/ml or PSA velocity > 0,75 ng/ml/year).

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16402723.001).
  • [ISSN] 1124-3562
  • [Journal-full-title] Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica
  • [ISO-abbreviation] Arch Ital Urol Androl
  • [Language] ITA
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


16. Brand TC, Thibault GP, Basler JW: Dealing with non-cancerous findings on prostate biopsy. Curr Urol Rep; 2006 May;7(3):186-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dealing with non-cancerous findings on prostate biopsy.
  • Most prostate biopsies do not show malignancy.
  • The proper management of non-cancerous pathologic findings of the prostate is controversial.
  • For this article, we reviewed the current literature for indications for repeat prostate biopsy after initial biopsies demonstrated non-cancerous prostatic tissue or benign prostatic hyperplasia.
  • This review includes discussions of management of asymptomatic prostatitis and how it may affect prostate-specific antigen, and also the management of several potentially premalignant lesions such as atrophy, atypical small acinar proliferation, and high-grade prostatic intraepithelial neoplasia.
  • [MeSH-major] Prostate / pathology. Prostatic Diseases / pathology
  • [MeSH-minor] Biopsy. Humans. Male. Prostatic Intraepithelial Neoplasia / pathology. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Prostate Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur Urol. 2005 Jan;47(1):38-44; discussion 44 [15582247.001]
  • [Cites] N Engl J Med. 1998 Oct 8;339(15):1036-42 [9761805.001]
  • [Cites] Eur Urol. 2000 Apr;37(4):404-12 [10765070.001]
  • [Cites] J Urol. 2004 Sep;172(3):906-8; discussion 908-9 [15310995.001]
  • [Cites] Scand J Urol Nephrol Suppl. 2000;(205):3-10 [11144902.001]
  • [Cites] BJU Int. 2003 Mar;91(4):350-4 [12603413.001]
  • [Cites] Urology. 2004 Mar;63(3):503-8 [15028446.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Am J Pathol. 2001 May;158(5):1767-73 [11337374.001]
  • [Cites] J Urol. 2000 Nov;164(5):1550-3 [11025702.001]
  • [Cites] Eur Urol. 2001 May;39(5):538-43 [11464034.001]
  • [Cites] Cleve Clin J Med. 2001 May;68(5):389-90, 392-3, 397 [11352318.001]
  • [Cites] Urology. 2005 Nov;66(5):1043-7 [16286121.001]
  • [Cites] J Urol. 2002 Apr;167(4):1723-6 [11912396.001]
  • [Cites] Urology. 2002 Jul;60(1):93-7 [12100931.001]
  • [Cites] J Urol. 1993 Mar;149(3):507-9 [7679753.001]
  • [Cites] Urology. 2004 Dec;64(6):1098-101 [15596176.001]
  • [Cites] J Urol. 1989 Jul;142(1):71-4; discussion 74-5 [2659827.001]
  • [Cites] J Reprod Fertil. 1970 Aug;22(3):573-4 [4989232.001]
  • [Cites] JAMA. 1984 Dec 21;252(23):3261-4 [6512929.001]
  • [Cites] J Urol. 2005 Jan;173(1):70-2 [15592031.001]
  • [Cites] Pathol Res Pract. 1995 Sep;191(9):838-41 [8606862.001]
  • [Cites] Arch Pathol Lab Med. 2003 Jul;127(7):840-4 [12823038.001]
  • [Cites] Urol Clin North Am. 2003 May;30(2):181-207 [12735497.001]
  • [Cites] BJU Int. 2004 Dec;94(9):1221-5 [15610093.001]
  • [Cites] BJU Int. 2004 Nov;94(7):963-4 [15541106.001]
  • [Cites] J Urol. 2003 Jan;169(1):12-9 [12478092.001]
  • [Cites] Urology. 2005 Apr;65(4):745-9 [15833520.001]
  • [Cites] Urology. 2000 Nov 1;56(5):828-32 [11068311.001]
  • [Cites] BJU Int. 2004 Dec;94(9):1239-44 [15610097.001]
  • [Cites] Curr Opin Urol. 2000 Jan;10(1):3-8 [10650506.001]
  • [Cites] Hum Pathol. 1999 Dec;30(12):1403-4 [10667415.001]
  • [Cites] Am J Pathol. 1999 Dec;155(6):1985-92 [10595928.001]
  • [Cites] Urology. 2004 Dec;64(6):1075-80 [15596172.001]
  • [Cites] J Urol. 1984 Oct;132(4):690-2 [6471214.001]
  • [Cites] Urology. 2005 Mar;65(3):538-42 [15780372.001]
  • [Cites] Urology. 2001 Dec;58(6):999-1003 [11744476.001]
  • [Cites] Urology. 2002 Nov;60(5):851-4 [12429314.001]
  • [Cites] J Urol. 2001 Aug;166(2):402-10 [11458037.001]
  • [Cites] Am J Surg Pathol. 2005 Sep;29(9):1201-7 [16096410.001]
  • [Cites] Urology. 1999 Apr;53(4):769-74 [10197854.001]
  • [Cites] J Natl Cancer Inst. 2005 Oct 5;97(19):1407-27 [16204691.001]
  • [Cites] J Urol. 1997 Apr;157(4):1301-3 [9120926.001]
  • [Cites] JAMA. 2005 Jul 6;294(1):66-70 [15998892.001]
  • [Cites] J Immunol. 1970 Jun;104(6):1329-39 [4986767.001]
  • [Cites] Public Health Rep. 2004 Mar-Apr;119(2):174-86 [15192905.001]
  • [Cites] World J Urol. 2003 Jun;21(2):105-8 [12687400.001]
  • (PMID = 16630522.001).
  • [ISSN] 1527-2737
  • [Journal-full-title] Current urology reports
  • [ISO-abbreviation] Curr Urol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 47
  •  go-up   go-down


17. Feldman EM, Koshy JC, Chike-Obi CJ, Hatef DA, Bullocks JM, Stal S: Contemporary techniques in inferior turbinate reduction: survey results of the American Society for Aesthetic Plastic Surgery. Aesthet Surg J; 2010 Sep;30(5):672-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A questionnaire was devised and sent to members of the American Society for Aesthetic Plastic Surgery (ASAPS) to determine their preferred methods for assessment and treatment of inferior turbinate hypertrophy.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20884896.001).
  • [ISSN] 1527-330X
  • [Journal-full-title] Aesthetic surgery journal
  • [ISO-abbreviation] Aesthet Surg J
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


18. Messieha Z, Ananda RC, Hoffman I, Hoffman W: Five year outcomes study of dental rehabilitation conducted under general anesthesia for special needs patients. Anesth Prog; 2007;54(4):170-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We assessed the safety of general anesthesia for dental treatment of special needs patients as it related to American Society of Anesthesiology Physical Status (ASAPS) classification, procedure, and other factors.
  • All records were evaluated by an independent evaluator who tabulated the patients' age, gender, ASAPS, and duration of procedure.
  • N = 363, age mean = 46.93 +/- 16.835 years, age median = 48 years, male patients = 180, female patients = 183, ASAPS I =183, ASAPS II = 127, ASAPS III = 53, duration of surgery mean = 140.631 +/- 23.104 minutes, duration of surgery median time = 142.000 minutes, and number of complications = 2.
  • One complication resulted in an ASAPS I 16-year-old boy, which was airway related, and a second was an ASAPS III 22-year-old woman, which was surgically related.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1999 Nov 27;354(9193):1864-6 [10584723.001]
  • [Cites] Spec Care Dentist. 2006 Jan-Feb;26(1):25-9 [16703931.001]
  • [Cites] Eur J Anaesthesiol. 2000 Apr;17(4):230-5 [10866005.001]
  • [Cites] Spec Care Dentist. 2000 May-Jun;20(3):81-92 [11203886.001]
  • [Cites] Anaesthesia. 2001 Aug;56(8):745-55 [11493237.001]
  • [Cites] Paediatr Anaesth. 2001 Nov;11(6):637-41 [11696137.001]
  • [Cites] Drugs Aging. 2002;19(6):429-51 [12149050.001]
  • [Cites] Dent Clin North Am. 1987 Jan;31(1):131-8 [3468008.001]
  • [Cites] Anesth Pain Control Dent. 1992 Winter;1(1):46-8 [1392682.001]
  • [Cites] Anaesthesia. 1997 May;52(5):477-82 [9165968.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1997 Jun;83(6):646-51 [9195616.001]
  • [Cites] Lancet. 1998 Mar 21;351(9106):857-61 [9525362.001]
  • [Cites] Dent Clin North Am. 1999 Apr;43(2):301-19, vi [10331145.001]
  • [Cites] Minerva Anestesiol. 1999 Jul-Aug;65(7-8):499-505 [10479836.001]
  • [Cites] Drugs. 1999 Sep;58(3):453-67 [10493273.001]
  • [Cites] Anaesthesia. 2000 Jan;55(1):32-41 [10594431.001]
  • (PMID = 18085838.001).
  • [ISSN] 0003-3006
  • [Journal-full-title] Anesthesia progress
  • [ISO-abbreviation] Anesth Prog
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2213248
  •  go-up   go-down


19. Ploussard G, Plennevaux G, Allory Y, Salomon L, Azoulay S, Vordos D, Hoznek A, Abbou CC, de la Taille A: High-grade prostatic intraepithelial neoplasia and atypical small acinar proliferation on initial 21-core extended biopsy scheme: incidence and implications for patient care and surveillance. World J Urol; 2009 Oct;27(5):587-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-grade prostatic intraepithelial neoplasia and atypical small acinar proliferation on initial 21-core extended biopsy scheme: incidence and implications for patient care and surveillance.
  • PURPOSE: To evaluate the incidence of high-grade prostatic intraepithelial neoplasia (HGPIN) and atypical small acinar proliferation (ASAP) in an initial 21-core extended biopsy scheme and to determine the prostate cancer detection rate in the repeated biopsy.
  • Incidences of cancer, ASAP and HGPIN were studied.
  • Cancer detection rate in the repeated 21-core extended biopsy for ASAP and HGPIN was reported and compared with those obtained on repeated biopsy for clinico-biological indications.
  • RESULTS: Incidences of HGPIN and ASAP were 1.7 and 1.1%, respectively.
  • Seven prostate cancers were found among the 17 re-biopsies for ASAP revealing a detection rate of 41.2% (p = 0.01).
  • CONCLUSION: Our report demonstrates the different risk profiles for HGPIN and ASAP in a 21-core extended biopsy scheme.
  • Repeated biopsy is warranted when ASAP is diagnosed because of a high risk of prostate cancer.
  • [MeSH-major] Prostatic Intraepithelial Neoplasia / pathology. Prostatic Neoplasms / pathology


20. Lucignani G: How early? ASAP: molecular and functional imaging! Eur J Nucl Med Mol Imaging; 2007 Apr;34(4):596-601
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] How early? ASAP: molecular and functional imaging!

  • MedlinePlus Health Information. consumer health - Nuclear Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nucl Med Commun. 2007 Jan;28(1):15-20 [17159544.001]
  • [Cites] N Engl J Med. 2006 Dec 21;355(25):2652-63 [17182990.001]
  • [Cites] Cancer Immunol Immunother. 2007 Aug;56(8):1163-71 [17171356.001]
  • [Cites] FASEB J. 2007 Feb;21(2):378-83 [17202248.001]
  • [Cites] Brain. 2006 Nov;129(Pt 11):2908-22 [17012294.001]
  • [Cites] N Engl J Med. 2006 Feb 2;354(5):496-507 [16452561.001]
  • [Cites] Clin Cancer Res. 2006 Oct 1;12 (19):5608-10 [17020961.001]
  • [Cites] Clin Cancer Res. 2006 Oct 1;12 (19):5659-67 [17020967.001]
  • [Cites] J Nucl Med. 2006 Nov;47(11):1778-86 [17079810.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Nov 1;66(3):845-51 [17011456.001]
  • [Cites] J Clin Oncol. 2006 Dec 1;24(34):5366-72 [17088570.001]
  • [Cites] Cancer. 2006 Dec 1;107(11):2678-87 [17063502.001]
  • [Cites] J Am Coll Cardiol. 2006 Dec 19;48(12 ):2448-57 [17174181.001]
  • (PMID = 17308918.001).
  • [ISSN] 1619-7070
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Radioisotopes; 0 / Radiopharmaceuticals
  • [Number-of-references] 14
  •  go-up   go-down


21. May DE, Kratochvil CJ, Puumala SE, Silva SG, Rezac AJ, Hallin MJ, Reinecke MA, Vitiello B, Weller EB, Pathak S, Simons AD, March JS: A manual-based intervention to address clinical crises and retain patients in the Treatment of Adolescents With Depression Study (TADS). J Am Acad Child Adolesc Psychiatry; 2007 May;46(5):573-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHOD: The use of adjunct services for attrition prevention (ASAP) is described for adolescents (ages 12-17 years) during the 12-week acute treatment in TADS, from 2000 to 2003.
  • RESULTS: Of 439 enrolled participants, 17.8% (n = 78) used ASAP primarily for suicidality or worsening of depression.
  • ASAP use did not differ between treatments (p =.97) and typically occurred early in treatment.
  • At the end of the 12 weeks, 37.2% of participants using ASAP remained in their assigned treatment, although 80.8% continued participating in assessments.
  • ASAP was associated with, at baseline, a higher severity of depression (p <.01), substance use (p <.01), and precontemplation level of change (p <.02).
  • CONCLUSIONS: ASAP may be useful to retain adolescent participants and as a safety intervention in placebo-controlled trials.
  • In clinical practice ASAP-like procedures may be useful to encourage adherence in patients engaging in long-term treatment.

  • Genetic Alliance. consumer health - Depression.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17450048.001).
  • [ISSN] 0890-8567
  • [Journal-full-title] Journal of the American Academy of Child and Adolescent Psychiatry
  • [ISO-abbreviation] J Am Acad Child Adolesc Psychiatry
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00006286
  • [Grant] United States / NIMH NIH HHS / MH / N01 MH80008
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


22. Brewer BR, Pradhan S, Carvell G, Delitto A: Application of modified regression techniques to a quantitative assessment for the motor signs of Parkinson's disease. IEEE Trans Neural Syst Rehabil Eng; 2009 Dec;17(6):568-75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have used commercially available sensors to create a protocol called Advanced Sensing for Assessment of Parkinson's disease (ASAP) to obtain a quantitative and reliable measure of motor impairment in early to moderate PD.
  • The ASAP protocol measures grip force as an individual tracks a sinusoidal or pseudorandom target force under three conditions of increasing cognitive load.
  • Thirty individuals with PD have completed the ASAP protocol.
  • The ASAP data for 26 of these individuals were summarized in terms of 36 variables, and modified regression techniques were used to predict an individual's score on the Unified Parkinson Disease Rating Scale based on ASAP data.
  • These results demonstrate that the ASAP protocol can measure differences for individuals who are clinically different.
  • This indicates that the ASAP protocol may be able to measure changes with time in the motor signs of an individual with PD.
  • [MeSH-minor] Data Interpretation, Statistical. Humans. Regression Analysis. Reproducibility of Results. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Movement Disorders.
  • MedlinePlus Health Information. consumer health - Parkinson's Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19884100.001).
  • [ISSN] 1558-0210
  • [Journal-full-title] IEEE transactions on neural systems and rehabilitation engineering : a publication of the IEEE Engineering in Medicine and Biology Society
  • [ISO-abbreviation] IEEE Trans Neural Syst Rehabil Eng
  • [Language] eng
  • [Grant] United States / NIA NIH HHS / AG / P30 AG024827
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS538314; NLM/ PMC4894031
  •  go-up   go-down


23. Robinson K, Creed J, Reguly B, Powell C, Wittock R, Klein D, Maggrah A, Klotz L, Parr RL, Dakubo GD: Accurate prediction of repeat prostate biopsy outcomes by a mitochondrial DNA deletion assay. Prostate Cancer Prostatic Dis; 2010 Jun;13(2):126-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accurate prediction of repeat prostate biopsy outcomes by a mitochondrial DNA deletion assay.
  • We previously provided evidence that one of these deletions has potential utility in resolving false from true-negative prostate needle biopsies.
  • Using an empirically established cycle threshold (Ct) cutoff of 31, and the lowest Ct for each patient as diagnostic of prostate cancer, as well as the histopathologic diagnosis on second biopsy, we calculated the clinical performance of the deletion.
  • The results suggest that the majority of men with atypical small acinar proliferation have a concurrent missed tumor and therefore require close monitoring for early detection.
  • [MeSH-major] Biopsy, Needle. DNA, Mitochondrial / genetics. Prostatic Neoplasms / diagnosis. Sequence Deletion
  • [MeSH-minor] False Negative Reactions. Humans. Male. Middle Aged. Polymerase Chain Reaction. Prostate / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20084081.001).
  • [ISSN] 1476-5608
  • [Journal-full-title] Prostate cancer and prostatic diseases
  • [ISO-abbreviation] Prostate Cancer Prostatic Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Mitochondrial
  •  go-up   go-down


24. van der Post L, Schoevers R, Koppelmans V, Visch I, Bernardt C, Mulder N, Beekman A, de Haan L, Dekker J: The Amsterdam Studies of Acute Psychiatry I (ASAP-I); a prospective cohort study of determinants and outcome of coercive versus voluntary treatment interventions in a metropolitan area. BMC Psychiatry; 2008;8:35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Amsterdam Studies of Acute Psychiatry I (ASAP-I); a prospective cohort study of determinants and outcome of coercive versus voluntary treatment interventions in a metropolitan area.
  • The number of studies that have examined this development and possible consequences in terms of optimizing health care delivery in emergency psychiatry is small and have a number of methodological shortcomings.
  • METHODS/DESIGN: This paper describes the design of the Amsterdam Study of Acute Psychiatry-I (ASAP-I).
  • The final aim is to find specific patient and health care factors that can be influenced by adjusting treatment programs in order to reduce the number of involuntary admissions.

  • MedlinePlus Health Information. consumer health - Psychotic Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Psychiatry Suppl. 2000;(39):s41-8 [10945077.001]
  • [Cites] Psychiatr Q. 2005 Summer;76(2):139-65 [15884742.001]
  • [Cites] Cochrane Database Syst Rev. 2002;(2):CD000011 [12076376.001]
  • [Cites] Soc Psychiatry Psychiatr Epidemiol. 2002 Jul;37(7):341-5 [12111027.001]
  • [Cites] J Clin Psychiatry. 2002 Oct;63(10):892-909 [12416599.001]
  • [Cites] Br J Psychiatry. 2003 Feb;182:105-16 [12562737.001]
  • [Cites] Br J Psychiatry. 2003 Feb;182:123-8 [12562739.001]
  • [Cites] Psychiatr Serv. 2003 Mar;54(3):351-5 [12610243.001]
  • [Cites] Soc Psychiatry Psychiatr Epidemiol. 2003 Sep;38(9):535-8 [14504739.001]
  • [Cites] J Clin Psychiatry. 2003;64 Suppl 16:24-33 [14680416.001]
  • [Cites] Br J Psychiatry. 2004 Feb;184:163-8 [14754830.001]
  • [Cites] Lancet. 2004 Jun 19;363(9426):2012-3 [15207948.001]
  • [Cites] Aust N Z J Psychiatry. 1976 Mar;10(1):27-32 [1065311.001]
  • [Cites] J Consult Clin Psychol. 1978 Jun;46(3):478-88 [670491.001]
  • [Cites] Psychol Med. 1983 Feb;13(1):177-83 [6133297.001]
  • [Cites] Psychol Med. 1985 Feb;15(1):189-94 [3991833.001]
  • [Cites] Arch Gen Psychiatry. 2005 Sep;62(9):975-83 [16143729.001]
  • [Cites] Am J Psychiatry. 2005 Oct;162(10):1785-804 [16199825.001]
  • [Cites] Ned Tijdschr Geneeskd. 2006 Feb 11;150(6):319-22 [16503024.001]
  • [Cites] Br J Psychiatry. 2006 Apr;188:386-91 [16582067.001]
  • [Cites] Psychiatr Prax. 2006 May;33(4):157-9 [16680625.001]
  • [Cites] Med Care. 1986 Jan;24(1):67-74 [3945130.001]
  • [Cites] Acta Psychiatr Scand. 1990 Jul;82(1):77-81 [2399824.001]
  • [Cites] J Pers Soc Psychol. 1990 Dec;59(6):1216-29 [2283588.001]
  • [Cites] Clin Neuropharmacol. 1991;14 Suppl 2:S33-44 [1684309.001]
  • [Cites] J Pers. 1992 Jun;60(2):175-215 [1635039.001]
  • [Cites] Acta Psychiatr Scand. 1992 Jul;86(1):32-7 [1414396.001]
  • [Cites] J Clin Psychiatry. 1993 Mar;54 Suppl:24-30 [8097195.001]
  • [Cites] Acta Psychiatr Scand. 1994 Jan;89(1):62-7 [7908156.001]
  • [Cites] Arch Gen Psychiatry. 1995 Mar;52(3):173-88 [7872841.001]
  • [Cites] Psychiatr Serv. 1996 May;47(5):487-96 [8740489.001]
  • [Cites] Lancet. 1996 Aug 10;348(9024):383-6 [8709739.001]
  • [Cites] Int Psychogeriatr. 1995 Fall;7(3):407-16 [8821348.001]
  • [Cites] Am J Psychiatry. 2005 Jan;162(1):12-24 [15625195.001]
  • [Cites] J Clin Pharm Ther. 2001 Oct;26(5):331-42 [11679023.001]
  • (PMID = 18479518.001).
  • [ISSN] 1471-244X
  • [Journal-full-title] BMC psychiatry
  • [ISO-abbreviation] BMC Psychiatry
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2413231
  •  go-up   go-down


25. Enerly E, Sheng Z, Li KB: Natural antisense as potential regulator of alternative initiation, splicing and termination. In Silico Biol; 2005;5(4):367-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our analyses are based on the ASAP splicing annotation database from UCLA, the antisense transcripts data from Yelin et al., 2003, and the H-invitational full-length cDNA database from JBIRC, Japan.
  • [MeSH-minor] Databases, Genetic. Humans. Molecular Sequence Data. Sequence Analysis, RNA

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16268781.001).
  • [ISSN] 1386-6338
  • [Journal-full-title] In silico biology
  • [ISO-abbreviation] In Silico Biol. (Gedrukt)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / RNA, Antisense
  •  go-up   go-down


26. Martens MB, Keller JH: Routine immunohistochemical staining for high-molecular weight cytokeratin 34-beta and alpha-methylacyl CoA racemase (P504S) in postirradiation prostate biopsies. Mod Pathol; 2006 Feb;19(2):287-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Routine immunohistochemical staining for high-molecular weight cytokeratin 34-beta and alpha-methylacyl CoA racemase (P504S) in postirradiation prostate biopsies.
  • A total of 43 cases of postirradiation prostate cores were assessed in an attempt to determine if routine use of alpha-methylacyl-CoA racemase (AMACR) in conjunction with high-molecular weight cytokeratin (HMWCK) would increase the recognition of carcinoma in postirradiation prostate biopsies.
  • We concluded that in most cases the addition of AMACR in conjunction with HMWCK does not increase the recognition of prostatic adenocarcinoma, however it is supportive in nature.
  • In one case the use of AMACR highlighted the extent of the adenocarcinoma which otherwise would have been designated as atypical small acinar proliferation (ASAP).
  • Further evaluation is required to assess the significance of a diagnosis of atypical small acinar proliferation in postirradiation prostate biopsies.
  • [MeSH-major] Keratins / analysis. Prostate / chemistry. Prostatic Neoplasms / metabolism. Racemases and Epimerases / analysis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16341144.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 68238-35-7 / Keratins; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


27. Kuroda N, Katto K, Tamura M, Shiotsu T, Nakamura S, Ohtsuki Y, Hes O, Michal M, Inoue K, Ohara M, Mizuno K, Lee GH: Immunohistochemical application of D2-40 as basal cell marker in evaluating atypical small acinar proliferation of initial routine prostatic needle biopsy materials. Med Mol Morphol; 2010 Sep;43(3):165-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical application of D2-40 as basal cell marker in evaluating atypical small acinar proliferation of initial routine prostatic needle biopsy materials.
  • D2-40 has been recently discovered as a lymphatic endothelial cell marker, and some investigators have found that D2-40 is also expressed in myoepithelial cells of salivary gland or breast.
  • In this study, we evaluated D2-40 expression of basal cells and applied D2-40 immunohistochemistry in the combination of P504S, cytokeratin 5, and p63 for ten lesions with atypical small acinar proliferation (ASAP) in initial prostatic needle biopsy.
  • As a result, D2-40 was expressed in basal cells, lymphatic endothelial cells, and some stromal fibroblasts of normal prostatic tissue.
  • Among ten ASAP lesions, the final diagnosis of seven lesions was resolved by combination immunohistochemistry.
  • However, we found some D2-40-positive stromal fibroblasts or D2-40-positive lumen-collapsed lymphatic vessels neighboring atypical glands.
  • In conclusion, the combination of immunohistochemistry of P504S, cytokeratin 5, p63, and D2-40 may contribute to the accurate diagnosis of ASAP in the initial prostatic needle biopsy.
  • [MeSH-major] Antibodies, Monoclonal / analysis. Biomarkers, Tumor / analysis. Carcinoma, Acinar Cell / diagnosis. Prostatic Neoplasms / diagnosis
  • [MeSH-minor] Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived. Biopsy, Needle. Early Diagnosis. Humans. Immunohistochemistry. Keratin-5 / isolation & purification. Male. Membrane Proteins / isolation & purification. Middle Aged. Prostate / pathology. Racemases and Epimerases / isolation & purification. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2004 Jul;28(7):946-52 [15223967.001]
  • [Cites] J Urol. 2004 Sep;172(3):906-8; discussion 908-9 [15310995.001]
  • [Cites] BJU Int. 2001 Jan;87(1):70-4 [11201402.001]
  • [Cites] Ann Diagn Pathol. 2006 Aug;10(4):205-8 [16844561.001]
  • [Cites] Am J Surg Pathol. 1999 Aug;23(8):925-31 [10435562.001]
  • [Cites] Med Mol Morphol. 2008 Jun;41(2):109-12 [18592165.001]
  • [Cites] Oral Oncol. 2006 Nov;42(10):1011-6 [16757205.001]
  • [Cites] Arch Pathol Lab Med. 2004 May;128(5):557-60 [15086303.001]
  • [Cites] Am J Surg Pathol. 2005 Nov;29(11):1435-41 [16224209.001]
  • [Cites] Am J Surg Pathol. 1997 Dec;21(12):1489-95 [9414193.001]
  • [Cites] Mod Pathol. 2006 Feb;19(2):287-90 [16341144.001]
  • [Cites] Histopathology. 2007 Nov;51(5):719-21 [17927601.001]
  • [Cites] BJU Int. 2007 Jan;99(1):49-52 [17227491.001]
  • [Cites] Am J Surg Pathol. 2002 Sep;26(9):1169-74 [12218573.001]
  • [Cites] Am J Surg Pathol. 2002 Sep;26(9):1161-8 [12218572.001]
  • [Cites] J Urol. 2005 Jan;173(1):70-2 [15592031.001]
  • [Cites] Mod Pathol. 2002 Apr;15(4):434-40 [11950918.001]
  • [Cites] Arch Pathol Lab Med. 2006 Jul;130(7):952-7 [16831049.001]
  • [Cites] Arch Pathol Lab Med. 2002 May;126(5):554-61 [11958660.001]
  • [Cites] Arch Pathol Lab Med. 2006 Jun;130(6):835-43 [16740037.001]
  • [Cites] Am J Surg Pathol. 1998 Nov;22(11):1430-1 [9808137.001]
  • [Cites] Hum Pathol. 2008 Feb;39(2):175-83 [18206495.001]
  • [Cites] Mod Pathol. 2004 Oct;17(10):1180-90 [15205683.001]
  • [Cites] J Urol. 2001 Sep;166(3):866-70 [11490235.001]
  • [Cites] Am J Surg Pathol. 2005 Sep;29(9):1201-7 [16096410.001]
  • [Cites] Am J Clin Pathol. 2000 Dec;114(6):896-909 [11338479.001]
  • [Cites] Histopathology. 2005 Jul;47(1):1-16 [15982318.001]
  • [Cites] Mod Pathol. 2006 Feb;19(2):180-5 [16341152.001]
  • [Cites] Am J Clin Pathol. 2004 Oct;122(4):517-23 [15487448.001]
  • (PMID = 20857265.001).
  • [ISSN] 1860-1499
  • [Journal-full-title] Medical molecular morphology
  • [ISO-abbreviation] Med Mol Morphol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Biomarkers, Tumor; 0 / CKAP4 protein, human; 0 / Keratin-5; 0 / Membrane Proteins; 0 / monoclonal antibody D2-40; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


28. Scattoni V, Roscigno M, Freschi M, Briganti A, Fantini GV, Bertini R, Salonia A, Montorsi F, Rigatti P: Predictors of prostate cancer after initial diagnosis of atypical small acinar proliferation at 10 to 12 core biopsies. Urology; 2005 Nov;66(5):1043-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictors of prostate cancer after initial diagnosis of atypical small acinar proliferation at 10 to 12 core biopsies.
  • OBJECTIVES: To evaluate the factors that predict prostate cancer detection by means of 10 to 12 core repeat biopsies in patients with atypical small acinar proliferation (ASAP) results on initial biopsy.
  • METHODS: From 1998 to 2004, 110 of 127 patients (87%) with a diagnosis of ASAP were rebiopsied with the same technique plus additional biopsies on the ASAP site (12.6 +/- 1.1 cores [mean +/- standard deviation]).
  • RESULTS: On initial biopsy, a concomitant high-grade prostatic intraepithelial neoplasia (HGPIN) was present in 26 patients (23%) with ASAP.
  • The overall cancer detection rate was significantly higher in patients who had ASAP associated with HGPIN (58%), compared with patients who had isolated ASAP (35%; P = 0.04).
  • In the group of patients who had isolated ASAP, the rate of cancer detection was significantly higher in patients who had a prostatic volume less than 50 mL (56%) than in patients with a prostatic volume of 50 mL or more (27%; P = 0.03).
  • CONCLUSIONS: The cancer detection rate was significantly higher in patients with an ASAP associated with HGPIN on initial biopsy than in patients with isolated ASAP.
  • In ASAP patients, the detection rate was lower for patients with a larger prostate than in those with a smaller prostate.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Acinar Cell / pathology. Prostatic Intraepithelial Neoplasia / pathology. Prostatic Neoplasms / pathology

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16286121.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Shearer AE, DeLuca AP, Hildebrand MS, Taylor KR, Gurrola J 2nd, Scherer S, Scheetz TE, Smith RJ: Comprehensive genetic testing for hereditary hearing loss using massively parallel sequencing. Proc Natl Acad Sci U S A; 2010 Dec 07;107(49):21104-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sequencing reads were mapped using GSMAPPER, BFAST, and BOWTIE, and pathogenic variants were identified using a custom-variant calling and annotation pipeline (ASAP) that incorporates publicly available in silico pathogenicity prediction tools (SIFT, BLOSUM, Polyphen2, and Align-GVGD).
  • [MeSH-major] Genetic Testing / methods. Hearing Loss / genetics. Sequence Analysis, DNA / methods
  • [MeSH-minor] DNA Mutational Analysis. Genotype. Humans. Polymorphism, Single Nucleotide. Software

  • Genetic Alliance. consumer health - Hereditary hearing loss.
  • MedlinePlus Health Information. consumer health - Genetic Testing.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Hum Genet. 1997 Apr;60(4):758-64 [9106521.001]
  • [Cites] PLoS One. 2010;5(7):e11804 [20668687.001]
  • [Cites] Lancet. 2005 Mar 5-11;365(9462):879-90 [15752533.001]
  • [Cites] Orphanet J Rare Dis. 2006;1:40 [17032466.001]
  • [Cites] J Med Genet. 2007 Apr;44(4):233-40 [17098888.001]
  • [Cites] Hum Mutat. 1999;14(6):493-501 [10571947.001]
  • [Cites] J Med Genet. 2000 Jan;37(1):41-3 [10633133.001]
  • [Cites] Nucleic Acids Res. 1989 Oct 25;17(20):8390 [2813076.001]
  • [Cites] Ann N Y Acad Sci. 1991;630:16-31 [1952587.001]
  • [Cites] Hum Mutat. 2007 Jul;28(7):683-93 [17370310.001]
  • [Cites] Mol Ther. 2008 Feb;16(2):224-36 [18223547.001]
  • [Cites] Eur J Hum Genet. 2008 May;16(5):593-602 [18212818.001]
  • [Cites] Hum Mutat. 2008 Jun;29(6):E37-46 [18429043.001]
  • [Cites] Genet Med. 2008 Nov;10(11):797-804 [18941426.001]
  • [Cites] Am J Med Genet A. 2009 Feb;149A(2):280-5 [19161137.001]
  • [Cites] Nat Biotechnol. 2009 Feb;27(2):182-9 [19182786.001]
  • [Cites] Mutat Res. 2009 Mar-Jun;681(2-3):189-96 [18804553.001]
  • [Cites] Genome Biol. 2009;10(3):R32 [19327155.001]
  • [Cites] Nature. 2009 Sep 10;461(7261):272-6 [19684571.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Nov 10;106(45):19096-101 [19861545.001]
  • [Cites] Genome Biol. 2009;10(10):R116 [19835619.001]
  • [Cites] Nat Rev Genet. 2010 Jan;11(1):31-46 [19997069.001]
  • [Cites] Nat Genet. 2010 Jan;42(1):30-5 [19915526.001]
  • [Cites] BMC Genomics. 2009;10:646 [20043857.001]
  • [Cites] Nat Methods. 2010 Feb;7(2):111-8 [20111037.001]
  • [Cites] BMC Biotechnol. 2010;10:10 [20146813.001]
  • [Cites] Hum Mutat. 2010 Apr;31(4):484-91 [20127978.001]
  • [Cites] N Engl J Med. 2010 Apr 1;362(13):1181-91 [20220177.001]
  • [Cites] JAMA. 1999 Jun 16;281(23):2211-6 [10376574.001]
  • (PMID = 21078986.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Grant] United States / NIDCD NIH HHS / DC / R01 DC002842; United States / NIDCD NIH HHS / DC / R01 DC003544; United States / NIGMS NIH HHS / GM / T32 GM082729; United States / NIDCD NIH HHS / DC / R01 DC02842
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3000272
  •  go-up   go-down


30. Dickinson SI: Premalignant and malignant prostate lesions: pathologic review. Cancer Control; 2010 Oct;17(4):214-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Premalignant and malignant prostate lesions: pathologic review.
  • BACKGROUND: High-grade prostatic intraepithelial neoplasia (HGPIN) is currently the only recognized premalignant lesion of prostatic carcinoma.
  • METHODS: This review article discusses HGPIN, its link to prostatic adenocarcinoma, and the significance of its presence on needle biopsy.
  • The criteria and clinical impact of the diagnosis of atypical small acinar proliferation on needle biopsy are reviewed.
  • Certain subtypes of prostate cancer that are not associated with HGPIN are of clinical relevance, and the unique clinicopathologic features of these subtypes are discussed.
  • Histologic variants of prostatic adenocarcinoma with distinct cell types are also described.
  • CONCLUSIONS: HGPIN has a strong association with acinar-type prostatic adenocarcinoma.
  • HGPIN and acinar-type prostatic adenocarcinoma both show similar molecular alterations, providing further evidence of their association.
  • [MeSH-major] Adenocarcinoma / pathology. Prostatic Intraepithelial Neoplasia / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Biopsy, Needle. Carcinoma, Acinar Cell / pathology. Humans. Male. Neoplasm Staging. Prognosis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20861809.001).
  • [ISSN] 1526-2359
  • [Journal-full-title] Cancer control : journal of the Moffitt Cancer Center
  • [ISO-abbreviation] Cancer Control
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


31. Elward AM, McAndrews JM, Young VL: Methicillin-sensitive and methicillin-resistant Staphylococcus aureus: preventing surgical site infections following plastic surgery. Aesthet Surg J; 2009 May-Jun;29(3):232-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • ASAPS members can complete this CME examination online by logging on to the ASAPS Members-Only Website (http://www.surgery.org/members) and clicking on "Clinical Education" in the menu bar.


32. Barton FE Jr: Aesthetic surgery of the face and neck. Aesthet Surg J; 2009 Nov-Dec;29(6):449-63; quiz 464-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • ASAPS members can complete this CME examination online by logging on to the ASAPS members-only website (http://www.surgery.org/members) and clicking on "Clinical Education" in the menu bar.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Aesthet Surg J. 2010 May;30(3):493
  • (PMID = 19944989.001).
  • [ISSN] 1527-330X
  • [Journal-full-title] Aesthetic surgery journal
  • [ISO-abbreviation] Aesthet Surg J
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


33. Merrick GS, Gutman S, Andreini H, Taubenslag W, Lindert DL, Curtis R, Adamovich E, Anderson R, Allen Z, Butler W, Wallner K: Prostate cancer distribution in patients diagnosed by transperineal template-guided saturation biopsy. Eur Urol; 2007 Sep;52(3):715-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostate cancer distribution in patients diagnosed by transperineal template-guided saturation biopsy.
  • OBJECTIVES: To determine the prostate cancer incidence, anatomic distribution, Gleason score profile, and tumor burden in patients diagnosed by transperineal template-guided saturation biopsy (TTSB).
  • Criteria for inclusion included an elevated PSA and/or the diagnosis of ASAP or high-grade PIN on prior biopsy.
  • The prostate gland was divided into 24 regional biopsy locations.
  • Multiple clinical parameters were evaluated as predictors for prostate cancer diagnosis.
  • RESULTS: The mean patient age was 64.8 yr with a mean PSA of 9.1 ng/ml and a prostate volume of 78.6 cm(3).
  • Prostate cancer was diagnosed in 43 patients (42.2%) with a Gleason score distribution of 6-9.
  • No anatomic region of the prostate gland was spared of cancer.
  • In patients with prostate cancer, an average of 9.9 cores were involved.
  • In multivariate analysis, prostate volume was the best predictor for prostate cancer diagnosis.
  • CONCLUSIONS: TTBS diagnosed prostate cancer in 42.2% of patients.
  • Considerable anatomic variability in prostate cancer distribution was documented.
  • On the basis of this and other reports, cancer eradication will depend on treatment of the entire prostate gland.
  • [MeSH-major] Biopsy / methods. Carcinoma, Acinar Cell / epidemiology. Prostatic Neoplasms / epidemiology
  • [MeSH-minor] Aged. Biomarkers, Tumor / blood. Diagnosis, Differential. Humans. Incidence. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging / methods. Perineum. Predictive Value of Tests. Prostate-Specific Antigen / blood. Retrospective Studies. United States / epidemiology


34. Newell KJ, Amrhein JF, Desai RJ, Middlebrook PF, Webster TM, Sawka BW, Rudrick BF: Prostate gland biopsies and prostatectomies: an Ontario community hospital experience. Can Urol Assoc J; 2008 Oct;2(5):518-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostate gland biopsies and prostatectomies: an Ontario community hospital experience.
  • OBJECTIVE: Transrectal ultrasound-guided core biopsies of the prostate gland and prostatectomies have become common procedures at many community hospitals in Canada, especially in the era of serum prostate-specific antigen (PSA) screening for prostate cancer.
  • The Gleason grading of prostate cancer in biopsies and prostatectomies is a major determinant used for treatment planning.
  • There is evidence in the literature that suggests important discordance between community hospital pathologists and urological pathologists with respect to the Gleason grading of prostate cancer.
  • Our objective was to determine the diagnostic rates and Gleason scoring patterns for prostate gland biopsies and prostatectomies at our institution compared with the literature.
  • METHODS: We conducted a retrospective review of all prostate gland biopsies and prostatectomies performed at the Grey Bruce Health Services from January 2005 to September 2005.
  • The rates of diagnosis from prostate gland biopsies of benign (17.6%), high-grade prostatic intraepithelial neoplasia (11.0%), atypical small acinar proliferation suspicious for invasive malignancy (13.2%) and invasive prostatic adenocarcinoma (58.2%) at our institution were significantly different than those reported in the literature (p < 0.001).
  • CONCLUSION: Our results showed a significant difference in prostate gland biopsy categorical diagnoses compared with the literature.
  • There were also significant differences in categorical diagnoses of prostate gland biopsies among the community hospital pathologists in our study.
  • We would encourage other community hospital pathologists, in collaboration with their urologists, to review periodically their prostate gland pathology practices in an attempt to improve the uniformity of diagnoses.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 2007 Mar;177(3):903-6 [17296372.001]
  • [Cites] Cancer. 2000 Oct 15;89(8):1818-23 [11042578.001]
  • [Cites] Arch Pathol Lab Med. 2006 Jul;130(7):952-7 [16831049.001]
  • [Cites] Arch Pathol Lab Med. 2006 Jun;130(6):835-43 [16740037.001]
  • [Cites] Histopathology. 2006 May;48(6):655-62 [16681680.001]
  • [Cites] Histopathology. 2006 May;48(6):644-54 [16681679.001]
  • [Cites] J Urol. 2006 Mar;175(3 Pt 1):820-34 [16469560.001]
  • [Cites] Mod Pathol. 2006 Feb;19(2):180-5 [16341152.001]
  • [Cites] Am J Surg Pathol. 2005 Sep;29(9):1228-42 [16096414.001]
  • [Cites] Arch Pathol Lab Med. 2005 Aug;129(8):1004-10 [16048389.001]
  • [Cites] Mod Pathol. 2005 Feb;18(2):228-34 [15475927.001]
  • [Cites] Arch Pathol Lab Med. 1999 Aug;123(8):687-92 [10420224.001]
  • [Cites] Urology. 1998 Feb;51(2):186-95 [9495696.001]
  • [Cites] Am J Surg Pathol. 1997 May;21(5):566-76 [9158682.001]
  • [Cites] Am J Surg Pathol. 1996 Jul;20(7):851-7 [8669533.001]
  • [Cites] Arch Pathol Lab Med. 2003 Aug;127(8):1007-8 [12873176.001]
  • [Cites] Hum Pathol. 2001 Jan;32(1):81-8 [11172299.001]
  • [Cites] Hum Pathol. 2001 Jan;32(1):74-80 [11172298.001]
  • [Cites] J Urol. 2006 Sep;176(3):979-84; discussion 984 [16890675.001]
  • (PMID = 18953449.001).
  • [ISSN] 1911-6470
  • [Journal-full-title] Canadian Urological Association journal = Journal de l'Association des urologues du Canada
  • [ISO-abbreviation] Can Urol Assoc J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2572237
  •  go-up   go-down


35. Lattouf JB, Grubb RL 3rd, Lee SJ, Bjurlin MA, Albert P, Singh AK, Ocak I, Choyke P, Coleman JA: Magnetic resonance imaging-directed transrectal ultrasonography-guided biopsies in patients at risk of prostate cancer. BJU Int; 2007 May;99(5):1041-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance imaging-directed transrectal ultrasonography-guided biopsies in patients at risk of prostate cancer.
  • OBJECTIVE: To evaluate whether using endorectal-coil magnetic resonance imaging (erMRI) before transrectal ultrasonography (TRUS)-guided biopsies of the prostate increases the yield of cancer in a high-risk population, and in a subset analysis to compare the yield with high-field (3 T) vs lower field (1.5 T) MRI.
  • PATIENTS AND METHODS: Between March 2003 and November 2005, 26 consecutive patients had erMRI before their TRUS biopsy of the prostate (median age 62 years, range 32-76).
  • The median prostate-specific antigen (PSA) level was 8.40 (2.1-85.9) ng/mL.
  • All patients had at least one previous negative prostate biopsy (median 3, range 1-12).
  • Twenty-three patients had at least one risk factor for prostate cancer (family history, high PSA velocity, low percentage of free PSA, prostatic intraepithelial neoplasia or atypical small acinar proliferation on previous biopsy).
  • [MeSH-major] Magnetic Resonance Imaging / standards. Prostatic Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Biopsy, Needle / methods. Digital Rectal Examination / methods. Humans. Male. Middle Aged. Predictive Value of Tests. Prostate-Specific Antigen / metabolism. Risk Factors. Sensitivity and Specificity. Ultrasonography, Interventional


36. Ding J, Erdal S, Borlawsky T, Liu J, Golden-Kreutz D, Kamal J, Payne PR: The design of a pre-encounter clinical trial screening tool: ASAP. AMIA Annu Symp Proc; 2008 Nov 06;:931
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The design of a pre-encounter clinical trial screening tool: ASAP.
  • In order to increase the efficiency of such processes, we have developed a web-based system, called Advanced Screening for Active Protocols (ASAP).

  • MedlinePlus Health Information. consumer health - Clinical Trials.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18998826.001).
  • [ISSN] 1942-597X
  • [Journal-full-title] AMIA ... Annual Symposium proceedings. AMIA Symposium
  • [ISO-abbreviation] AMIA Annu Symp Proc
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / UL1 RR025755
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Hu K, Berenjian S, Larsson R, Gullbo J, Nygren P, Lövgren T, Morein B: Nanoparticulate Quillaja saponin induces apoptosis in human leukemia cell lines with a high therapeutic index. Int J Nanomedicine; 2010;5:51-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two fractions of QS were selected for particle formation, one with an acyl-chain (ASAP) was used to form killing and growth-inhibiting (KGI) particles, and the other without the acyl-chain (DSAP) was used to formulate blocking and balancing effect (BBE) particles.
  • The monoblastoid lymphoma cell line U937 was selected for analyzing the mode of action.

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Nutr. 1995 Mar;125(3 Suppl):717S-724S [7884557.001]
  • [Cites] Biochemistry. 1988 Nov 29;27(24):8861-9 [2853972.001]
  • [Cites] Vaccine. 2005 Mar 18;23(17-18):2331-5 [15755622.001]
  • [Cites] Trends Immunol. 2005 Jul;26(7):381-7 [15978523.001]
  • [Cites] Cancer Biol Ther. 2005 Aug;4(8):874-82 [16082187.001]
  • [Cites] Carcinogenesis. 2007 Jun;28(6):1347-55 [17148504.001]
  • [Cites] J Immunol. 1991 Jan 15;146(2):431-7 [1987271.001]
  • [Cites] Adv Drug Deliv Rev. 2001 Sep 23;51(1-3):149-59 [11516786.001]
  • [Cites] Toxicol Appl Pharmacol. 2002 Jun 15;181(3):192-202 [12079428.001]
  • [Cites] J Intern Med. 2003 Jan;253(1):46-75 [12588538.001]
  • [Cites] Curr Med Chem Anticancer Agents. 2004 May;4(3):263-72 [15134504.001]
  • [Cites] Mol Cancer Ther. 2004 May;3(5):521-6 [15141009.001]
  • [Cites] Cancer Res. 1970 Jun;30(6):1874-82 [4318708.001]
  • [Cites] Biochim Biophys Acta. 1976 Mar 26;424(3):469-80 [1259971.001]
  • [Cites] Cancer Res. 1991 Feb 1;51(3):995-1002 [1988143.001]
  • [Cites] Biochim Biophys Acta. 1991 Feb 25;1062(2):165-71 [2004105.001]
  • [Cites] Mol Immunol. 1991 Mar;28(3):285-6 [2017197.001]
  • [Cites] Int J Cancer. 1992 Jan 21;50(2):177-85 [1730510.001]
  • [Cites] Int J Cancer. 1994 Jul 15;58(2):269-74 [7913083.001]
  • [Cites] Nature. 1984 Mar 29-Apr 4;308(5958):457-60 [6709052.001]
  • [Cites] Cancer Res. 1986 Oct;46(10):5125-30 [2875788.001]
  • [Cites] Vaccine. 1995 Oct;13(14):1375-82 [8585296.001]
  • (PMID = 20161987.001).
  • [ISSN] 1178-2013
  • [Journal-full-title] International journal of nanomedicine
  • [ISO-abbreviation] Int J Nanomedicine
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Plant Extracts
  • [Other-IDs] NLM/ PMC2819906
  • [Keywords] NOTNLM ; Quillaja saponin / anticancer drug / apoptosis / nanoparticle
  •  go-up   go-down


38. Schiaffino E: The natural history: how has prostate cancer trend modified? Arch Ital Urol Androl; 2005 Jun;77(3):167-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The natural history: how has prostate cancer trend modified?
  • The patients' number submitted to prostate fine-needle biopsy has constantly increased in the last years, posing technical and diagnostic problems to the pathologist.
  • In other cases, when only a few atypical glands are present, a very cautious behaviour is the rule.
  • The acronym "ASAP" (atypical small acinar proliferation) has been suggested in such cases.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16372513.001).
  • [ISSN] 1124-3562
  • [Journal-full-title] Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica
  • [ISO-abbreviation] Arch Ital Urol Androl
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


39. Pepe P, Aragona F: Prostate needle biopsy: 12 vs. 18 cores -- is it necessary? Urol Int; 2005;74(1):19-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostate needle biopsy: 12 vs. 18 cores -- is it necessary?
  • INTRODUCTION: The aim of this study is to compare the histological results of a prostate needle biopsy scheme of 12 and 18 cores used in 372 consecutive patients submitted to an early stage diagnosis programme for prostate cancer (PCa).
  • MATERIALS AND METHODS: From February 2002 to July 2003 a transperineal TRUS-guided prostate needle biopsy was performed in 372 patients aged 40-73.
  • RESULTS: 159 (42.7%) patients were diagnosed with PCa, 138 (37%) with BPH, 58 (15.7%) with chronic prostatitis, 15 (4%) with a HGPIN, 2 (0.6%) with ASAP.
  • CONCLUSIONS: Extended schemes of prostate needle biopsy of 18 or more cores increases the PCa diagnosis in early stage and should be adopted for young patients with a PSA <10 ng/ml, negative DRE and in case of rebiopsies.
  • [MeSH-major] Biopsy, Needle / statistics & numerical data. Prostate / pathology. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15711103.001).
  • [ISSN] 0042-1138
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down


40. Flannery RB Jr, Walker AP: Characteristics of patients in restraint: fifteen-year analysis of the Assaulted Staff Action Program (ASAP) with EMS implications. Int J Emerg Ment Health; 2008;10(3):191-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics of patients in restraint: fifteen-year analysis of the Assaulted Staff Action Program (ASAP) with EMS implications.
  • This study compared restrained/nonrestrained subjects on the demographic, precipitant variables and added three clinical variables (past violence to others, personal victimization, and substance use disorder) to assess the possible predictive power of clinical variables.
  • [MeSH-major] Emergency Medical Services. Program Development. Psychotic Disorders / psychology. Restraint, Physical. Violence / psychology

  • MedlinePlus Health Information. consumer health - Emergency Medical Services.
  • MedlinePlus Health Information. consumer health - Psychotic Disorders.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19112931.001).
  • [ISSN] 1522-4821
  • [Journal-full-title] International journal of emergency mental health
  • [ISO-abbreviation] Int J Emerg Ment Health
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Yanke BV, Salzhauer EW, Colon I: Is race a positive predictor of cancer on repeat prostate biopsy? J Urol; 2006 Sep;176(3):1114-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is race a positive predictor of cancer on repeat prostate biopsy?
  • PURPOSE: High grade intraepithelial neoplasia and atypical small acinar proliferation increase the probability of cancer on a subsequent prostate biopsy.
  • We investigated whether race is prognostic for detecting cancer in patients undergoing repeat prostate biopsies.
  • MATERIALS AND METHODS: At a single institution 416 men underwent 2 or more prostate biopsies from January 1993 through June 2003 for a total of 1,023 biopsies.
  • We retrospectively examined multiple factors, including patient age, race, total number of biopsy cores total number of previously negative biopsy cores, prostate specific antigen, prostate specific antigen slope, digital rectal examination and family history of prostate cancer.
  • Previous high grade intraepithelial neoplasia, atypical small acinar proliferation and Gleason score in positive biopsies were recorded from the histopathology review.
  • The Cox proportional hazards model was used for multivariate analysis.
  • When clinical and pathological variables were compared between the racial groups, black men had significantly higher prostate specific antigen (p = 0.02).
  • There was no statistically significant difference in patient age, total number of cores, number of previous negative cores, prostate specific antigen slope, abnormal digital rectal examination, family history, or previous high grade intraepithelial neoplasia or atypical small acinar proliferation.
  • Multivariate analysis showed that race approached but did not achieve statistical significance as a predictor of prostate cancer on repeat biopsy (p = 0.09).
  • Previous high grade intraepithelial neoplasia (p = 0.0025), previous atypical small acinar proliferation (p = 0.0049), digital rectal examination (p = 0.0076) and prostate specific antigen slope (p = 0.0005) were independent predictors of prostate cancer on repeat biopsy.
  • Of patients with previous atypical small acinar proliferation black men had a significantly higher rate of cancer detection on repeat biopsy.
  • CONCLUSIONS: Previous high grade intraepithelial neoplasia, atypical small acinar proliferation, digital rectal examination and prostate specific antigen slope were independent predictors of prostate cancer on repeat biopsy.
  • [MeSH-major] Biopsy, Needle / statistics & numerical data. Prostatic Neoplasms / ethnology. Prostatic Neoplasms / pathology

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16890704.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Ahyai SA, Isbarn H, Karakiewicz PI, Chun FK, Reichert M, Walz J, Steuber T, Jeldres C, Schlomm T, Heinzer H, Salomon G, Budäus L, Perrotte P, Huland H, Graefen M, Haese A: The presence of prostate cancer on saturation biopsy can be accurately predicted. BJU Int; 2010 Mar;105(5):636-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The presence of prostate cancer on saturation biopsy can be accurately predicted.
  • OBJECTIVE: To improve the ability of our previously reported saturation biopsy nomogram quantifying the risk of prostate cancer, as the use of office-based saturation biopsy has increased.
  • PATIENTS AND METHODS: Saturation biopsies of 540 men with one or more previously negative 6-12 core biopsies were used to develop a multivariable logistic regression model-based nomogram, predicting the probability of prostate cancer.
  • Candidate predictors were used in their original or stratified format, and consisted of age, total prostate-specific antigen (PSA) level, percentage free PSA (%fPSA), gland volume, findings on a digital rectal examination, cumulative number of previous biopsy sessions, presence of high-grade prostatic intraepithelial neoplasia on any previous biopsy, and presence of atypical small acinar proliferation (ASAP) on any previous biopsy.
  • RESULTS: Prostate cancer was diagnosed in 39.4% of saturation biopsies.
  • Age, total PSA, %fPSA, gland volume, number of previous biopsies, and presence of ASAP at any previous biopsy were independent predictors for prostate cancer (all P < 0.05).
  • The nomogram was 77.2% accurate and had a virtually perfect correlation between predicted and observed rates of prostate cancer.
  • CONCLUSIONS: We improved the accuracy of the saturation biopsy nomogram from 72% to 77%; it relies on three previously included variables, i.e. age, %fPSA and prostate volume, and on three previously excluded variables, i.e.
  • PSA, the number of previous biopsy sessions, and evidence of ASAP on previous biopsy.
  • [MeSH-major] Nomograms. Prostate / pathology. Prostatic Intraepithelial Neoplasia / pathology. Prostatic Neoplasms / pathology


43. Bialocerkowski A, Kurlowicz K, Vladusic S, Grimmer K: Effectiveness of primary conservative management for infants with obstetric brachial plexus palsy. Int J Evid Based Healthc; 2005 Mar;3(2):27-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Search strategy  A systematic literature search was performed using 14 databases: TRIP, MEDLINE, CINAHL, AMED, Web of Science, Proquest 5000, Evidence Based Medicine Reviews, Expanded Academic ASAP, Meditext, Science Direct, Physiotherapy Evidence Database, Proquest Digital Dissertations, Open Archives Initiative Search Engine, Australian Digital Thesis Program.
  • Data collection and analysis  Two independent reviewers assessed the eligibility of each study for inclusion into the review, the study design used and its methodological quality.

  • COS Scholar Universe. author profiles.
  • PubMed Health. DARE review .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21631743.001).
  • [ISSN] 1744-1595
  • [Journal-full-title] International journal of evidence-based healthcare
  • [ISO-abbreviation] Int J Evid Based Healthc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


44. Mearini L, Costantini E, Bellezza G, Cavaliere A, Zucchi A, Bini V, Porena M: Is there any clinical parameter able to predict prostate cancer after initial diagnosis of atypical small acinar proliferation? Urol Int; 2008;81(1):29-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is there any clinical parameter able to predict prostate cancer after initial diagnosis of atypical small acinar proliferation?
  • INTRODUCTION: Tissue samples from prostate biopsy may contain atypical small acinar proliferation (ASAP): present guidelines recommend a repeat biopsy policy.
  • MATERIALS AND METHODS: From 1999 to 2005, 1,274 patients underwent a prostate biopsy: in 5.9% ASAP was found, and patients underwent a second biopsy.
  • Uni- and multivariate analysis compared the clinical patterns of cancer patients with the no cancer group at second biopsy.
  • RESULTS: Univariate analysis showed significant differences in PSA ratio density, prostate volume, final PSA values and Delta PSA; at multivariate logistic regression analysis, only PSA ratio (OR = 0.743, 95% CI 0.620-0.891) and prostate volume (OR = 0.960, 95% CI 0.924-0.998) were predictive of malignancy.
  • CONCLUSIONS: In our experience, PSA ratio and prostate volume seem to be independent predictors of prostate cancer at re-biopsy.
  • [MeSH-major] Cell Proliferation. Prostatic Neoplasms / diagnosis. Prostatic Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Biopsy. Humans. Male. Medical Oncology / methods. Middle Aged. Multivariate Analysis. Predictive Value of Tests. Prostate-Specific Antigen / biosynthesis. ROC Curve. Regression Analysis. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 S. Karger AG, Basel.
  • (PMID = 18645268.001).
  • [ISSN] 1423-0399
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


45. Twohig M, Skilton SJ, Fujimoto G, Ellor N, Plumb RS: Rapid detection and identification of counterfeit and [corrected] adulterated products of synthetic phosphodiesterase type-5 inhibitors with an atmospheric solids analysis probe. Drug Test Anal; 2010 Feb;2(2):45-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapid detection and identification of counterfeit and [corrected] adulterated products of synthetic phosphodiesterase type-5 inhibitors with an atmospheric solids analysis probe.
  • An Atmospheric Solids Analysis Probe (ASAP) was used for the direct analysis of the counterfeit pharmaceuticals and herbal products.
  • Using the ASAP combined with time-of-flight mass spectrometry (TOF MS) it was possible to detect fraudulent counterfeit tablets.
  • Detecting adulteration for five herbal supplements marketed as natural alternatives to PDE-5 inhibitors was also possible using the ASAP.

  • MedlinePlus Health Information. consumer health - Drug Safety.
  • Hazardous Substances Data Bank. SILDENAFIL .
  • Hazardous Substances Data Bank. TADALAFIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 John Wiley & Sons, Ltd.
  • [ErratumIn] Drug Test Anal. 2011 Mar;3(3):191-3
  • (PMID = 20878886.001).
  • [ISSN] 1942-7611
  • [Journal-full-title] Drug testing and analysis
  • [ISO-abbreviation] Drug Test Anal
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carbolines; 0 / Counterfeit Drugs; 0 / Phosphodiesterase 5 Inhibitors; 0 / Piperazines; 0 / Plant Preparations; 0 / Purines; 0 / Sulfones; 742SXX0ICT / Tadalafil; BW9B0ZE037 / Sildenafil Citrate
  •  go-up   go-down


46. Radhika P, Gowda SJ, Kadoo NY, Mhase LB, Jamadagni BM, Sainani MN, Chandra S, Gupta VS: Development of an integrated intraspecific map of chickpea (Cicer arietinum L.) using two recombinant inbred line populations. Theor Appl Genet; 2007 Jul;115(2):209-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RAPD, ISSR, RGA, SSR and ASAP were analyzed along with three yield related traits: double podding, seeds per pod and seed weight.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Theor Appl Genet. 2005 Feb;110(3):492-510 [15712010.001]
  • [Cites] Theor Appl Genet. 2006 Jan;112(2):347-57 [16328234.001]
  • [Cites] Genetics. 1992 Mar;130(3):649-63 [1551583.001]
  • [Cites] Genetics. 1992 Dec;132(4):1141-60 [1360934.001]
  • [Cites] Theor Appl Genet. 2002 Sep;105(4):604-607 [12582510.001]
  • [Cites] Mol Gen Genet. 1999 Aug;262(1):90-101 [10503540.001]
  • [Cites] Theor Appl Genet. 2003 May;106(8):1447-56 [12750788.001]
  • [Cites] Theor Appl Genet. 1999 Aug;99(3-4):425-31 [22665174.001]
  • [Cites] Theor Appl Genet. 1995 Mar;90(3-4):542-8 [24173949.001]
  • [Cites] Theor Appl Genet. 2004 Feb;108(3):414-22 [13679975.001]
  • [Cites] Theor Appl Genet. 2005 May;110(7):1347-53 [15806343.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Feb 15;89(4):1477-81 [1346933.001]
  • [Cites] Theor Appl Genet. 2003 May;106(7):1196-202 [12748770.001]
  • [Cites] Theor Appl Genet. 1993 Jul;86(6):705-12 [24193780.001]
  • [Cites] Mol Gen Genet. 1997 Feb 20;253(5):535-45 [9065686.001]
  • [Cites] Theor Appl Genet. 2004 Aug;109(4):733-9 [15146319.001]
  • [Cites] Genome. 1999 Apr;42(2):210-7 [10231957.001]
  • [Cites] Theor Appl Genet. 2004 Apr;108(6):1079-88 [15067394.001]
  • [Cites] Theor Appl Genet. 2006 May;112(8):1416-28 [16534564.001]
  • [Cites] J Hered. 2002 Jan-Feb;93(1):77-8 [12011185.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11746-50 [8876208.001]
  • [Cites] Theor Appl Genet. 2005 Jul;111(2):185-95 [15918010.001]
  • [Cites] Chromosome Res. 2002;10(8):695-706 [12575797.001]
  • [Cites] Theor Appl Genet. 1998 Mar;96(3-4):348-53 [24710870.001]
  • [Cites] Theor Appl Genet. 1993 May;86(4):417-26 [24193588.001]
  • [Cites] J Hered. 2000 May-Jun;91(3):234-6 [10833050.001]
  • (PMID = 17503013.001).
  • [ISSN] 0040-5752
  • [Journal-full-title] TAG. Theoretical and applied genetics. Theoretische und angewandte Genetik
  • [ISO-abbreviation] Theor. Appl. Genet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / DNA, Recombinant; 0 / Genetic Markers
  •  go-up   go-down


47. Eot-Houllier G, Venoux M, Vidal-Eychenié S, Hoang MT, Giorgi D, Rouquier S: Plk1 regulates both ASAP localization and its role in spindle pole integrity. J Biol Chem; 2010 Sep 17;285(38):29556-68
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plk1 regulates both ASAP localization and its role in spindle pole integrity.
  • ASAP (aster-associated protein or MAP9) is a centrosome- and spindle-associated protein, the deregulation of which induces severe mitotic defects.
  • Here, we show that ASAP is localized to the spindle poles by Polo-like kinase 1 (Plk1) (a mitotic kinase that plays an essential role in centrosome regulation and mitotic spindle assembly) through the γ-TuRC-dependent pathway.
  • We also demonstrate that ASAP is a novel substrate of Plk1 phosphorylation and have identified serine 289 as the major phosphorylation site by Plk1 in vivo.
  • ASAP phosphorylated on serine 289 is localized to centrosomes during mitosis, but this phosphorylation is not required for its Plk1-dependent localization at the spindle poles.
  • We show that phosphorylated ASAP on serine 289 contributes to spindle pole stability in a microtubule-dependent manner.
  • These data reveal a novel function of ASAP in centrosome integrity.
  • Our results highlight dual ASAP regulation by Plk1 and further confirm the importance of ASAP for spindle pole organization, bipolar spindle assembly, and mitosis.

  • PhosphoSitePlus. gene/protein/disease-specific - PhosphoSitePlus® - comprehensive post-translational modification resource .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell Cycle. 2006 Apr;5(8):853-64 [16627997.001]
  • [Cites] J Cell Biol. 2006 Feb 13;172(4):505-15 [16461362.001]
  • [Cites] J Cell Sci. 2006 Oct 15;119(Pt 20):4143-53 [17038541.001]
  • [Cites] Int J Cancer. 2006 Dec 15;119(12):2717-23 [17016823.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 Jun;8(6):451-63 [17505520.001]
  • [Cites] Cancer Res. 2007 Jun 1;67(11):5362-70 [17545617.001]
  • [Cites] Mol Biol Cell. 2007 Oct;18(10):4024-36 [17671160.001]
  • [Cites] Nat Rev Cancer. 2007 Dec;7(12):911-24 [18004399.001]
  • [Cites] Hum Mol Genet. 2008 Jan 15;17(2):215-24 [17925329.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Feb 5;105(5):1442-7 [18234856.001]
  • [Cites] Dev Cell. 2008 Mar;14(3):331-41 [18331714.001]
  • [Cites] Dev Cell. 2008 May;14(5):646-59 [18477449.001]
  • [Cites] Science. 2008 Jun 20;320(5883):1655-8 [18566290.001]
  • [Cites] Nature. 2008 Sep 4;455(7209):119-23 [18615013.001]
  • [Cites] Chromosoma. 2008 Oct;117(5):457-69 [18521620.001]
  • [Cites] Genes Dev. 2008 Oct 1;22(19):2707-20 [18832073.001]
  • [Cites] J Cell Biol. 2008 Dec 1;183(5):835-48 [19029337.001]
  • [Cites] Biol Cell. 2009 Jan;101(1):1-11 [19055485.001]
  • [Cites] Oncogene. 2009 Jan 8;28(1):107-16 [18820703.001]
  • [Cites] J Cell Sci. 2009 May 1;122(Pt 9):1334-41 [19351716.001]
  • [Cites] Curr Biol. 2009 May 26;19(10):816-26 [19427217.001]
  • [Cites] Cancer Res. 2009 Jun 1;69(11):4555-8 [19487276.001]
  • [Cites] J Cell Sci. 2009 Jul 1;122(Pt 13):2240-51 [19509060.001]
  • [Cites] PLoS One. 2009;4(6):e5976 [19543530.001]
  • [Cites] Nat Rev Mol Cell Biol. 2009 Jul;10(7):478-87 [19546858.001]
  • [Cites] Trends Cell Biol. 2009 Jul;19(7):334-46 [19570677.001]
  • [Cites] EMBO J. 2009 Jul 22;28(14):2066-76 [19536135.001]
  • [Cites] J Cell Sci. 2009 Aug 1;122(Pt 15):2750-9 [19596795.001]
  • [Cites] Cell Cycle. 2009 Aug;8(15):2413-9 [19556869.001]
  • [Cites] EMBO J. 2009 Sep 16;28(18):2786-93 [19680222.001]
  • [Cites] Cell Mol Life Sci. 2010 Jun;67(12):1957-70 [20148280.001]
  • [Cites] Nat Cell Biol. 2000 Sep;2(9):672-6 [10980711.001]
  • [Cites] J Cell Biol. 2001 Apr 2;153(1):149-58 [11285281.001]
  • [Cites] Mol Cell Biol. 2002 Sep;22(17):6209-21 [12167714.001]
  • [Cites] Nat Rev Cancer. 2002 Nov;2(11):815-25 [12415252.001]
  • [Cites] Science. 2003 Feb 21;299(5610):1228-31 [12595692.001]
  • [Cites] Cell. 2003 Oct 3;115(1):83-95 [14532005.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 Jun;5(6):429-40 [15173822.001]
  • [Cites] J Biol Chem. 2004 Aug 27;279(35):36841-54 [15210710.001]
  • [Cites] Curr Biol. 2004 Oct 5;14(19):1712-22 [15458642.001]
  • [Cites] Nat Rev Cancer. 2005 Jan;5(1):42-50 [15630414.001]
  • [Cites] Oncogene. 2005 Jan 10;24(2):248-59 [15640840.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Aug 9;102(32):11302-7 [16049101.001]
  • [Cites] Mol Biol Cell. 2006 Jan;17(1):448-59 [16267267.001]
  • [Cites] Nat Cell Biol. 2006 Feb;8(2):137-47 [16378099.001]
  • [Cites] Nat Cell Biol. 2006 Oct;8(10):1095-101 [16980960.001]
  • (PMID = 20615875.001).
  • [ISSN] 1083-351X
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / MAP9 protein, human; 0 / Microtubule-Associated Proteins; 0 / NEDD1 protein, human; 0 / Proto-Oncogene Proteins; 0 / Tubulin; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / polo-like kinase 1
  • [Other-IDs] NLM/ PMC2937987
  •  go-up   go-down


48. Shao W, Wu J, Chen J, Lee DM, Tishkina A, Harris TJ: A modifier screen for Bazooka/PAR-3 interacting genes in the Drosophila embryo epithelium. PLoS One; 2010 Apr 01;5(4):e9938
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We found that GFP fusion proteins for Drosophila ASAP, Arf79F, CG11210, Septin 5 and Sds22 could be recruited to the apical circumference of epithelial cells.

  • FlyBase. FlyBase .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dev Cell. 2008 Feb;14(2):205-15 [18267089.001]
  • [Cites] Nature. 2008 May 29;453(7195):657-61 [18408709.001]
  • [Cites] Development. 2008 Jul;135(13):2227-38 [18508861.001]
  • [Cites] Science. 2008 Jul 18;321(5887):401-4 [18635802.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10402-7 [18641122.001]
  • [Cites] PLoS One. 2008;3(8):e2918 [18698375.001]
  • [Cites] J Cell Biol. 2008 Sep 22;182(6):1039-44 [18809720.001]
  • [Cites] Curr Biol. 2008 Nov 11;18(21):1639-48 [18976911.001]
  • [Cites] Curr Biol. 2008 Nov 11;18(21):1631-8 [18976918.001]
  • [Cites] J Cell Biol. 2008 Dec 15;183(6):1129-43 [19064670.001]
  • [Cites] BMC Dev Biol. 2009;9:14 [19228425.001]
  • [Cites] J Cell Biol. 2009 Apr 6;185(1):129-45 [19349583.001]
  • [Cites] J Cell Biol. 2009 Jun 1;185(5):787-96 [19468069.001]
  • [Cites] Curr Biol. 2009 Jul 14;19(13):1065-74 [19540120.001]
  • [Cites] Dev Cell. 2007 Jul;13(1):15-28 [17609107.001]
  • [Cites] Genes Dev. 1996 Mar 15;10(6):672-85 [8598295.001]
  • [Cites] Development. 1996 Mar;122(3):951-9 [8631272.001]
  • [Cites] J Cell Biol. 1996 Jun;133(6):1205-15 [8682859.001]
  • [Cites] J Cell Biol. 1996 Jul;134(1):149-63 [8698811.001]
  • [Cites] Dev Biol. 1996 Jul 10;177(1):217-25 [8660889.001]
  • [Cites] Curr Biol. 1998 Dec 17-31;8(25):1357-65 [9889099.001]
  • [Cites] Science. 1999 Mar 12;283(5408):1733-5 [10073938.001]
  • [Cites] EMBO J. 1999 Jun 15;18(12):3187-92 [10369659.001]
  • [Cites] Bioessays. 2005 Feb;27(2):126-35 [15666355.001]
  • [Cites] Nat Cell Biol. 2005 Mar;7(3):262-9 [15723052.001]
  • [Cites] Dev Dyn. 2005 Mar;232(3):685-94 [15712202.001]
  • [Cites] Dev Dyn. 2005 Mar;232(3):865-75 [15712282.001]
  • [Cites] Development. 2005 Apr;132(7):1675-86 [15743877.001]
  • [Cites] Dev Cell. 2005 Apr;8(4):493-504 [15809032.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Aug;6(8):622-34 [16025097.001]
  • [Cites] J Cell Biol. 2005 Aug 29;170(5):813-23 [16129788.001]
  • [Cites] Development. 2005 Nov;132(21):4819-31 [16207756.001]
  • [Cites] Curr Opin Cell Biol. 2006 Feb;18(1):86-94 [16364625.001]
  • [Cites] Development. 2006 Feb;133(4):711-23 [16421189.001]
  • [Cites] J Cell Sci. 2006 Feb 15;119(Pt 4):711-21 [16449319.001]
  • [Cites] J Cell Biol. 2006 Feb 27;172(5):671-8 [16505165.001]
  • [Cites] J Cell Sci. 2006 Mar 15;119(Pt 6):979-87 [16525119.001]
  • [Cites] J Cell Sci. 2006 Apr 1;119(Pt 7):1203-11 [16554436.001]
  • [Cites] Nature. 2006 Aug 3;442(7102):580-4 [16862128.001]
  • [Cites] Dev Cell. 2006 Sep;11(3):375-85 [16908221.001]
  • [Cites] Development. 2006 Oct;133(19):3745-54 [16943281.001]
  • [Cites] Curr Biol. 2006 Sep 19;16(18):1783-95 [16979555.001]
  • [Cites] Science. 2006 Nov 3;314(5800):832-6 [17082460.001]
  • [Cites] Nat Cell Biol. 2007 Sep;9(9):1066-73 [17704769.001]
  • [Cites] Cell. 2007 Oct 5;131(1):174-87 [17923096.001]
  • [Cites] Curr Opin Cell Biol. 2007 Oct;19(5):508-14 [17935963.001]
  • [Cites] J Biol Chem. 2007 Nov 30;282(48):35259-68 [17906294.001]
  • [Cites] Cell. 2000 May 12;101(4):345-8 [10830161.001]
  • [Cites] Curr Opin Cell Biol. 2001 Feb;13(1):68-75 [11163136.001]
  • [Cites] Trends Genet. 2001 Sep;17(9):511-9 [11525834.001]
  • [Cites] Annu Rev Genet. 2001;35:747-84 [11700298.001]
  • [Cites] Nat Cell Biol. 2002 Feb;4(2):E39-44 [11835058.001]
  • [Cites] Development. 2002 Aug;129(16):3771-82 [12135916.001]
  • [Cites] Gene. 2002 Sep 4;297(1-2):69-78 [12384287.001]
  • [Cites] Science. 2002 Dec 6;298(5600):1955-9 [12471248.001]
  • [Cites] Nat Cell Biol. 2003 Jan;5(1):46-52 [12510193.001]
  • [Cites] Nat Cell Biol. 2003 Jan;5(1):53-8 [12510194.001]
  • [Cites] Nat Cell Biol. 2003 Apr;5(4):287-93 [12669082.001]
  • [Cites] Nature. 2003 Apr 17;422(6933):766-74 [12700771.001]
  • [Cites] Curr Biol. 2003 Aug 5;13(15):1330-4 [12906794.001]
  • [Cites] Curr Opin Cell Biol. 2003 Dec;15(6):747-52 [14644201.001]
  • [Cites] Cell. 2003 Dec 12;115(6):691-704 [14675534.001]
  • [Cites] Traffic. 2004 Jan;5(1):1-9 [14675420.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 Mar;5(3):220-31 [14991002.001]
  • [Cites] Dev Cell. 2004 Mar;6(3):343-55 [15030758.001]
  • [Cites] Nat Cell Biol. 2004 Apr;6(4):328-34 [15048131.001]
  • [Cites] Dev Cell. 2004 Jun;6(6):845-54 [15177032.001]
  • [Cites] Cell Cycle. 2004 Apr;3(4):391-2 [14752271.001]
  • [Cites] Genes Dev. 2004 Aug 15;18(16):1909-25 [15314019.001]
  • [Cites] J Cell Biol. 2004 Aug 16;166(4):549-57 [15302858.001]
  • [Cites] Curr Biol. 2004 Aug 24;14(16):1425-35 [15324659.001]
  • [Cites] Curr Biol. 2004 Aug 24;14(16):1451-61 [15324661.001]
  • [Cites] J Cell Biol. 2004 Oct 11;167(1):135-47 [15479740.001]
  • [Cites] Nature. 1980 Oct 30;287(5785):795-801 [6776413.001]
  • [Cites] Dev Biol. 1994 Oct;165(2):716-26 [7958432.001]
  • [Cites] Development. 1994 Apr;120(4):827-41 [7600960.001]
  • [Cites] Kidney Int. 2007 Dec;72(12):1448-58 [17914350.001]
  • [Cites] Mol Cell. 2007 Dec 14;28(5):886-98 [18082612.001]
  • [Cites] J Cell Biol. 2008 Jan 28;180(2):295-303 [18209106.001]
  • (PMID = 20368978.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] Canada / Canadian Institutes of Health Research / / MOP-82829
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Drosophila Proteins; 0 / Intracellular Signaling Peptides and Proteins; 0 / Proteins; 0 / bazooka protein, Drosophila
  • [Other-IDs] NLM/ PMC2848566
  •  go-up   go-down


49. Morote J, Rigau M, Garcia M, Mir C, Ballesteros C, Planas J, Raventós CX, Placer J, de Torres IM, Reventós J, Doll A: Behavior of the PCA3 gene in the urine of men with high grade prostatic intraepithelial neoplasia. World J Urol; 2010 Dec;28(6):677-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Behavior of the PCA3 gene in the urine of men with high grade prostatic intraepithelial neoplasia.
  • OBJECTIVE: An ideal marker for the early detection of prostate cancer (PCa) should also differentiate between men with isolated high grade prostatic intraepithelial neoplasia (HGPIN) and those with PCa.
  • Prostate Cancer Gene 3 (PCA3) is a highly specific PCa gene and its score, in relation to the PSA gene in post-prostate massage urine (PMU-PCA3), seems to be useful in ruling out PCa, especially after a negative prostate biopsy.
  • PATIENTS AND METHODS: The PMU-PCA3 score was assessed by quantitative PCR (multiplex research assay) in 244 men subjected to prostate biopsy: 64 men with an isolated HGPIN (no cancer detected after two or more repeated biopsies), 83 men with PCa and 97 men with benign pathology findings (BP: no PCa, HGPIN or ASAP).
  • The AUC in the ROC analysis was 0.705 in the subset of men with BP and PCa, while it decreased to 0.629 when only men with isolated HGPIN and PCa were included in the analysis.
  • [MeSH-major] Antigens, Neoplasm / urine. Biomarkers, Tumor / urine. Prostatic Intraepithelial Neoplasia / diagnosis. Prostatic Intraepithelial Neoplasia / urine. Prostatic Neoplasms / diagnosis. Prostatic Neoplasms / urine

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2007 Feb 1;13(3):939-43 [17289888.001]
  • [Cites] Clin Chem. 2006 Jun;52(6):1089-95 [16627561.001]
  • [Cites] Cancer Res. 1999 Dec 1;59(23):5975-9 [10606244.001]
  • [Cites] J Urol. 2008 Apr;179(4):1587-92 [18295257.001]
  • [Cites] Urology. 2004 Aug;64(2):311-5; discussion 315-6 [15302485.001]
  • [Cites] Eur Urol. 2004 Aug;46(2):182-6; discussion 187 [15245811.001]
  • [Cites] Eur Urol. 2009 Oct;56(4):659-67 [19304372.001]
  • [Cites] Eur Urol. 2003 Jul;44(1):8-15; discussion 15-6 [12814669.001]
  • [Cites] Mod Pathol. 2007 Nov;20(11):1121-7 [17873893.001]
  • [Cites] Eur Urol. 2008 Nov;54(5):1081-8 [18602209.001]
  • [Cites] Clin Cancer Res. 2008 May 1;14(9):2617-22 [18451224.001]
  • [Cites] Cancer Res. 2002 May 1;62(9):2695-8 [11980670.001]
  • [Cites] Urology. 2007 Mar;69(3):532-5 [17382159.001]
  • [Cites] Urology. 2006 Mar;67(3):458-60 [16504254.001]
  • (PMID = 20607245.001).
  • [ISSN] 1433-8726
  • [Journal-full-title] World journal of urology
  • [ISO-abbreviation] World J Urol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / prostate cancer antigen 3, human
  •  go-up   go-down


50. Scattoni V, Roscigno M, Freschi M, Dehò F, Raber M, Briganti A, Fantini G, Nava L, Montorsi F, Rigatti P: Atypical small acinar proliferation (ASAP) on extended prostatic biopsies: predictive factors of cancer detection on repeat biopsies. Arch Ital Urol Androl; 2005 Mar;77(1):31-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical small acinar proliferation (ASAP) on extended prostatic biopsies: predictive factors of cancer detection on repeat biopsies.
  • OBJECTIVE: To evaluate the clinical and histopathologic factors that may help to predict cancer detection by means of extended repeated prostate needle biopsies in patients with Jumma atypical small acinar proliferation (ASAP) results on initial prostate biopsy.
  • MATERIALS AND METHODS: From 1998 to September 2003, 105 out of 121 (86%) patients with a diagnosis of ASAP after a first set of 10 to 12 systematic biopsies, were rebiopsied using the same technique plus additional biopsies on the ASAP site (mean number of repeat biopsy samples, 12.6).
  • RESULTS: On initial biopsy, a concomitant HGPIN was present in 18 patients (17%) with ASAP The overall cancer detection rate in those who underwent two or three sets of biopsies was 39% (41/105); it was 35% (37/105) and 21% (4/19) in second and third biopsies, respectively.
  • The overall cancer detection rate was higher in patients who had ASAP associated with HGPIN (50%) compared with patients who had isolated ASAP (37%) (p = 0.3).
  • Statistical analysis showed that levels of prostate-specific antigen (PSA), PSA density, prostatic volume, digital rectal examination results, transrectal ultrasound findings, time until rebiopsy (less vs. more than 6 months), and histological level of suspicion were not significant predictors of prostate cancer at the time of rebiopsy.
  • In a univariate analysis, the mean prostate volume was statistically different in patients with cancer compared with those without (56.4 +/- 6.3 and 78.9 +/- 5.3 respectively; p = 0.009), but only in the group of patients who had isolated ASAP In these patients, the rate of cancer detection was significantly higher in patients who had a prostatic volume less than 60 mL (56%) than in patients with a prostatic volume greater than or equal to 60 mL (27%) (p = 0.03).
  • CONCLUSIONS: Patients with an initial ASAP diagnosis after extended biopsies had an overall cancer detection rate less than 40% after two sets of extended biopsy.
  • Despite the extended rebiopsy plus the additional biopsies targeted to the ASAP lesion, the detection rate was lower for patients with a larger prostate than those with a smaller prostate.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15906787.001).
  • [ISSN] 1124-3562
  • [Journal-full-title] Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica
  • [ISO-abbreviation] Arch Ital Urol Androl
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


51. McEwen C, Gutteridge S: Analysis of the inhibition of the ergosterol pathway in fungi using the atmospheric solids analysis probe (ASAP) method. J Am Soc Mass Spectrom; 2007 Jul;18(7):1274-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of the inhibition of the ergosterol pathway in fungi using the atmospheric solids analysis probe (ASAP) method.
  • Fungal cells treated with various inhibitors to the ergosterol pathway were analyzed using an Orbitrap mass spectrometer equipped with an atmospheric solids analysis probe (ASAP).
  • Furthermore, in an inhibitor concentration study, the ASAP method was able to rapidly provide an estimate of the effectiveness of inhibition.
  • In this method the cells are inserted directly into a hot nitrogen stream, thus eliminating extensive sample workup before analysis.
  • [MeSH-minor] Atmospheric Pressure. Transducers

  • Hazardous Substances Data Bank. ERGOSTEROL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anal Chem. 2005 Nov 1;77(21):6755-64 [16255571.001]
  • [Cites] Chem Commun (Camb). 2007 Feb 28;(8):807-9 [17308638.001]
  • [Cites] Anal Chem. 2005 Apr 15;77(8):2297-302 [15828760.001]
  • [Cites] Science. 2004 Oct 15;306(5695):471-3 [15486296.001]
  • [Cites] Chem Commun (Camb). 2005 Apr 21;(15):1950-2 [15834468.001]
  • [Cites] Anal Chem. 2005 Dec 1;77(23):7826-31 [16316194.001]
  • [Cites] Eur J Mass Spectrom (Chichester). 2004;10(2):197-204 [15103096.001]
  • [Cites] Bioorg Med Chem. 2000 May;8(5):925-36 [10882005.001]
  • [Cites] J Am Soc Mass Spectrom. 2005 Nov;16(11):1730-8 [16185892.001]
  • [Cites] J Agric Food Chem. 2000 Nov;48(11):5389-95 [11087490.001]
  • [Cites] Anal Chem. 2001 Nov 1;73(21):5061-5 [11721900.001]
  • [Cites] Chem Commun (Camb). 2007 Jan 7;(1):61-3 [17279261.001]
  • (PMID = 17482834.001).
  • [ISSN] 1044-0305
  • [Journal-full-title] Journal of the American Society for Mass Spectrometry
  • [ISO-abbreviation] J. Am. Soc. Mass Spectrom.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Z30RAY509F / Ergosterol
  •  go-up   go-down


52. Brimo F, Vollmer RT, Corcos J, Humphrey PA, Bismar TA: Outcome for repeated biopsy of the prostate: roles of serum PSA, small atypical glands, and prostatic intraepithelial neoplasia. Am J Clin Pathol; 2007 Oct;128(4):648-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome for repeated biopsy of the prostate: roles of serum PSA, small atypical glands, and prostatic intraepithelial neoplasia.
  • We studied the relationships between the outcome in the last follow-up prostate biopsy specimen and serum prostate-specific antigen (PSA), prostatic intraepithelial neoplasia (PIN), and atypical small acinar proliferations (ASAPs) at the occasion of the initial biopsy in 244 cases in which the initial specimen was negative for tumor and at least 1 follow-up biopsy was done.
  • PSA levels and ASAPs were significantly associated with cancer in the follow-up biopsy specimen (<P < .005; logistic regression analysis); however, the presence of PIN in the initial biopsy specimen did not relate to cancer in the follow-up specimen (P > .1).
  • Thus, the probability that a follow-up biopsy demonstrates cancer depends on PSA and ASAPs, and even when ASAPs are present, serum PSA exerts an influence.
  • For example, low PSA values, 5 ng/mL (5 mug/L) or less, are associated with low probabilities of a positive follow-up biopsy result, even when ASAPs were present in the first biopsy specimen.
  • For higher PSA values, the presence of ASAPs dramatically increases the probability of a positive follow-up biopsy result compared with cases with no atypia or PIN in the first biopsy specimen.
  • [MeSH-major] Prostate / pathology. Prostate-Specific Antigen / blood. Prostatic Intraepithelial Neoplasia / pathology. Prostatic Neoplasms / pathology


53. Sutton PA, Smith BE, Rowland SJ: Mass spectrometry of polycyclic tetracarboxylic ('ARN') acids and tetramethyl esters. Rapid Commun Mass Spectrom; 2010 Nov 15;24(21):3195-204
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although several of the acids have been isolated and characterised (as regioisomeric mixtures) by nuclear magnetic resonance spectroscopy, mass spectrometric methods are likely to be much more useful for the routine analysis of oils and deposits containing the acids.
  • We now report the characterisation of several of the purified acids and of the tetramethyl esters by electrospray ionisation mass spectrometry (ESI-MS) in both positive ion and negative ion modes, by multistage ESI-MS with a suggested rationalisation of the ions produced, by positive ion atmospheric solids analysis probe (ASAP) atmospheric pressure chemical ionisation (APCI), and by positive ion electron ionisation (EI)-MS.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 John Wiley & Sons, Ltd.
  • (PMID = 20941768.001).
  • [ISSN] 1097-0231
  • [Journal-full-title] Rapid communications in mass spectrometry : RCM
  • [ISO-abbreviation] Rapid Commun. Mass Spectrom.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carboxylic Acids; 0 / Esters; 0 / Petroleum; 0 / Polycyclic Compounds
  •  go-up   go-down


54. Trilla E, Morote J: [Prostate cancer. New diagnostic techniques. Current status of prostate biopsy]. Arch Esp Urol; 2006 Dec;59(10):945-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prostate cancer. New diagnostic techniques. Current status of prostate biopsy].
  • OBJECTIVES: Ultrasound guided prostate biopsy is the only method to obtain the confirmation diagnosis of prostate cancer.
  • METHODS: Bibliographic review and critical analysis of the literature on prostate biopsy.
  • RESULTS/CONCLUSIONS: Published studies suggest extensive biopsy schemes increase detection rates in comparison to sextant biopsies, both first and successive biopsies, being necessary to sample the most lateral areas of the gland and the dorsal apex where the diagnostic yield is greater.
  • The indications for repeated biopsies after a negative one include high grade PIN and/or Atypical Small Acinar Proliferation (ASAP), persistent PSA elevation and/or total PSA doubling time increase.
  • [MeSH-major] Prostatic Neoplasms / pathology
  • [MeSH-minor] Aged. Biopsy / methods. Biopsy / statistics & numerical data. Humans. Male. Middle Aged. Prostate-Specific Antigen / blood


55. Ibold Y, Lübke C, Pelz S, Augst H, Kaps C, Ringe J, Sittinger M: Effect of different ascorbate supplementations on in vitro cartilage formation in porcine high-density pellet cultures. Tissue Cell; 2009 Aug;41(4):249-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hydroxyproline content increased as well, but here, medium concentration of AsAP and low concentration of AsA showed a more pronounced effect.

  • MedlinePlus Health Information. consumer health - Vitamin C.
  • Hazardous Substances Data Bank. Sodium ascorbate .
  • Hazardous Substances Data Bank. L-Ascorbic Acid .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19167737.001).
  • [ISSN] 1532-3072
  • [Journal-full-title] Tissue & cell
  • [ISO-abbreviation] Tissue Cell
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 23313-12-4 / ascorbate-2-phosphate; PQ6CK8PD0R / Ascorbic Acid; RMB44WO89X / Hydroxyproline
  •  go-up   go-down


56. Oderda M, Gontero P: High-grade prostatic intraepithelial neoplasia and atypical small acinar proliferation: is repeat biopsy still necessary? BJU Int; 2009 Dec;104(11):1554-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-grade prostatic intraepithelial neoplasia and atypical small acinar proliferation: is repeat biopsy still necessary?
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Acinar Cell / pathology. Prostatic Intraepithelial Neoplasia / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Biopsy, Needle. Humans. Male. Prostate / pathology. Retreatment

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19817745.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


57. Shi HY, Wei LX, Zhou ZH, Wen ZL: [Morphologic diagnosis and clinical significance of prostatic atypical small acinar proliferation suspicious but not diagnostic of cancer]. Zhonghua Bing Li Xue Za Zhi; 2006 Nov;35(11):660-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Morphologic diagnosis and clinical significance of prostatic atypical small acinar proliferation suspicious but not diagnostic of cancer].
  • OBJECTIVE: To study the morphologic features and clinical significance of atypical small acinar proliferation (ASAP) suspicious but not diagnostic of cancer in prostatic biopsies.
  • METHODS: The slides of 11 cases of prostatic needle biopsies collected during a two-year period with the diagnosis of ASAP were reviewed.
  • RESULTS: All the 11 ASAP cases were characterized by the presence of a few compacted small acini in the prostatic stroma.
  • The nuclei were slightly enlarged with small or inconspicuous nucleoli.
  • CONCLUSIONS: ASAP is a morphologic interpretation closely associated with prostatic adenocarcinoma.
  • The histologic features are suspicious of but not diagnostic of cancer, due to insufficient criteria in terms of acinar number, cytologic or architectural abnormalities.
  • [MeSH-major] Adenocarcinoma / pathology. Prostate / pathology. Prostatic Hyperplasia / pathology. Prostatic Intraepithelial Neoplasia / pathology. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17374209.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


58. Young VL, Watson ME: The need for venous thromboembolism (VTE) prophylaxis in plastic surgery. Aesthet Surg J; 2006 Mar-Apr;26(2):157-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • ASAPS members can also complete this CME examination online by logging onto the ASAPS Members-Only Web site (http://www.surgery.org/members) and clicking on "Clinical Education" in the menu bar.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19338896.001).
  • [ISSN] 1527-330X
  • [Journal-full-title] Aesthetic surgery journal
  • [ISO-abbreviation] Aesthet Surg J
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


59. Ohnuma S, Miura K, Horii A, Fujibuchi W, Kaneko N, Gotoh O, Nagasaki H, Mizoi T, Tsukamoto N, Kobayashi T, Kinouchi M, Okabe M, Sasaki H, Shiiba K, Miyagawa K, Sasaki I: Cancer-associated splicing variants of the CDCA1 and MSMB genes expressed in cancer cell lines and surgically resected gastric cancer tissues. Surgery; 2009 Jan;145(1):57-68
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: In this study, we analyzed 17 genes by reverse transcriptase-polymerase chain reaction (RT-PCR) that were predicted to have cancer-specific alternative splicing by using the splicing database, the Alternative Splicing Annotation Project (ASAP) by Lee et al, between 38 cancer cell lines from various organs and 9 corresponding normal tissues.
  • [MeSH-major] Alternative Splicing. Cell Adhesion Molecules / metabolism. Cell Cycle Proteins / metabolism. GTP-Binding Proteins / metabolism. GTPase-Activating Proteins / metabolism. Hyaluronoglucosaminidase / metabolism. Prostatic Secretory Proteins / metabolism. Stomach Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19081476.001).
  • [ISSN] 1532-7361
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Adhesion Molecules; 0 / Cell Cycle Proteins; 0 / GPI-Linked Proteins; 0 / GTPase-Activating Proteins; 0 / NUF2 protein, human; 0 / Prostatic Secretory Proteins; 0 / beta-microseminoprotein; EC 3.2.1.25 / Hyal2 protein, human; EC 3.2.1.35 / Hyaluronoglucosaminidase; EC 3.6.1.- / GTP-Binding Proteins; EC 3.6.1.- / MRIP-1 protein, human
  •  go-up   go-down


60. Joselin AP, Schulze-Osthoff K, Schwerk C: Loss of Acinus inhibits oligonucleosomal DNA fragmentation but not chromatin condensation during apoptosis. J Biol Chem; 2006 May 5;281(18):12475-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Acinus is also involved in mRNA splicing and a component of the apoptosis and splicing-associated protein (ASAP) complex.
  • We show that Acinus is not required for nuclear localization and interaction of the other ASAP subunits SAP18 and RNPS1; however, knockdown of Acinus leads to a reduction in cell growth.
  • In contrast, although apoptosis proceeds rapidly, analysis of nuclear DNA from apoptotic Acinus knockdown cells shows inhibition of oligonucleosomal DNA fragmentation.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16537548.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ACIN1 protein, human; 0 / Chromatin; 0 / Nuclear Proteins; 0 / Nucleosomes; 9007-49-2 / DNA; EC 3.4.22.- / Caspases
  •  go-up   go-down


61. Auprich M, Haese A, Walz J, Pummer K, de la Taille A, Graefen M, de Reijke T, Fisch M, Kil P, Gontero P, Irani J, Chun FK: External validation of urinary PCA3-based nomograms to individually predict prostate biopsy outcome. Eur Urol; 2010 Nov;58(5):727-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] External validation of urinary PCA3-based nomograms to individually predict prostate biopsy outcome.
  • OBJECTIVE: To assess accuracy and generalizability of previously reported, internally validated, prebiopsy prostate cancer antigen 3 (PCA3) gene-based nomograms when applied to a large, external, European cohort of men at risk of prostate cancer (PCa).
  • INTERVENTION: All patients underwent a ≥10-core prostate biopsy.
  • Biopsy indication was based on suspicious digital rectal examination, persistently elevated prostate-specific antigen level (2.5-10 ng/ml) and/or suspicious histology (atypical small acinar proliferation of the prostate, >/= two cores affected by high-grade prostatic intraepithelial neoplasia in first set of biopsies).
  • MEASUREMENTS: PCA3 scores were assessed using the Progensa assay (Gen-Probe Inc, San Diego, CA, USA).
  • Consequently, in presence of a PCA3 score, these nomograms may be safely used to assist clinicians when prostate biopsy is contemplated.
  • [MeSH-major] Antigens, Neoplasm / urine. Biomarkers, Tumor / urine. Nomograms. Prostatic Intraepithelial Neoplasia. Prostatic Neoplasms
  • [MeSH-minor] Biopsy. Humans. Male. Predictive Value of Tests. Prostate / pathology. Reproducibility of Results. Risk Factors

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 European Association of Urology. Published by Elsevier B.V. All rights reserved.
  • (PMID = 20619529.001).
  • [ISSN] 1873-7560
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / prostate cancer antigen 3, human
  •  go-up   go-down


62. Barrett KM, Ding YH, Wagner DP, Kallmes DF, Johnston KC, ASAP Investigators: Change in diffusion-weighted imaging infarct volume predicts neurologic outcome at 90 days: results of the Acute Stroke Accurate Prediction (ASAP) trial serial imaging substudy. Stroke; 2009 Jul;40(7):2422-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Change in diffusion-weighted imaging infarct volume predicts neurologic outcome at 90 days: results of the Acute Stroke Accurate Prediction (ASAP) trial serial imaging substudy.
  • METHODS: The prospective Acute Stroke Accurate Prediction (ASAP) Study included a prespecified serial imaging subgroup who underwent DWI studies at baseline (<24 hours after symptom onset) and Day 5 (+/-2 days).
  • Univariate and multivariable regression analysis was performed to assess the relationship between change in DWI lesion volume and excellent neurological outcome (modified Rankin Scale 0, 1, and Barthel Index >or=95).
  • RESULTS: In total, 169 cases from the ASAP study had serial DWI scans with a measurable lesion at baseline, follow-up, or both.

  • MedlinePlus Health Information. consumer health - Stroke.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Stroke. 1999 Nov;30(11):2347-54 [10548669.001]
  • [Cites] Stroke. 2007 Jun;38(6):1820-5 [17446421.001]
  • [Cites] AJNR Am J Neuroradiol. 2000 Sep;21(8):1434-40 [11003275.001]
  • [Cites] Stroke. 2000 Nov;31(11):2597-602 [11062281.001]
  • [Cites] Lancet. 2001 Jun 30;357(9274):2095-9 [11445104.001]
  • [Cites] Neurology. 2002 Nov 12;59(9):1381-7 [12427888.001]
  • [Cites] Stroke. 2004 Jan;35(1):158-62 [14684776.001]
  • [Cites] J Rehabil Res Dev. 2003 Jan-Feb;40(1):1-8 [15150715.001]
  • [Cites] Stroke. 1988 May;19(5):604-7 [3363593.001]
  • [Cites] Ann Neurol. 1995 Feb;37(2):231-41 [7847864.001]
  • [Cites] Stroke. 1995 Mar;26(3):392-8 [7886712.001]
  • [Cites] Stat Med. 1996 Feb 28;15(4):361-87 [8668867.001]
  • [Cites] Ann Neurol. 1997 May;41(5):581-9 [9153519.001]
  • [Cites] Stroke. 1998 Nov;29(11):2268-76 [9804633.001]
  • [Cites] Neurology. 1999 Jul 13;53(1):126-31 [10408548.001]
  • [Cites] Ann Neurol. 1999 Oct;46(4):568-78 [10514093.001]
  • [Cites] Md State Med J. 1965 Feb;14:61-5 [14258950.001]
  • [Cites] Neurology. 2006 Apr 25;66(8):1159-63 [16525124.001]
  • [Cites] Stroke. 2006 Dec;37(12):2951-6 [17082470.001]
  • [Cites] Stroke. 2000 Feb;31(2):448-55 [10657421.001]
  • (PMID = 19443798.001).
  • [ISSN] 1524-4628
  • [Journal-full-title] Stroke; a journal of cerebral circulation
  • [ISO-abbreviation] Stroke
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / K24 NS052141; United States / NINDS NIH HHS / NS / K23 NS002168; United States / NINDS NIH HHS / NS / K23NS02168; United States / NINDS NIH HHS / NS / NS052141-04; United States / NINDS NIH HHS / NS / K24 NS052141-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS145284; NLM/ PMC2772139
  •  go-up   go-down


63. Terry K: Get your NPI asap! Med Econ; 2006 Dec 1;83(23):44-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Get your NPI asap!

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17212333.001).
  • [ISSN] 0025-7206
  • [Journal-full-title] Medical economics
  • [ISO-abbreviation] Med Econ
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Deye DL: CME ASAP. Minn Med; 2010 Nov;93(11):30-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CME ASAP.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21197879.001).
  • [ISSN] 0026-556X
  • [Journal-full-title] Minnesota medicine
  • [ISO-abbreviation] Minn Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Venoux M, Delmouly K, Milhavet O, Vidal-Eychenié S, Giorgi D, Rouquier S: Gene organization, evolution and expression of the microtubule-associated protein ASAP (MAP9). BMC Genomics; 2008;9:406
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene organization, evolution and expression of the microtubule-associated protein ASAP (MAP9).
  • BACKGROUND: ASAP is a newly characterized microtubule-associated protein (MAP) essential for proper cell-cycling.
  • We have previously shown that expression deregulation of human ASAP results in profound defects in mitotic spindle formation and mitotic progression leading to aneuploidy, cytokinesis defects and/or cell death.
  • In the present work we analyze the structure and evolution of the ASAP gene, as well as the domain composition of the encoded protein.
  • RESULTS: Bona fide ASAP orthologs are found in vertebrates with more distantly related potential orthologs in invertebrates.
  • ASAP is composed of approximately 42% alpha helical structures, and two main coiled-coil regions have been identified.
  • As with human ASAP, the mouse and Xenopus proteins localize to the microtubule network in interphase and to the mitotic spindle during mitosis.
  • In situ hybridization in testis localized ASAP to the germ cells, whereas in culture neurons ASAP localized to the cell body and growing neurites.
  • CONCLUSION: The conservation of ASAP indicated in our results reflects an essential function in vertebrates.
  • We have cloned the ASAP orthologs in mouse and Xenopus, two valuable models to study the function of ASAP.
  • Tissue expression of ASAP revealed a high expression in brain and testis, two tissues rich in microtubules.
  • ASAP associates to the mitotic spindle and cytoplasmic microtubules, and represents a key factor of mitosis with possible involvement in other cell cycle processes.
  • Possible involvement in neuron dynamics also highlights ASAP as a candidate target in neurodegenerative diseases.

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • Xenbase. Xenbase .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Dev. 2000 Jun 1;14(11):1332-42 [10837026.001]
  • [Cites] Cell Motil Cytoskeleton. 2000 Aug;46(4):235-46 [10962478.001]
  • [Cites] Annu Rev Biochem. 2000;69:95-114 [10966454.001]
  • [Cites] Annu Rev Biochem. 2000;69:277-302 [10966460.001]
  • [Cites] Nat Rev Neurosci. 2007 May;8(5):368-78 [17453017.001]
  • [Cites] Science. 2007 May 25;316(5828):1160-6 [17525332.001]
  • [Cites] Cell Mol Life Sci. 2007 Aug;64(15):1891-914 [17483873.001]
  • [Cites] Hum Mol Genet. 2008 Jan 15;17(2):215-24 [17925329.001]
  • [Cites] Nat Cell Biol. 2001 Jan;3(1):E28-34 [11146647.001]
  • [Cites] Science. 2001 Oct 19;294(5542):543-7 [11641489.001]
  • [Cites] Hum Mol Genet. 2001 Nov 15;10(24):2813-20 [11734546.001]
  • [Cites] Hum Mol Genet. 2002 Jan 15;11(2):153-63 [11809724.001]
  • [Cites] Trends Cell Biol. 2002 Jan;12(1):21-7 [11854006.001]
  • [Cites] Trends Cell Biol. 2002 Jun;12(6):267-73 [12074886.001]
  • [Cites] Nature. 2000 Sep 7;407(6800):41-7 [10993066.001]
  • [Cites] Nature. 1984 Nov 15-21;312(5991):237-42 [6504138.001]
  • [Cites] Mol Biol Evol. 1987 Jul;4(4):406-25 [3447015.001]
  • [Cites] Cell Motil Cytoskeleton. 1988;10(1-2):185-96 [3180243.001]
  • [Cites] J Cell Biol. 1989 Dec;109(6 Pt 2):3367-76 [2480963.001]
  • [Cites] J Mol Biol. 1990 Oct 5;215(3):403-10 [2231712.001]
  • [Cites] J Biol Chem. 1991 May 25;266(15):9841-6 [2033072.001]
  • [Cites] J Cell Sci. 1991 Jan;98 ( Pt 1):27-36 [1905296.001]
  • [Cites] J Biol Chem. 1991 Nov 15;266(32):21886-96 [1718985.001]
  • [Cites] Biol Reprod. 1992 Jan;46(1):120-9 [1547309.001]
  • [Cites] J Cell Biol. 1993 Feb;120(4):935-45 [8432733.001]
  • [Cites] Nature. 1993 Aug 19;364(6439):717-21 [8355785.001]
  • [Cites] J Cell Sci. 1994 Mar;107 ( Pt 3):661-72 [8006079.001]
  • [Cites] Nucleic Acids Res. 1994 Nov 11;22(22):4673-80 [7984417.001]
  • [Cites] Biol Reprod. 1996 Apr;54(4):896-904 [8924511.001]
  • [Cites] Nature. 1996 Aug 1;382(6590):420-5 [8684481.001]
  • [Cites] J Cell Biol. 1997 Sep 8;138(5):953-6 [9281574.001]
  • [Cites] Annu Rev Cell Dev Biol. 1997;13:83-117 [9442869.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 May 26;95(11):5857-64 [9600884.001]
  • [Cites] Exp Cell Res. 1998 Jul 10;242(1):60-8 [9665802.001]
  • [Cites] J Cell Sci. 1998 Nov;111 ( Pt 21):3167-77 [9763511.001]
  • [Cites] Mol Cell Biol. 1998 Nov;18(11):6653-65 [9774680.001]
  • [Cites] Curr Opin Struct Biol. 1998 Dec;8(6):785-91 [9914260.001]
  • [Cites] Neuron. 1999 Jan;22(1):23-31 [10027286.001]
  • [Cites] Curr Opin Cell Biol. 1999 Feb;11(1):134-41 [10047516.001]
  • [Cites] Bioinformatics. 1999 May;15(5):413-21 [10366661.001]
  • [Cites] J Cell Biol. 1999 Sep 20;146(6):1205-10 [10491385.001]
  • [Cites] Hum Mol Genet. 2005 Aug 1;14(15):2155-65 [15972725.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Aug 9;102(32):11302-7 [16049101.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13813-8 [16174732.001]
  • [Cites] Hum Mol Genet. 2005 Nov 1;14(21):3113-28 [16203747.001]
  • [Cites] Hum Mol Genet. 2005 Oct 15;14 Spec No. 2:R291-300 [16244328.001]
  • [Cites] Nucleic Acids Res. 2006 Jan 1;34(Database issue):D257-60 [16381859.001]
  • [Cites] Stem Cells. 2006 Oct;24(10):2284-91 [16741225.001]
  • [Cites] Biochim Biophys Acta. 2007 Apr;1772(4):457-66 [17158035.001]
  • [Cites] Nat Cell Biol. 2002 Jul;4(7):E177-84 [12105431.001]
  • [Cites] Nat Genet. 2002 Aug;31(4):347-8 [12134148.001]
  • [Cites] Annu Rev Cell Dev Biol. 2002;18:193-219 [12142285.001]
  • [Cites] Development. 2003 May;130(9):1783-94 [12642484.001]
  • [Cites] Genomics. 2003 Apr;81(4):437-41 [12676568.001]
  • [Cites] Nature. 2003 Apr 17;422(6933):753-8 [12700769.001]
  • [Cites] Nat Cell Biol. 2003 Jun;5(6):505-11 [12776127.001]
  • [Cites] J Neuropathol Exp Neurol. 2003 Aug;62(8):878-82 [14503643.001]
  • [Cites] Neuromolecular Med. 2003;4(1-2):37-48 [14528051.001]
  • [Cites] Bioinformatics. 2004 Feb 12;20(3):426-7 [14960472.001]
  • [Cites] FEBS Lett. 2004 May 21;566(1-3):71-6 [15147871.001]
  • [Cites] Clin Genet. 2004 Oct;66(4):341-8 [15355437.001]
  • [Cites] J Cell Biochem. 2004 Oct 1;93(2):242-50 [15368352.001]
  • [Cites] J Cell Biol. 2004 Sep 27;166(7):949-55 [15452138.001]
  • [Cites] J Cell Biol. 1984 Dec;99(6):2287-96 [6501426.001]
  • [Cites] Nat Genet. 1999 Nov;23(3):296-303 [10610178.001]
  • [Cites] Trends Biochem Sci. 2000 Mar;25(3):147-50 [10694887.001]
  • [Cites] Genome Res. 2000 Apr;10(4):577-86 [10779500.001]
  • [Cites] Trends Genet. 2000 Jun;16(6):276-7 [10827456.001]
  • (PMID = 18782428.001).
  • [ISSN] 1471-2164
  • [Journal-full-title] BMC genomics
  • [ISO-abbreviation] BMC Genomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ASAP protein, Xenopus; 0 / DNA, Complementary; 0 / MAP9 protein, human; 0 / Microtubule-Associated Proteins; 0 / Mtap9 protein, mouse; 0 / Xenopus Proteins
  • [Other-IDs] NLM/ PMC2551623
  •  go-up   go-down


66. Sani MU, Karaye KM, Borodo MM: Prevalence and pattern of rheumatic heart disease in the Nigerian savannah: an echocardiographic study. Cardiovasc J Afr; 2007 Sep-Oct;18(5):295-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There is an urgent need to implement the ASAP programme of the Drakensberg declaration to avert this scourge.

  • Genetic Alliance. consumer health - Heart Disease.
  • MedlinePlus Health Information. consumer health - Heart Valve Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Circulation. 1980 Aug;62(2):212-7 [7397962.001]
  • [Cites] Circulation. 1978 Dec;58(6):1072-83 [709763.001]
  • [Cites] J Am Coll Cardiol. 1987 Apr;9(4):952-9 [3558992.001]
  • [Cites] Ann Trop Paediatr. 1987 Mar;7(1):54-8 [2439005.001]
  • [Cites] N Engl J Med. 1988 Feb 4;318(5):280-6 [3336421.001]
  • [Cites] Ann Trop Paediatr. 1991;11(3):233-40 [1719922.001]
  • [Cites] Cardiol Clin. 1992 Feb;10(1):41-57 [1531447.001]
  • [Cites] Curr Opin Cardiol. 1994 May;9(3):389-400 [8049597.001]
  • [Cites] Med J Aust. 1996 Feb 5;164(3):146-9 [8628132.001]
  • [Cites] Trop Doct. 1996 Apr;26(2):67-9 [8685969.001]
  • [Cites] Trop Doct. 1996 Jul;26(3):125-8 [8783957.001]
  • [Cites] Ann Intern Med. 1997 Feb 1;126(3):200-9 [9027270.001]
  • [Cites] Lancet. 1997 Mar 29;349(9056):935-42 [9093263.001]
  • [Cites] Pediatrics. 1998 Jul;102(1 Pt 3):272-4; discussion 288-9 [9719793.001]
  • [Cites] Cent Afr J Med. 1998 Jun;44(6):140-4 [9810393.001]
  • [Cites] East Afr Med J. 1999 Jan;76(1):23-7 [10442143.001]
  • [Cites] Lancet. 2005 Jul 9-15;366(9480):155-68 [16005340.001]
  • [Cites] Lancet Infect Dis. 2005 Nov;5(11):685-94 [16253886.001]
  • [Cites] S Afr Med J. 2006 Mar;96(3 Pt 2):237-9 [16607438.001]
  • [Cites] S Afr Med J. 2006 Mar;96(3 Pt 2):241 [16607440.001]
  • [Cites] S Afr Med J. 2006 Mar;96(3 Pt 2):246 [16610104.001]
  • [Cites] Niger J Med. 2006 Apr-Jun;15(2):132-6 [16805168.001]
  • [Cites] J Am Soc Echocardiogr. 2002 Feb;15(2):167-84 [11836492.001]
  • [Cites] Arch Med Res. 2003 Sep-Oct;34(5):382-7 [14602504.001]
  • [Cites] Circulation. 1973 May;47(5):1022-31 [4267508.001]
  • [Cites] Trop Geogr Med. 1976 Mar;28(1):9-15 [941246.001]
  • [Cites] Trop Geogr Med. 1981 Mar;33(1):8-13 [7245345.001]
  • (PMID = 17957324.001).
  • [ISSN] 1995-1892
  • [Journal-full-title] Cardiovascular journal of Africa
  • [ISO-abbreviation] Cardiovasc J Afr
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] South Africa
  • [Other-IDs] NLM/ PMC3975544
  •  go-up   go-down


67. Bialocerkowski A, Gelding B: Lack of evidence of the effectiveness of primary brachial plexus surgery for infants (under the age of two years) diagnosed with obstetric brachial plexus palsy. Int J Evid Based Healthc; 2006 Dec;4(4):264-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Search strategy  A systematic literature search was performed using 13 databases: TRIP, MEDLINE, CINAHL, Web of Science, Proquest 5000, Evidence Based Medicine Reviews, Expanded Academic ASAP, Meditext, Science Direct, the Physiotherapy Evidence Database, Proquest Digital Dissertations, Open Archives Initiative Search Engine, the Australian Digital Thesis program.
  • Data collection and analysis  Two independent reviewers assessed the eligibility of each study for inclusion into the review, the study design used and its methodological quality.

  • COS Scholar Universe. author profiles.
  • PubMed Health. DARE review .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21631772.001).
  • [ISSN] 1744-1595
  • [Journal-full-title] International journal of evidence-based healthcare
  • [ISO-abbreviation] Int J Evid Based Healthc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


68. Beer KR: Nasal reconstruction using 20 mg/ml cross-linked hyaluronic acid. J Drugs Dermatol; 2006 May;5(5):465-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • According to American Society for Aesthetic Plastic Surgery (ASAPS), 200,924 people had rhinoplasties in 2005.

  • Hazardous Substances Data Bank. HYALURONIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16703786.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 9004-61-9 / Hyaluronic Acid
  •  go-up   go-down


69. Baker DP, Krokos KJ: Development and validation of Aviation Causal Contributors for Error Reporting Systems (ACCERS). Hum Factors; 2007 Apr;49(2):185-99
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: This investigation sought to develop a reliable and valid classification system for identifying and classifying the underlying causes of pilot errors reported under the Aviation Safety Action Program (ASAP).
  • BACKGROUND: ASAP is a voluntary safety program that air carriers may establish to study pilot and crew performance on the line.
  • In ASAP programs, similar to the Aviation Safety Reporting System, pilots self-report incidents by filing a short text description of the event.
  • The reliability and utility of ACCERS was then tested in studies 3a and 3b by having pilots independently classify the primary and secondary causes of ASAP reports.
  • CONCLUSIONS: ACCERS appears to be a useful system for studying human error captured under pilot ASAP reports.
  • Future work should focus on how ACCERS is organized and whether it can be used or modified to classify human error in ASAP programs for other aviation-related job categories such as dispatchers.
  • [MeSH-major] Accidents, Aviation / classification. Aviation / standards. Risk Management / methods. Safety. Task Performance and Analysis
  • [MeSH-minor] Causality. Classification / methods. Factor Analysis, Statistical. Forms and Records Control / methods. Humans. Reproducibility of Results. Research Design

  • MedlinePlus Health Information. consumer health - Safety.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17447662.001).
  • [ISSN] 0018-7208
  • [Journal-full-title] Human factors
  • [ISO-abbreviation] Hum Factors
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Validation Studies
  • [Publication-country] United States
  •  go-up   go-down


70. Bostwick DG, Meiers I: Atypical small acinar proliferation in the prostate: clinical significance in 2006. Arch Pathol Lab Med; 2006 Jul;130(7):952-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical small acinar proliferation in the prostate: clinical significance in 2006.
  • About 2% of contemporary prostate needle biopsy specimens contain collections of small acini that are suspicious for cancer but that fall below the diagnostic threshold and are reported as atypical small acinar proliferation suspicious for but not diagnostic of malignancy.
  • Prostate cancer has been identified in specimens from subsequent biopsies in up to 60% of cases of atypical small acinar proliferation, indicating that this finding is a significant predictor of cancer.
  • Identification of atypical small acinar proliferation warrants repeat biopsy for concurrent or subsequent invasive carcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Precancerous Conditions / pathology. Prostate / pathology. Prostatic Hyperplasia / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Biopsy, Needle. Cell Proliferation. Diagnosis, Differential. Follow-Up Studies. Humans. Male

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16831049.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 32
  •  go-up   go-down


71. Zilberman MV, Karpawich PP: Alternate site atrial pacing in the young: conventional echocardiography and tissue Doppler analysis of the effects on atrial function and ventricular filling. Pacing Clin Electrophysiol; 2007 Jun;30(6):755-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alternate site atrial pacing in the young: conventional echocardiography and tissue Doppler analysis of the effects on atrial function and ventricular filling.
  • BACKGROUND: Although the right atrial appendage (RAA) is typically used for atrial pacing lead implant, recent studies have shown benefits of alternate site atrial pacing (ASAP) in the elderly.
  • METHODS: To investigate effects of ASAP on cardiac function and atrioventricular mechanical interactions in the young, 26 subjects (ages 10 to 23 years) with normal cardiac anatomy, function, and atrioventricular node conduction underwent echocardiography during electrophysiology studies while in sinus rhythm (NSR), and with temporary pacing from high right atrium (HRA), RAA, mid septal right atrium approximating Bachmann's bundle (BB), and left atrium (LA) via the distal coronary sinus (CS).
  • RESULTS: The total and systolic LA ejection fractions were higher during the NSR compared to all ASAP.
  • Mitral inflow velocities changed significantly with ASAP.
  • There were significant changes in late diastolic tissue Doppler velocities during ASAP compared to NSR.
  • The MPI during ASAP differed from those during the NSR.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17547608.001).
  • [ISSN] 0147-8389
  • [Journal-full-title] Pacing and clinical electrophysiology : PACE
  • [ISO-abbreviation] Pacing Clin Electrophysiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Bosio A, De Maria C, Bisconti A, Carchedi M, Buffardi A, Negro C, Petracchini M, Munoz F, Cirillo S, Fontana D: [Re-biopsies of the prostate after endo-magnetic resonancen imaging (MRI) and spectroscopy (MRS) in patients with ASAP: preliminary results]. Urologia; 2009;76 Suppl 15:4-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Re-biopsies of the prostate after endo-magnetic resonancen imaging (MRI) and spectroscopy (MRS) in patients with ASAP: preliminary results].

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21104676.001).
  • [ISSN] 1724-6075
  • [Journal-full-title] Urologia
  • [ISO-abbreviation] Urologia
  • [Language] ita
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. Moussa AS, Kattan MW, Berglund R, Yu C, Fareed K, Jones JS: A nomogram for predicting upgrading in patients with low- and intermediate-grade prostate cancer in the era of extended prostate sampling. BJU Int; 2010 Feb;105(3):352-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A nomogram for predicting upgrading in patients with low- and intermediate-grade prostate cancer in the era of extended prostate sampling.
  • Nomogram predictor variables included age, race, digital rectal examination, prostate-specific antigen (PSA) level, number of cores taken, number of positive cores, maximum percentage cancer in any core, number of previous biopsies, prostate volume, clinical stage, high-grade prostatic intraepithelial neoplasia, atypical small acinar proliferation, inflammation and perineural invasion.
  • CONCLUSIONS: Our nomogram for predicting upgrading provides important additional information for deciding on treatment to both the urologist and the patient with low- and intermediate-grade prostate cancer.
  • [MeSH-major] Nomograms. Prostate / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Biopsy. Digital Rectal Examination. Humans. Male. Middle Aged. Prostate-Specific Antigen / blood. Regression Analysis


74. Flannery RB Jr, Laudani L, Levitre V, Walker AP: Precipitants of psychiatric patient assaults on staff: three-year empirical inquiry of the Assaulted Staff Action Program (ASAP). Int J Emerg Ment Health; 2006;8(1):15-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Precipitants of psychiatric patient assaults on staff: three-year empirical inquiry of the Assaulted Staff Action Program (ASAP).
  • Patient violence toward health care staff is a complex function of person x event x environment model.
  • Thirty-five years of research on the characteristics of patient assailants and staff victims has yielded no predictive markers and researchers are examining other possible components of the model.
  • Although research to date has been sparse, acute psychosis, excessive sensory stimulation, and staff restrictions on patient behaviors (denial of services, privileges, etc.) appear to be common precipitants.
  • No statistically significant interactions were obtained for patient / staff victim variables and these precipitants.
  • [MeSH-major] Health Personnel. Mental Disorders / psychology. Patients / psychology. Professional-Patient Relations. Program Development. Violence

  • MedlinePlus Health Information. consumer health - Child Mental Health.
  • MedlinePlus Health Information. consumer health - Mental Disorders.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16573249.001).
  • [ISSN] 1522-4821
  • [Journal-full-title] International journal of emergency mental health
  • [ISO-abbreviation] Int J Emerg Ment Health
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Ryu JH, Kim YB, Lee JK, Kim YJ, Jung TY: Predictive factors of prostate cancer at repeat biopsy in patients with an initial diagnosis of atypical small acinar proliferation of the prostate. Korean J Urol; 2010 Nov;51(11):752-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictive factors of prostate cancer at repeat biopsy in patients with an initial diagnosis of atypical small acinar proliferation of the prostate.
  • PURPOSE: The factors that predict prostate cancer detection on repeat biopsy were evaluated in patients with atypical small acinar proliferation (ASAP) on the initial biopsy.
  • MATERIALS AND METHODS: From 2003 to 2008, 3,130 men with suspected prostate cancer underwent a prostate needle biopsy, and 244 (7.8%) were diagnosed as having ASAP.
  • They were classified into a prostate cancer group and a noncancer group according to the final pathological diagnosis.
  • The database of rebiopsied patients included age, initial prostate-specific antigen (PSA), PSA density (PSAD), PSA velocity (PSAV), total prostate volume (TPV), and transitional zone volume of the prostate (TZV).
  • RESULTS: A total of 57 patients (33.5%) with ASAP were ultimately shown to have prostate cancer.
  • Univariate analysis showed that PSAD (p=0.002), PSAV (p=0.001), TPV (p=0.035), and TZV (p=0.005) differed significantly between the cancer and noncancer groups.
  • The results of the multivariate analysis showed that PSAD (p=0.022), PSAV (p<0.001), and TPV (p=0.037) had a statistically significant correlation with cancer detection.
  • CONCLUSIONS: PSAD, PSAV, and TPV are predictive factors of prostate cancer in patients with an initial diagnosis of ASAP of the prostate.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21165194.001).
  • [ISSN] 2005-6745
  • [Journal-full-title] Korean journal of urology
  • [ISO-abbreviation] Korean J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2991571
  • [Keywords] NOTNLM ; Diagnosis / Needle biopsy / Prostatic neoplasms
  •  go-up   go-down


76. van der Post L, Mulder CL, Bernardt CM, Schoevers RA, Beekman AT, Dekker J: Involuntary admission of emergency psychiatric patients: report from the Amsterdam Study of Acute Psychiatry. Psychiatr Serv; 2009 Nov;60(11):1543-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: This brief report presents initial data from the Amsterdam Study of Acute Psychiatry (ASAP-I) about factors associated with the decision to admit patients compulsorily (involuntarily) to emergency psychiatric services in the Amsterdam region of the Netherlands.

  • MedlinePlus Health Information. consumer health - Mental Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19880477.001).
  • [ISSN] 1557-9700
  • [Journal-full-title] Psychiatric services (Washington, D.C.)
  • [ISO-abbreviation] Psychiatr Serv
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


77. Pavlakis K, Stravodimos K, Kapetanakis T, Gregorakis A, Athanassiadou S, Tzaida O, Constantinides C: Evaluation of routine application of P504S, 34betaE12 and p63 immunostaining on 250 prostate needle biopsy specimens. Int Urol Nephrol; 2010 Jun;42(2):325-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of routine application of P504S, 34betaE12 and p63 immunostaining on 250 prostate needle biopsy specimens.
  • BACKGROUND: We aimed to determine whether a standard P504S, 34betaE12 and p63 immunostaining of prostate core needle biopsy specimens can optimize diagnostic accuracy of conventional staining methods.
  • MATERIALS AND METHODS: The staining properties of all three antibodies were evaluated on 250 prostate biopsies formerly diagnosed as benign.
  • With the aid of P504S positivity, a case of prostate cancer as well as another of atypical small acinar proliferation was discovered.
  • CONCLUSION: Despite its potential for important aid in accurate diagnosis, standard application of immunohistochemistry in prostate biopsy is not justified and should be reserved for equivocal cases where conventional pathology fails to be conclusive.
  • [MeSH-major] Keratins / analysis. Membrane Proteins / analysis. Prostate / chemistry. Prostate / pathology. Prostatic Neoplasms / chemistry. Prostatic Neoplasms / pathology. Racemases and Epimerases / analysis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BJU Int. 2006 May;97(5):1109-15 [16643500.001]
  • [Cites] Urology. 1999 Feb;53(2):351-5 [9933053.001]
  • [Cites] Am J Clin Pathol. 2007 Feb;127(2):248-53 [17210521.001]
  • [Cites] Am J Surg Pathol. 1997 Dec;21(12):1489-95 [9414193.001]
  • [Cites] Am J Surg Pathol. 2002 Sep;26(9):1161-8 [12218572.001]
  • [Cites] Am J Pathol. 1984 Feb;114(2):309-21 [6320650.001]
  • [Cites] Am J Clin Pathol. 2004 Feb;121(2):220-5 [14983935.001]
  • [Cites] Arch Pathol Lab Med. 2000 Dec;124(12):1764-7 [11100054.001]
  • [Cites] Am J Surg Pathol. 2002 Jul;26(7):921-5 [12131160.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2004 Mar;12(1):75-8 [15163024.001]
  • [Cites] Am J Surg Pathol. 2005 May;29(5):579-87 [15832080.001]
  • [Cites] Am J Clin Pathol. 2005 Feb;123(2):231-6 [15842047.001]
  • [Cites] Mod Pathol. 1999 May;12(5):472-8 [10349984.001]
  • [Cites] Am J Surg Pathol. 2004 Jun;28(6):701-5 [15166661.001]
  • [Cites] Am J Clin Pathol. 2004 Oct;122(4):517-23 [15487448.001]
  • [Cites] Am J Surg Pathol. 1998 Oct;22(10):1239-46 [9777986.001]
  • (PMID = 19655267.001).
  • [ISSN] 1573-2584
  • [Journal-full-title] International urology and nephrology
  • [ISO-abbreviation] Int Urol Nephrol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / CK-34 beta E12; 0 / CKAP4 protein, human; 0 / Membrane Proteins; 68238-35-7 / Keratins; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


78. Jiang S, Crogan-Grundy C, Drewe J, Tseng B, Cai SX: Discovery of (naphthalen-4-yl)(phenyl)methanones and N-methyl-N-phenylnaphthalen-1-amines as new apoptosis inducers using a cell- and caspase-based HTS assay. Bioorg Med Chem Lett; 2008 Nov 1;18(21):5725-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report the discovery of a series of (naphthalen-4-yl)(phenyl)methanones as potent inducers of apoptosis using our proprietary cell- and caspase-based ASAP HTS assay.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18849165.001).
  • [ISSN] 1464-3405
  • [Journal-full-title] Bioorganic & medicinal chemistry letters
  • [ISO-abbreviation] Bioorg. Med. Chem. Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Naphthalenes; EC 3.4.22.- / Caspases
  •  go-up   go-down


79. Cautin RL: The Founding of the Association for Psychological Science: Part 2. The Tipping Point and Early Years. Perspect Psychol Sci; 2009 May;4(3):224-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In 1987, the Assembly for Scientific and Applied Psychologists (ASAP) formed to encourage APA reorganization, and in early 1988, the APA Council approved a reorganization plan; that plan was, however, rejected by the membership.
  • In August 1988, the ASAP became the APS.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2009 Association for Psychological Science.
  • (PMID = 26158960.001).
  • [ISSN] 1745-6916
  • [Journal-full-title] Perspectives on psychological science : a journal of the Association for Psychological Science
  • [ISO-abbreviation] Perspect Psychol Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Montironi R, Vela Navarrete R, Lopez-Beltran A, Mazzucchelli R, Mikuz G, Bono AV: Histopathology reporting of prostate needle biopsies. 2005 update. Virchows Arch; 2006 Jul;449(1):1-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histopathology reporting of prostate needle biopsies. 2005 update.
  • This report reviews the diagnostic and prognostic importance of the pathologic findings in prostate needle biopsies.
  • The morphological findings of the needle biopsy may be placed into one of the following five categories: prostate cancer, atypical small acinar proliferation, high-grade prostatic intraepithelial neoplasia, inflammation, and benign prostatic tissue.
  • While the prime goal of the biopsy is to diagnose prostatic adenocarcinoma, once carcinoma is detected, further descriptive information regarding the type, amount of cancer, and grade forms the cornerstone for contemporary management of the patient and for assessment of the potential for local cure and the risk for distant metastasis.
  • [MeSH-major] Adenocarcinoma / pathology. Biopsy, Needle / trends. Prostate / pathology. Prostatic Intraepithelial Neoplasia / pathology. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur Urol. 2000 Apr;37(4):404-12 [10765070.001]
  • [Cites] Cancer Res. 2000 Mar 15;60(6):1677-82 [10749139.001]
  • [Cites] Arch Pathol Lab Med. 1995 May;119(5):444-7 [7748073.001]
  • [Cites] Hum Pathol. 1995 Aug;26(8):887-91 [7543443.001]
  • [Cites] Scand J Urol Nephrol Suppl. 2005 May;(216):82-93 [16019760.001]
  • [Cites] BJU Int. 2006 Mar;97(3):492-7 [16469014.001]
  • [Cites] Am J Surg Pathol. 2002 Dec;26(12):1588-96 [12459625.001]
  • [Cites] J Urol. 2002 Jun;167(6):2440-2 [11992053.001]
  • [Cites] J Urol. 2002 Feb;167(2 Pt 1):516-20 [11792909.001]
  • [Cites] Hum Pathol. 2001 Aug;32(8):828-33 [11521227.001]
  • [Cites] J Urol. 2003 Oct;170(4 Pt 1):1203-8 [14501725.001]
  • [Cites] Cytometry. 1993;14(5):497-500 [8354122.001]
  • [Cites] Am J Surg Pathol. 1989 May;13(5):389-96 [2469333.001]
  • [Cites] Mod Pathol. 1998 Jun;11(6):543-51 [9647592.001]
  • [Cites] Am J Surg Pathol. 2004 May;28(5):629-33 [15105651.001]
  • [Cites] Mod Pathol. 2004 Mar;17(3):307-15 [14739905.001]
  • [Cites] Am J Surg Pathol. 1997 Dec;21(12):1489-95 [9414193.001]
  • [Cites] Urology. 2004 Jun;63(6):1105-10 [15183961.001]
  • [Cites] Urol Clin North Am. 1993 Nov;20(4):589-95 [8273267.001]
  • [Cites] BJU Int. 2005 Jun;95(8):1146-52 [15877724.001]
  • [Cites] Am J Clin Pathol. 2002 Sep;118(3):442-50 [12219787.001]
  • [Cites] Am J Surg Pathol. 2002 Sep;26(9):1169-74 [12218573.001]
  • [Cites] Cancer. 1987 Feb 15;59(4):788-94 [2433020.001]
  • [Cites] J Surg Oncol. 1996 Sep;63(1):41-5 [8841465.001]
  • [Cites] Am J Surg Pathol. 2005 Sep;29(9):1228-42 [16096414.001]
  • [Cites] Am J Surg Pathol. 2002 Sep;26(9):1161-8 [12218572.001]
  • [Cites] Pathology. 2003 Dec;35(6):472-9 [14660096.001]
  • [Cites] Pathol Res Pract. 1995 Sep;191(9):838-41 [8606862.001]
  • [Cites] Hum Pathol. 1998 Apr;29(4):424-5 [9563798.001]
  • [Cites] Scand J Urol Nephrol Suppl. 2005 May;(216):20-33 [16019757.001]
  • [Cites] Cancer. 2003 Apr 15;97(8):1884-93 [12673714.001]
  • [Cites] Cancer. 2003 Dec 1;98(11):2344-50 [14635068.001]
  • [Cites] J Urol. 2004 Mar;171(3):1093-7 [14767278.001]
  • [Cites] Cancer. 1991 Jun 15;67(12 ):2949-58 [1710531.001]
  • [Cites] Urology. 2003 Mar;61(3):589-95 [12639653.001]
  • [Cites] J Urol. 2004 Mar;171(3):1122-7 [14767284.001]
  • [Cites] Cancer. 1990 Aug 15;66(4):752-7 [2386903.001]
  • [Cites] Am J Clin Pathol. 1994 Mar;101(3):266-8 [8135180.001]
  • [Cites] Mod Pathol. 2000 Nov;13(11):1186-91 [11106075.001]
  • [Cites] J Urol. 2002 Nov;168(5):1994-9 [12394693.001]
  • [Cites] Am J Clin Pathol. 2001 Dec;116(6):823-30 [11764070.001]
  • [Cites] Am J Surg Pathol. 2002 Sep;26(9):1151-60 [12218571.001]
  • [Cites] Eur Urol. 1993;23 Suppl 2:64-76 [7685705.001]
  • [Cites] J Urol. 1995 Nov;154(5):1791-4 [7563348.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Jan 1;58(1):19-24 [14697416.001]
  • [Cites] Hum Pathol. 2001 Jan;32(1):74-80 [11172298.001]
  • [Cites] BMJ. 2001 Feb 17;322(7283):378-9 [11179143.001]
  • [Cites] Am J Surg Pathol. 2002 Jul;26(7):926-31 [12131161.001]
  • [Cites] Urology. 2005 Mar;65(3):538-42 [15780372.001]
  • [Cites] J Urol. 2003 Jun;169(6):2136-41 [12771735.001]
  • [Cites] Urol Int. 2003;70(4):297-302 [12740495.001]
  • [Cites] Am J Clin Pathol. 1994 Oct;102(4 Suppl 1):S31-7 [7524305.001]
  • [Cites] Scand J Urol Nephrol Suppl. 2005 May;(216):8-19 [16019756.001]
  • [Cites] Urology. 1999 Apr;53(4):752-6 [10197851.001]
  • [Cites] Prostate. 1996 Aug;29(2):117-34 [8700801.001]
  • [Cites] Am J Surg Pathol. 2002 Jul;26(7):921-5 [12131160.001]
  • [Cites] Am J Pathol. 1997 May;150(5):1511-21 [9137077.001]
  • [Cites] J Urol. 2001 Aug;166(2):402-10 [11458037.001]
  • [Cites] Arch Pathol Lab Med. 1995 Nov;119(11):1050-4 [7487406.001]
  • [Cites] Eur Urol. 2004 Aug;46(2):177-81 [15245810.001]
  • [Cites] J Urol. 2003 Nov;170(5):1792-7 [14532778.001]
  • [Cites] Am J Surg Pathol. 2000 Apr;24(4):477-8 [10757394.001]
  • [Cites] Am J Surg Pathol. 2001 Aug;25(8):1079-85 [11474294.001]
  • [Cites] Pathol Res Pract. 1993 Jun;189(5):542-8 [7690954.001]
  • [Cites] Urology. 1996 Jul;48(1):47-57 [8693651.001]
  • [Cites] Arch Ital Urol Androl. 2005 Mar;77(1):31-6 [15906787.001]
  • [Cites] Am J Surg Pathol. 2001 Nov;25(11):1397-404 [11684956.001]
  • [Cites] J Urol. 1997 Apr;157(4):1301-3 [9120926.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jul 15;41(5):1087-92 [9719119.001]
  • [Cites] Cancer. 2001 Jun 1;91(11):2196-204 [11391602.001]
  • [Cites] Hum Pathol. 1993 Nov;24(11):1159-67 [8244315.001]
  • [Cites] Scand J Urol Nephrol Suppl. 2005 May;(216):94-110 [16019761.001]
  • [Cites] Urology. 1997 Jun;49(6):857-62 [9187691.001]
  • [Cites] Am J Clin Pathol. 1999 Feb;111(2):223-8 [9930144.001]
  • (PMID = 16633784.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Germany
  • [Number-of-references] 81
  •  go-up   go-down


81. Flury SC, Galgano MT, Mills SE, Smolkin ME, Theodorescu D: Atypical small acinar proliferation: biopsy artefact or distinct pathological entity? BJU Int; 2007 Apr;99(4):780-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical small acinar proliferation: biopsy artefact or distinct pathological entity?
  • OBJECTIVE: To determine if atypical small acinar proliferation (ASAP) represents minimally sampled prostate cancer not fully evaluated on a biopsy or a distinct pathological entity, by examining prostates removed at radical cystectomy, as a finding of ASAP of the prostate on needle-core biopsy is closely associated with the detection of cancer on subsequent biopsy.
  • PATIENTS AND METHODS: In all, 65 consecutive cystoprostatectomy specimens taken from June 1990 to March 2004 had prostatic material reviewed by one genitourinary pathologist (S.E.M.).
  • The presence of high-grade prostatic intraepithelial neoplasia (HGPIN), ASAP, and adenocarcinoma was recorded.
  • Foci of ASAP found in the absence of cancer were assessed with additional sectioning, high-molecular weight keratin (CK903), and alpha-methylacyl coenzyme A racemase (AMACR) immunohistochemistry.
  • Of the 41 without cancer, 18 (44%) had neither HGPIN nor ASAP, 14 (34%) had HGPIN alone, three (7%) had ASAP alone (four foci), and six had both HGPIN and ASAP (15%).
  • Two foci of ASAP were not present on any further sectioning.
  • CONCLUSION: ASAP identified in incidental prostates represented marginally sampled cancer in at least two of 10 foci assessed.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Acinar Cell / pathology. Prostatic Intraepithelial Neoplasia / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy, Needle. Cell Proliferation. Cystectomy / methods. Humans. Immunohistochemistry. Male. Middle Aged. Predictive Value of Tests. Prostate / pathology. Prostatectomy / methods

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17378841.001).
  • [ISSN] 1464-4096
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


82. Crowley CM, Doyle J, Towler MR, Rushe N, Hampshire S: Influence of acid washing on the surface morphology of ionomer glasses and handling properties of glass ionomer cements. J Mater Sci Mater Med; 2007 Aug;18(8):1497-506
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The influence of acid washing on the particle size distribution and surface area of four glasses was examined by scanning electron microscopy (SEM), particle size analysis (PSA) and accelerated surface area porosimetry (ASAP) and the working and setting times of cements, produced from the glasses, correlated to changes in surface morphology.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Mater. 1991;7(4):325-31 [10149145.001]
  • [Cites] Biomaterials. 1998 Mar;19(6):467-78 [9645552.001]
  • [Cites] Dent Mater. 1996 Jan;12 (1):25-9 [8598247.001]
  • [Cites] J Dent Res. 1988 Dec;67(12 ):1446-50 [3198840.001]
  • [Cites] Ann N Y Acad Sci. 1988;523:54-71 [2837945.001]
  • [Cites] J Oral Rehabil. 2004 Apr;31(4):373-8 [15089945.001]
  • [Cites] J Dent Res. 1976 Nov-Dec;55(6):1023-31 [187629.001]
  • [Cites] Dent Mater. 1996 Mar;12(2):88-95 [9002849.001]
  • [Cites] Biomaterials. 2000 Feb;21(4):399-403 [10656322.001]
  • [Cites] J Dent Res. 1999 Jan;78(1):86-90 [10065950.001]
  • [Cites] Biomaterials. 2003 Oct;24(23):4173-9 [12853247.001]
  • [Cites] Biomaterials. 1994 Mar;15(4):299-306 [8031991.001]
  • [Cites] Biomaterials. 1998 Mar;19(6):485-94 [9645554.001]
  • [Cites] Biomaterials. 1985 Nov;6(6):378-82 [3910125.001]
  • [Cites] J Dent Res. 2001 Aug;80(8):1764-7 [11669490.001]
  • [Cites] Dent Mater. 2005 Jun;21(6):505-10 [15904692.001]
  • [Cites] J Dent Res. 1996 Dec;75(12):1920-7 [9033445.001]
  • [Cites] Br Dent J. 1992 Nov 7;173(8):275-7 [1449858.001]
  • [Cites] J Prosthet Dent. 2003 May;89(5):466-73 [12806324.001]
  • [Cites] J Dent Res. 1999 Jul;78(7):1312-8 [10403458.001]
  • [Cites] J Dent Res. 1998 Dec;77(12 ):2005-11 [9839789.001]
  • [Cites] Clin Mater. 1993;12(2):113-5 [10148339.001]
  • [Cites] Dent Mater. 2003 Dec;19(8):747-57 [14511733.001]
  • [Cites] Biomaterials. 2004 Aug;25(17):3907-13 [15020167.001]
  • [Cites] J Dent Res. 1990 May;69(5):1175-9 [2335651.001]
  • [Cites] Biomaterials. 2000 Apr;21(7):693-8 [10711966.001]
  • (PMID = 17387590.001).
  • [ISSN] 0957-4530
  • [Journal-full-title] Journal of materials science. Materials in medicine
  • [ISO-abbreviation] J Mater Sci Mater Med
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Acids; 0 / Biocompatible Materials; 0 / Glass Ionomer Cements
  •  go-up   go-down


83. Kim N, Alekseyenko AV, Roy M, Lee C: The ASAP II database: analysis and comparative genomics of alternative splicing in 15 animal species. Nucleic Acids Res; 2007 Jan;35(Database issue):D93-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The ASAP II database: analysis and comparative genomics of alternative splicing in 15 animal species.
  • We have greatly expanded the Alternative Splicing Annotation Project (ASAP) database: (i) its human alternative splicing data are expanded approximately 3-fold over the previous ASAP database, to nearly 90,000 distinct alternative splicing events;.
  • ASAP II provides a new web interface enabling more detailed exploration of the data, and integrating comparative genomics information with alternative splicing data.
  • We provide a set of tools for advanced data-mining of ASAP II with Pygr (the Python Graph Database Framework for Bioinformatics) including powerful features such as graph query, multigenome alignment query, etc.
  • ASAP II is available at http://www.bioinformatics.ucla.edu/ASAP2.

  • COS Scholar Universe. author profiles.
  • SciCrunch. SciCrunch Registry: Resource: Registry .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nucleic Acids Res. 2003 Oct 1;31(19):5635-43 [14500827.001]
  • [Cites] Nat Genet. 2003 Jun;34(2):177-80 [12730695.001]
  • [Cites] FEBS Lett. 2003 Dec 18;555(3):572-8 [14675776.001]
  • [Cites] Science. 2003 Dec 19;302(5653):2141-4 [14684825.001]
  • [Cites] Nucleic Acids Res. 2004;32(4):1261-9 [14982953.001]
  • [Cites] Genome Res. 2004 Mar;14(3):426-41 [14962984.001]
  • [Cites] Genome Res. 2004 Apr;14(4):708-15 [15060014.001]
  • [Cites] J Mol Med (Berl). 1997 Oct;75(10):694-8 [9382993.001]
  • [Cites] Nucleic Acids Res. 2004;32(22):e180 [15598820.001]
  • [Cites] BMC Bioinformatics. 2004 Dec 7;5:189 [15581431.001]
  • [Cites] Nucleic Acids Res. 2005 Jan 1;33(Database issue):D501-4 [15608248.001]
  • [Cites] Nucleic Acids Res. 2005 Jan 1;33(Database issue):D54-8 [15608257.001]
  • [Cites] Nucleic Acids Res. 2005 Jan 1;33(Database issue):D75-9 [15608289.001]
  • [Cites] Nucleic Acids Res. 2006 Jan 1;34(Database issue):D556-61 [16381931.001]
  • [Cites] Genome Res. 2005 Apr;15(4):566-76 [15805497.001]
  • [Cites] Bioinformatics. 2005 Apr 15;21(8):1358-64 [15673565.001]
  • [Cites] IDrugs. 2005 Sep;8(9):725-9 [16118693.001]
  • [Cites] Nucleic Acids Res. 2005;33(16):5026-33 [16147986.001]
  • [Cites] Mol Biol Evol. 2005 Nov;22(11):2198-208 [16049198.001]
  • [Cites] Nucleic Acids Res. 2006 Jan 1;34(Database issue):D16-20 [16381837.001]
  • [Cites] Nucleic Acids Res. 2006 Jan 1;34(Database issue):D590-8 [16381938.001]
  • [Cites] Nucleic Acids Res. 2006 Jan 1;34(Database issue):D56-62 [16381932.001]
  • [Cites] Nucleic Acids Res. 2006 Jan 1;34(Database issue):D46-55 [16381912.001]
  • [Cites] PLoS Genet. 2005 Sep;1(3):e34 [16170410.001]
  • [Cites] Mol Biol Evol. 2006 Mar;23(3):675-82 [16368777.001]
  • [Cites] Genetics. 2006 Jul;173(3):1787-91 [16702427.001]
  • [Cites] Trends Genet. 2001 Feb;17(2):100-7 [11173120.001]
  • [Cites] Nucleic Acids Res. 2001 Jul 1;29(13):2850-9 [11433032.001]
  • [Cites] Trends Genet. 2002 Apr;18(4):186-93 [11932019.001]
  • [Cites] Nature. 2002 Jul 11;418(6894):236-43 [12110900.001]
  • [Cites] Nucleic Acids Res. 2002 Sep 1;30(17):3754-66 [12202761.001]
  • [Cites] Genome Res. 2002 Dec;12(12):1837-45 [12466287.001]
  • [Cites] Nucleic Acids Res. 2003 Jan 1;31(1):101-5 [12519958.001]
  • [Cites] Annu Rev Biochem. 2003;72:291-336 [12626338.001]
  • (PMID = 17108355.001).
  • [ISSN] 1362-4962
  • [Journal-full-title] Nucleic acids research
  • [ISO-abbreviation] Nucleic Acids Res.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / U54 RR021813
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA Splice Sites
  • [Other-IDs] NLM/ PMC1669709
  •  go-up   go-down


84. Iczkowski KA: Current prostate biopsy interpretation: criteria for cancer, atypical small acinar proliferation, high-grade prostatic intraepithelial neoplasia, and use of immunostains. Arch Pathol Lab Med; 2006 Jun;130(6):835-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current prostate biopsy interpretation: criteria for cancer, atypical small acinar proliferation, high-grade prostatic intraepithelial neoplasia, and use of immunostains.
  • CONTEXT: The past decade has brought major changes in prostate biopsy sampling, interpretation, and reporting.
  • OBJECTIVE: To summarize current information on diagnostic decision making, Gleason grading, "atypical" diagnoses, and use of immunostaining.
  • CONCLUSIONS: Diagnosis begins by evaluating a focus of atypical single-cell layer lined acini according to the 3 minimal diagnostic criteria for cancer: an infiltrative pattern, nuclear enlargement and hyperchromasia, and prominent nucleoli.
  • Atypical small acinar proliferation suspicious for malignancy designates foci that have either qualitative or quantitative limitations in atypia precluding a definite cancer diagnosis.
  • Isolated high-grade prostatic intraepithelial neoplasia has a 3% to 14% incidence and predicts cancer on repeat biopsy in 23% of cases.
  • Immunostaining for a marker of benign prostate (cytoplasmic keratin 34betaE12 or nuclear p63) and a marker of cancer (alpha-methylacyl coA racemase, clone P504S) may or may not resolve atypical small acinar proliferation diagnoses.
  • Performance of 34betaE12 and P504S immunostains resolved 76% of atypical small acinar proliferation diagnoses per consensus of 3 urologic pathologists studied; a technical limitation is preservation of the focus in question on the levels used for immunostaining.
  • [MeSH-major] Immunohistochemistry / methods. Precancerous Conditions / pathology. Prostate / pathology. Prostatic Intraepithelial Neoplasia / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Biomarkers, Tumor / analysis. Biopsy, Needle. Cell Nucleus / pathology. Cell Proliferation. Humans. Male

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16740037.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 58
  •  go-up   go-down


85. Petucci C, Diffendal J: Atmospheric solids analysis probe: a rapid ionization technique for small molecule drugs. J Mass Spectrom; 2008 Nov;43(11):1565-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atmospheric solids analysis probe: a rapid ionization technique for small molecule drugs.
  • [MeSH-major] Electrodes. Pharmaceutical Preparations / analysis. Specimen Handling / instrumentation. Spectrometry, Mass, Electrospray Ionization / instrumentation. Transducers
  • [MeSH-minor] Atmospheric Pressure. Equipment Design. Equipment Failure Analysis. Molecular Weight. Powders

  • MedlinePlus Health Information. consumer health - Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18470958.001).
  • [ISSN] 1076-5174
  • [Journal-full-title] Journal of mass spectrometry : JMS
  • [ISO-abbreviation] J Mass Spectrom
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Pharmaceutical Preparations; 0 / Powders
  •  go-up   go-down


86. Dong J, Dai WD, Fang TL, Lin H, Uemura T: [Osteoblastic differentiation and in vivo osteogenic activity of marrow-derived mesenchymal stem cells stimulated by Tacrolimus: experiment with rats]. Zhonghua Yi Xue Za Zhi; 2007 Jan 16;87(3):190-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Some MSCs were cultured with L-ascorbic acid-2-phosphate (AsAP) and beta-glycerophosphate (beta-GP) or FK506 plus AsAP and beta-GP.
  • Multiparous beta-tricalcium phosphate (beta-TCP) ceramic cubes were dipped into 2 kinds of suspension of MSCs, treated by FK506 + AsAP + beta-GP or AsAP + beta-GP, so as to produce 48 pieces of MSCs/beta-TCP complex that were randomly divided into 2 equal groups to be cultured with AsAP + beta-GP or AsAP + beta-GP + FK506 for 4 weeks.
  • RESULTS: In vitro assays showed that the APase activity, calcium deposition, expression of osteocalcin mRNA of the FK506 + AsAP + beta-GP group at any time points were all significantly higher than those of the AsAP + beta-GP group (all P < 0.05).
  • SEM showed that since the 16th day after culture calcified nodules began to be seen in the FK506 + AsAP + beta-GP group.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17425851.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 0 / RNA, Messenger; 104982-03-8 / Osteocalcin; EC 3.1.3.1 / Alkaline Phosphatase; WM0HAQ4WNM / Tacrolimus
  •  go-up   go-down


87. McFarland BH, Gabriel RM, Bigelow DA, Walker RD: Organization and financing of alcohol and substance abuse programs for American Indians and Alaska Natives. Am J Public Health; 2006 Aug;96(8):1469-77
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Organization and financing of alcohol and substance abuse programs for American Indians and Alaska Natives.
  • OBJECTIVES: Although American Indians and Alaska Natives have high rates of substance abuse, few data about treatment services for this population are available.
  • METHODS: Using data from the Indian Health Service (IHS), the Substance Abuse and Mental Health Services Administration, the National Institute on Alcohol Abuse and Alcoholism, the Henry J.
  • Kaiser Family Foundation, and the Census Bureau, we estimated the number of American Indians served by substance abuse treatment programs that apparently are unaffiliated with either the IHS or tribal governments.
  • RESULTS: Half of the American Indians and Alaska Natives treated for substance abuse were served by programs (chiefly in urban areas) apparently unaffiliated with the IHS or tribal governments.
  • IHS substance abuse expenditures were roughly what we expected.
  • Medicaid participation by tribal programs was not universal.
  • CONCLUSIONS: Many Native people with substance abuse problems are served by programs unaffiliated with the IHS.

  • MedlinePlus Health Information. consumer health - Drug Abuse.
  • MedlinePlus Health Information. consumer health - Drugs and Young People.
  • MedlinePlus Health Information. consumer health - Native American Health.
  • MedlinePlus Health Information. consumer health - Opioid Abuse and Addiction.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Drug Alcohol Depend. 2004 Jun 11;74(3):223-34 [15194200.001]
  • [Cites] Am J Public Health. 2004 Jan;94(1):53-9 [14713698.001]
  • [Cites] Am J Public Health. 2000 Mar;90(3):344-51 [10705850.001]
  • [Cites] Am J Med Qual. 2000 Jul-Aug;15(4):148-56 [10948787.001]
  • [Cites] J Addict Dis. 2000;19(3):13-34 [11076117.001]
  • [Cites] Am J Public Health. 2000 Nov;90(11):1720-3 [11076238.001]
  • [Cites] Psychiatr Serv. 2001 Jan;52(1):68-74 [11141531.001]
  • [Cites] J Psychoactive Drugs. 2002 Jan-Mar;34(1):1-6 [12003107.001]
  • [Cites] Psychiatr Serv. 2002 Jul;53(7):802 [12096160.001]
  • [Cites] J Addict Dis. 2003;22(2):15-29 [12703666.001]
  • [Cites] Alcohol Clin Exp Res. 2003 Aug;27(8):1333-6 [12966333.001]
  • [Cites] J Stud Alcohol Suppl. 1981 Jan;9:143-58 [7012345.001]
  • [Cites] Public Health Rep. 1988 Nov-Dec;103(6):611-20 [3141955.001]
  • [Cites] J Subst Abuse Treat. 1992;9(2):93-102 [1512807.001]
  • [Cites] West J Med. 1992 Sep;157(3):281-5 [1413770.001]
  • [Cites] Addiction. 1993 Mar;88(3):315-35 [8461850.001]
  • [Cites] Am J Health Promot. 1995 Mar-Apr;9(4):288-99 [10150732.001]
  • [Cites] J Subst Abuse. 1995;7(1):1-8 [7655307.001]
  • [Cites] J Subst Abuse. 1995;7(1):135-50 [7655309.001]
  • [Cites] J Subst Abuse. 1995;7(1):27-42 [7655310.001]
  • [Cites] Am Indian Alsk Native Ment Health Res. 1995;6(3):31-45 [8555352.001]
  • [Cites] J Stud Alcohol. 1995 Nov;56(6):597-610 [8558890.001]
  • [Cites] Lancet. 1996 Jan 27;347(8996):237-40 [8551886.001]
  • [Cites] J Clin Epidemiol. 1996 Apr;49(4):473-82 [8622000.001]
  • [Cites] JAMA. 1996 Jun 19;275(23):1786-8 [8642709.001]
  • [Cites] J Stud Alcohol. 1996 May;57(3):229-43 [8709580.001]
  • [Cites] J Stud Alcohol. 1996 Jan;57(1):65-72 [8747503.001]
  • [Cites] JAMA. 1997 Apr 2;277(13):1039-45 [9091691.001]
  • [Cites] JAMA. 1997 Apr 2;277(13):1079-80 [9091699.001]
  • [Cites] Adm Policy Ment Health. 1997 Jul;24(6):459-74 [9385711.001]
  • [Cites] Med Care Res Rev. 1997 Dec;54(4):490-507 [9437178.001]
  • [Cites] N Engl J Med. 1998 Feb 26;338(9):592-602 [9475768.001]
  • [Cites] Am J Public Health. 1998 Feb;88(2):193-5 [9491006.001]
  • [Cites] J Behav Health Serv Res. 1998 Nov;25(4):377-96 [9796161.001]
  • [Cites] Subst Use Misuse. 1998 Nov;33(13):2605-46 [9818991.001]
  • [Cites] J Subst Abuse Treat. 1999 Jan;16(1):71-80 [9888124.001]
  • [Cites] Am J Public Health. 2005 May;95(5):766-8 [15855449.001]
  • [Cites] J Behav Health Serv Res. 2000 Feb;27(1):17-28 [10695238.001]
  • (PMID = 16809606.001).
  • [ISSN] 1541-0048
  • [Journal-full-title] American journal of public health
  • [ISO-abbreviation] Am J Public Health
  • [Language] ENG
  • [Grant] United States / NIAAA NIH HHS / AA / R21 AA014050; United States / NIAAA NIH HHS / AA / 1R21 AA014050; United States / CSAP SAMHSA HHS / SP / 1U79 SP10346
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1522117
  •  go-up   go-down


88. Sirisoma N, Pervin A, Drewe J, Tseng B, Cai SX: Discovery of substituted N'-(2-oxoindolin-3-ylidene)benzohydrazides as new apoptosis inducers using a cell- and caspase-based HTS assay. Bioorg Med Chem Lett; 2009 May 15;19(10):2710-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report the discovery of a series of substituted N'-(2-oxoindolin-3-ylidene)benzohydrazides as inducers of apoptosis using our proprietary cell- and caspase-based ASAP HTS assay.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19369076.001).
  • [ISSN] 1464-3405
  • [Journal-full-title] Bioorganic & medicinal chemistry letters
  • [ISO-abbreviation] Bioorg. Med. Chem. Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Hydrazines; 0 / N'-(4-bromo-5-methyl-2-oxoindolin-3-ylidene)-3,4,5-trimethoxybenzohydrazide; 0 / Tubulin Modulators; EC 3.4.22.- / Caspases
  •  go-up   go-down


89. Kim KH, Kim YB, Lee JK, Kim YJ, Jung TY: Pathologic results of radical prostatectomies in patients with simultaneous atypical small acinar proliferation and prostate cancer. Korean J Urol; 2010 Jun;51(6):398-402
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathologic results of radical prostatectomies in patients with simultaneous atypical small acinar proliferation and prostate cancer.
  • PURPOSE: The incidence of adenocarcinoma on a subsequent biopsy following a diagnosis of atypical small acinar proliferation (ASAP) ranges from 34% to 60%.
  • We reexamined radical prostatectomy (RP) specimens of patients diagnosed as having synchronous ASAP with prostate cancer (PCa) to evaluate pathological entities and the clinical significance of ASAP.
  • MATERIALS AND METHODS: From January 2007 to December 2008, a total of 118 patients who had been diagnosed with adenocarcinoma on prostate needle biopsy underwent RP.
  • Forty-six of the 118 patients (39%) were diagnosed as having synchronous ASAP with PCa on the prostate needle biopsy.
  • Using whole-mount sections and prostate mapping, we evaluated the RP specimens that were close sections to the ASAP on prostate needle biopsy.
  • RESULTS: Thirty-six of the 46 patients (78%) were diagnosed as having adenocarcinoma at sites of ASAP on the initial prostate needle biopsies.
  • CONCLUSIONS: Most ASAP on initial prostate needle biopsy was a true pathological entity, in other words, prostatic adenocarcinoma.
  • Aggressive approaches including more extended repeat biopsy with additional biopsy of the site of the ASAP are needed to diagnose PCa in patients with ASAP.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Urol. 2009 Oct;27(5):587-92 [19373471.001]
  • [Cites] J Urol. 2001 May;165(5):1409-14 [11342887.001]
  • [Cites] Eur Urol. 2008 Dec;54(6):1306-13 [18083294.001]
  • [Cites] BJU Int. 2007 Apr;99(4):780-5 [17378841.001]
  • [Cites] BJU Int. 2007 Jan;99(1):49-52 [17227491.001]
  • [Cites] Eur Urol. 2006 Oct;50(4):666-74 [16930809.001]
  • [Cites] Arch Pathol Lab Med. 2006 Jun;130(6):835-43 [16740037.001]
  • [Cites] Anal Quant Cytol Histol. 2006 Apr;28(2):104-10 [16637513.001]
  • [Cites] Eur Urol. 2006 Jan;49(1):49-53; discussion 53 [16314035.001]
  • [Cites] Am J Surg Pathol. 2005 Sep;29(9):1201-7 [16096410.001]
  • [Cites] Int J Urol. 2005 Apr;12(4):353-60 [15948721.001]
  • [Cites] Am J Clin Pathol. 2005 Feb;123(2):231-6 [15842047.001]
  • [Cites] Urology. 1999 Feb;53(2):351-5 [9933053.001]
  • [Cites] Urology. 1998 May;51(5):749-57; discussion 757-8 [9610588.001]
  • [Cites] Virchows Arch. 1997 Jan;430(1):1-16 [9037309.001]
  • [Cites] Hum Pathol. 1993 Aug;24(8):819-32 [8375853.001]
  • [Cites] J Urol. 1989 Jul;142(1):71-4; discussion 74-5 [2659827.001]
  • [Cites] J Urol. 2004 Sep;172(3):906-8; discussion 908-9 [15310995.001]
  • [Cites] Arch Pathol Lab Med. 2004 May;128(5):557-60 [15086303.001]
  • [Cites] Am J Surg Pathol. 2004 Feb;28(2):239-43 [15043314.001]
  • [Cites] J Urol. 2003 Aug;170(2 Pt 1):370-2 [12853777.001]
  • [Cites] Int J Urol. 2003 Feb;10(2):68-71 [12588600.001]
  • [Cites] Urology. 2002 Nov;60(5):851-4 [12429314.001]
  • [Cites] J Urol. 2001 Aug;166(2):402-10 [11458037.001]
  • [Cites] BJU Int. 2001 Jul;88(2):147-57 [11446873.001]
  • [Cites] Urol Oncol. 2009 Sep-Oct;27(5):509-13 [18625570.001]
  • (PMID = 20577606.001).
  • [ISSN] 2005-6745
  • [Journal-full-title] Korean journal of urology
  • [ISO-abbreviation] Korean J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2890056
  • [Keywords] NOTNLM ; Needle biopsy / Prostatectomy / Prostatic neoplasms / Surgical pathology
  •  go-up   go-down


90. Ray AD, Hammond J, Major H: Molecular ions and protonated molecules observed in the atmospheric solids analysis probe analysis of steroids. Eur J Mass Spectrom (Chichester); 2010;16(2):169-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular ions and protonated molecules observed in the atmospheric solids analysis probe analysis of steroids.
  • Atmospheric pressure chemical ionisation (APCI) has often been used to ionise steroids in mass spectrometry, usually when interfaced to high-performance liquid chromatography (HPLC).
  • The recently introduced technique of atmospheric solids analysis probe (ASAP) has the advantage that the sample can be analysed directly and does not need to be interfaced to HPLC.
  • Existing ionisation sources such as direct analysis in real time (DART) and desorption electrospray ionisation (DESI) have shown the advantage of direct analysis techniques in a variety of applications.
  • ASAP can be performed on commercial atmospheric pressure ionisation (API) mass spectrometers with only simple modifications to API sources.
  • A range of commercially available steroids were analysed by ASAP to investigate the mechanism of ionisation.
  • ASAP analysis of steroids generally results in the formation of the parent molecular ion as either the radical cation M+* or the protonated molecule MH+.
  • [MeSH-major] Atmospheric Pressure. Protons. Spectrometry, Mass, Electrospray Ionization / methods. Steroids / chemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20212333.001).
  • [ISSN] 1469-0667
  • [Journal-full-title] European journal of mass spectrometry (Chichester, England)
  • [ISO-abbreviation] Eur J Mass Spectrom (Chichester)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Protons; 0 / Steroids
  •  go-up   go-down


91. Bravo LC, Asian Strategic Alliance for Pneumococcal Disease Prevention (ASAP) Working Group: Overview of the disease burden of invasive pneumococcal disease in Asia. Vaccine; 2009 Dec 9;27(52):7282-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This paper represents a collaborative effort by the Asian Strategic Alliance for Pneumococcal Disease Prevention (ASAP) Working Group to collate data on the disease burden due to invasive pneumococcal disease (IPD) in participating Asian countries and territories; namely, Hong Kong, India, Indonesia, Korea, Macau, Malaysia, Pakistan, the Philippines, Singapore, Sri Lanka, Taiwan and Thailand.
  • A review of both published and unpublished data revealed that the incidence of IPD in some countries is well documented by way of large, long-duration studies, while in other countries, much of the available data have been extrapolated from international studies or have come from small population studies of limited geographical coverage.

  • MedlinePlus Health Information. consumer health - Pneumococcal Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19393708.001).
  • [ISSN] 1873-2518
  • [Journal-full-title] Vaccine
  • [ISO-abbreviation] Vaccine
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 68
  • [Investigator] Chan CW; Lee KK; Lui KM; Shah N; Kukreja S; Kartasasmita C; Hadinegoro SR; Lee HJ; Nordin Mb; Yusoff NK; Ismail Z; Memon IA; Maqbool S; Bhutta ZA; Ong-Lim AL; Maramba CC; Chong CY; Goh DY; Lamabadusuriya SP; Chiu CH; Lee PI; Lolekha S; Thisyakorn U
  •  go-up   go-down


92. Samaratunga H, Gardiner RA, Yaxley J, Brown I: Atypical prostatic glandular proliferations on needle biopsy: Diagnostic implications, use of immunohistochemistry, and clinical significance. Anal Quant Cytol Histol; 2006 Apr;28(2):104-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical prostatic glandular proliferations on needle biopsy: Diagnostic implications, use of immunohistochemistry, and clinical significance.
  • In recent times, PSA screening and a substantial increase in prostate needle biopsies have not only resulted in detection of minute foci of cancer but have also very likely resulted in increased detection of atypical glandular proliferations.
  • Not uncommonly, there are only a limited number of atypical glands in these biopsies, and these require careful evaluation to enable an accurate diagnosis.
  • Foci of atypical glands, also labeled atypical small acinar proliferation of uncertain significance, have features suspicious for but not diagnostic of cancer.
  • Atypical foci include a broad group of lesions of differing clinical significance.
  • These include benign, small acinar proliferations mimicking prostate cancer and atypical glandular proliferations suspicious for carcinoma.
  • Patients with atypical glands on prostate needle biopsy have a high risk for harboring cancer and therefore have an increased risk for having cancer detected in subsequent biopsies.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16637513.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 35
  •  go-up   go-down


93. Paradela S, Martínez-Gómez W, Fernández-Jorge B, Castiñeiras I, Yebra-Pimentel T, Llinares P, Fonseca Capdevila E: Toxic epidermal necrolysis-like acute cutaneous lupus erythematosus. Lupus; 2007;16(9):741-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The term "Acute Syndrome of Apoptotic Pan-Epidermolysis" (ASAP) designs clinical entities characterized by massive cleavage of the epidermis resulting from hyperacute epidermal basal cell apoptotic injury.
  • Although most cases of ASAP in the setting of LE are drug-induced TEN, there are reported cases of "TEN-like" LE with subacute progression, absence of systemic involvement and lack of drug ingestion.


94. Luo R, Miller Jenkins LM, Randazzo PA, Gruschus J: Dynamic interaction between Arf GAP and PH domains of ASAP1 in the regulation of GAP activity. Cell Signal; 2008 Nov;20(11):1968-77
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • ASAP family Arf GAPs induce the hydrolysis of GTP bound to the Ras superfamily protein Arf1, regulate cell adhesion and migration and have been implicated in carcinogenesis.
  • The ASAP proteins have a core catalytic domain of PH, Arf GAP and Ank repeat domains.
  • Here, using NMR spectroscopy and biochemical analysis, we have further tested this hypothesis and characterized the interdomain interaction.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2003 Jun 6;278(23):21099-104 [12657629.001]
  • [Cites] J Biol Chem. 2003 May 16;278(20):18393-400 [12637522.001]
  • [Cites] Dev Cell. 2003 Sep;5(3):513-21 [12967569.001]
  • [Cites] Cell Signal. 2004 Sep;16(9):1033-44 [15212764.001]
  • [Cites] EMBO J. 2004 Oct 13;23(20):3918-28 [15457207.001]
  • [Cites] Eur J Biochem. 1991 Dec 5;202(2):569-74 [1761056.001]
  • [Cites] J Biomol NMR. 1993 Mar;3(2):185-204 [8477186.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jan 31;92(3):816-20 [7846058.001]
  • [Cites] J Biomol NMR. 1995 Nov;6(3):277-93 [8520220.001]
  • [Cites] Science. 1995 Dec 22;270(5244):1999-2002 [8533093.001]
  • [Cites] Structure. 1995 Nov 15;3(11):1185-95 [8591029.001]
  • [Cites] Cell. 1996 May 31;85(5):621-4 [8646770.001]
  • [Cites] Mol Cell Biol. 1998 Dec;18(12):7038-51 [9819391.001]
  • [Cites] J Magn Reson. 1999 Oct;140(2):451-9 [10497050.001]
  • [Cites] J Biol Chem. 2005 Mar 11;280(10):8884-92 [15632162.001]
  • [Cites] EMBO J. 2005 Mar 9;24(5):963-73 [15719014.001]
  • [Cites] Clin Cancer Res. 2005 May 15;11(10):3609-13 [15897555.001]
  • [Cites] Cell Signal. 2005 Oct;17(10):1276-88 [16038802.001]
  • [Cites] J Cell Sci. 2005 Aug 1;118(Pt 15):3555-66 [16079295.001]
  • [Cites] Curr Biol. 2005 Dec 6;15(23):2164-9 [16332543.001]
  • [Cites] Methods Enzymol. 2005;404:147-63 [16413266.001]
  • [Cites] Methods Enzymol. 2005;404:164-74 [16413267.001]
  • [Cites] Curr Biol. 2006 Jan 24;16(2):130-9 [16431365.001]
  • [Cites] J Cell Sci. 2006 Apr 1;119(Pt 7):1203-11 [16554436.001]
  • [Cites] J Biomol NMR. 2006;36 Suppl 1:21 [16642402.001]
  • [Cites] Biochemistry. 2006 Dec 26;45(51):15301-9 [17176052.001]
  • [Cites] Biochem J. 2007 Mar 15;402(3):439-47 [17112341.001]
  • [Cites] J Biol Chem. 2007 Apr 13;282(15):11356-64 [17277311.001]
  • [Cites] EMBO J. 2007 Jul 25;26(14):3484-93 [17581628.001]
  • [Cites] Biol Cell. 2007 Oct;99(10):583-600 [17868031.001]
  • [Cites] Traffic. 2007 Nov;8(11):1465-75 [17666108.001]
  • [Cites] Traffic. 2007 Nov;8(11):1644-55 [17760859.001]
  • [Cites] Mol Cell Biol. 2007 Dec;27(23):8271-83 [17893324.001]
  • [Cites] J Biol Chem. 1994 Apr 8;269(14):10758-63 [8144664.001]
  • [Cites] EMBO J. 1999 Dec 15;18(24):6890-8 [10601011.001]
  • [Cites] J Biol Chem. 2000 Mar 31;275(13):9653-63 [10734117.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4011-6 [10725410.001]
  • [Cites] Methods Enzymol. 2001;329:343-54 [11210554.001]
  • [Cites] EMBO J. 2002 Mar 15;21(6):1315-26 [11889037.001]
  • [Cites] FEBS Lett. 2002 Feb 20;513(1):71-6 [11911883.001]
  • [Cites] Mol Biol Cell. 2002 Jun;13(6):2147-56 [12058076.001]
  • [Cites] Genome Res. 2002 Nov;12(11):1625-41 [12421749.001]
  • [Cites] J Struct Biol. 2003 Jan;141(1):63-76 [12576021.001]
  • [Cites] Traffic. 2003 Apr;4(4):201-13 [12694559.001]
  • [Cites] Curr Opin Cell Biol. 2003 Aug;15(4):396-404 [12892779.001]
  • (PMID = 18675341.001).
  • [ISSN] 0898-6568
  • [Journal-full-title] Cellular signalling
  • [ISO-abbreviation] Cell. Signal.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 BC007365-13; United States / Intramural NIH HHS / / Z99 CA999999
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / GTPase-Activating Proteins; 0 / Inositol Phosphates; 0 / Lipid Bilayers; 0 / Phosphatidylinositol 4,5-Diphosphate; 0 / Phospholipids; EC 3.6.5.2 / ADP-Ribosylation Factors
  • [Other-IDs] NLM/ NIHMS58368; NLM/ PMC2574850
  •  go-up   go-down


95. Lum PS, Mulroy S, Amdur RL, Requejo P, Prilutsky BI, Dromerick AW: Gains in upper extremity function after stroke via recovery or compensation: Potential differential effects on amount of real-world limb use. Top Stroke Rehabil; 2009 Jul-Aug;16(4):237-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Therefore, amount of arm use may depend critically on the location, extent, and type of functional gains, which can be quantified with comprehensive kinematic and EMG analysis of ADL performance.
  • A new treatment approach called Accelerated Skill Acquisition Program (ASAP) focuses on impairment reduction coupled with repetitive, task-specific training of the paretic arm during ADLs.
  • We present pilot data that show recovery in subjects who received the ASAP, while a usual care control subject showed increased use of compensation over the same period.
  • Finally, we discuss the advantages of data reduction methods such as principal components analysis, confirmatory factor analysis, and structural equation modeling, which can potentially distill large kinematic and EMG data sets into the key latent variables that predict amount of real-world use.

  • MedlinePlus Health Information. consumer health - Stroke.
  • MedlinePlus Health Information. consumer health - Stroke Rehabilitation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19740730.001).
  • [ISSN] 1074-9357
  • [Journal-full-title] Topics in stroke rehabilitation
  • [ISO-abbreviation] Top Stroke Rehabil
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


96. Singh KK, Erkelenz S, Rattay S, Dehof AK, Hildebrandt A, Schulze-Osthoff K, Schaal H, Schwerk C: Human SAP18 mediates assembly of a splicing regulatory multiprotein complex via its ubiquitin-like fold. RNA; 2010 Dec;16(12):2442-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RNPS1, Acinus, and SAP18 form the apoptosis- and splicing-associated protein (ASAP) complex, which is also part of the exon junction complex.
  • Here we have investigated splicing regulatory activities of the ASAP components.
  • Detailed mutational analysis and three-dimensional modeling data revealed that the ubiquitin-like fold of SAP18 was required for efficient splicing regulatory activity.

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] RNA. 2000 Sep;6(9):1197-211 [10999598.001]
  • [Cites] Mol Cell Biol. 2008 Apr;28(8):2549-58 [18250153.001]
  • [Cites] RNA. 2001 Mar;7(3):421-34 [11333022.001]
  • [Cites] Nature. 2002 Jul 11;418(6894):236-43 [12110900.001]
  • [Cites] Genome Res. 2002 Aug;12(8):1231-45 [12176931.001]
  • [Cites] Nature. 2002 Sep 12;419(6903):182-5 [12226669.001]
  • [Cites] Annu Rev Genet. 2002;36:333-60 [12429696.001]
  • [Cites] Mol Cell Biol. 2003 Apr;23(8):2981-90 [12665594.001]
  • [Cites] Mol Cell. 2003 Jul;12(1):5-14 [12887888.001]
  • [Cites] Nat Biotechnol. 2003 Aug;21(8):921-6 [12872131.001]
  • [Cites] Nat Rev Mol Cell Biol. 2003 Aug;4(8):605-12 [12923522.001]
  • [Cites] Annu Rev Biochem. 2003;72:291-336 [12626338.001]
  • [Cites] Mol Cell Biol. 2004 Feb;24(3):1174-87 [14729963.001]
  • [Cites] J Virol. 2004 Jun;78(12):6517-26 [15163745.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 8;101(23):8551-6 [15161980.001]
  • [Cites] Prog Nucleic Acid Res Mol Biol. 2004;78:37-88 [15210328.001]
  • [Cites] Mol Biol Cell. 2004 Aug;15(8):3876-90 [15169873.001]
  • [Cites] Mol Cell Biol. 1986 Sep;6(9):3173-9 [3023965.001]
  • [Cites] Biochemistry. 1987 Dec 15;26(25):8221-7 [3327519.001]
  • [Cites] EMBO J. 1993 Feb;12(2):595-600 [8440248.001]
  • [Cites] EMBO J. 1994 Dec 1;13(23):5679-88 [7988565.001]
  • [Cites] Genes Dev. 1996 Jul 1;10(13):1569-79 [8682289.001]
  • [Cites] Curr Protoc Bioinformatics. 2006 Oct;Chapter 5:Unit 5.6 [18428767.001]
  • [Cites] Nat Struct Mol Biol. 2008 May;15(5):444-51 [18425143.001]
  • [Cites] Genes Dev. 2010 Jun 1;24(11):1073-4 [20516191.001]
  • [Cites] J Virol. 1997 Apr;71(4):2757-64 [9060629.001]
  • [Cites] Cell. 1997 May 2;89(3):357-64 [9150135.001]
  • [Cites] Nucleic Acids Res. 1998 Mar 1;26(5):1345-51 [9469847.001]
  • [Cites] J Cell Sci. 1998 Jun;111 ( Pt 11):1495-506 [9580558.001]
  • [Cites] EMBO J. 1999 Aug 16;18(16):4560-70 [10449421.001]
  • [Cites] Nature. 1999 Sep 9;401(6749):168-73 [10490026.001]
  • [Cites] Curr Biol. 2004 Dec 29;14(24):2283-8 [15620657.001]
  • [Cites] Mol Cell Biol. 2005 Feb;25(4):1446-57 [15684395.001]
  • [Cites] Trends Biochem Sci. 2005 Mar;30(3):115-8 [15752982.001]
  • [Cites] J Biol Chem. 2005 Jun 17;280(24):22641-50 [15837790.001]
  • [Cites] Mol Cell. 2005 Jul 1;19(1):1-13 [15989960.001]
  • [Cites] EMBO J. 2005 Oct 19;24(20):3543-54 [16177823.001]
  • [Cites] RNA. 2005 Dec;11(12):1869-83 [16314458.001]
  • [Cites] J Mol Biol. 2006 Jan 27;355(4):821-44 [16310215.001]
  • [Cites] RNA. 2006 Feb;12(2):292-302 [16428608.001]
  • [Cites] Bioinformatics. 2006 Feb 1;22(3):365-6 [16332707.001]
  • [Cites] BMC Struct Biol. 2006;6:1 [16396680.001]
  • [Cites] J Comput Aided Mol Des. 2005 Nov;19(11):791-800 [16470421.001]
  • [Cites] J Biol Chem. 2006 May 5;281(18):12475-84 [16537548.001]
  • [Cites] Genes Dev. 2006 Jul 1;20(13):1755-65 [16766678.001]
  • [Cites] Biochemistry. 2006 Oct 3;45(39):11974-82 [17002296.001]
  • [Cites] Protein Sci. 2006 Nov;15(11):2507-24 [17075131.001]
  • [Cites] Biochim Biophys Acta. 2008 Feb;1780(2):214-25 [18022399.001]
  • [Cites] Nucleic Acids Res. 2008 Mar;36(5):1450-63 [18203748.001]
  • [Cites] Bioinformatics. 2000 Sep;16(9):815-24 [11108704.001]
  • (PMID = 20966198.001).
  • [ISSN] 1469-9001
  • [Journal-full-title] RNA (New York, N.Y.)
  • [ISO-abbreviation] RNA
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Multiprotein Complexes; 0 / RNPS1 protein, human; 0 / Ribonucleoproteins; 0 / SAP18 protein, human; 0 / Ubiquitin
  • [Other-IDs] NLM/ PMC2995405
  •  go-up   go-down


97. Pascual Mateo C, Luján Galán M, Rodríguez García N, Llanes González L, Berenguer Sánchez A: [Clinical significance of prostatic intraepithelial neoplasm and atypical small acinar proliferation: relationship with prostate cancer]. Actas Urol Esp; 2008 Jul-Aug;32(7):680-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical significance of prostatic intraepithelial neoplasm and atypical small acinar proliferation: relationship with prostate cancer].
  • [Transliterated title] Significado clínico de la neoplasia intraepitelial prostática y de la proliferación acinar focal atípica: relación con el cáncer de próstata.
  • INTRODUCTION: Prostatic intraepithelial neoplasia (PIN) and atypical small acinar proliferation (ASAP) in the setting of prostatic needle biopsies are considered premalignant although questions still remain.
  • MATERIAL AND METHODS: We collected 138 subjects (108 PIN, 30 ASAP); in 67% we performed a second biopsy and the rate of cancer in this late biopsy were 19% and 27% respectively.
  • We cannot identify any clinical factor to predict the finding of cancer in the re-biopsy (PSA, age, digital rectal examination, prostatic volume).
  • RESULTS: In the follow-up, we observed higher rates of cancer for the ASAP; the finding of ASAP was the single clinical or histopathological factor that was an independent predictor of cancer.
  • CONCLUSIONS: We observed that the finding of ASAP was an indication for re-biopsy because of the higher rates of cancer; on the contrary, the paper of PIN in the prostatic needle biopsy still requires further investigation.
  • [MeSH-major] Prostatic Intraepithelial Neoplasia / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Biopsy. Cell Proliferation. Humans. Male. Middle Aged. Retrospective Studies


98. Pereira TC, Clayton AC, Tazelaar HD, Liu Y, Leon M, Silverman JF: Critical values in cytology. Diagn Cytopathol; 2006 Jun;34(6):447-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • (1) no phone call necessary, (2) phone call within 24 hr, (3) phone call as soon as possible (ASAP).
  • Most respondents agreed on the need for a phone call ASAP in many situations, and important additional CV cases were suggested.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16680772.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


99. Flannery RB Jr, Walker AP, Flannery GJ: Elderly patient assaults: empirical data from the Assaulted Staff Action Program (ASAP) with risk management implications for EMS personnel. Int J Emerg Ment Health; 2006;8(4):221-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elderly patient assaults: empirical data from the Assaulted Staff Action Program (ASAP) with risk management implications for EMS personnel.
  • Data on the assault characteristics of elderly patients are presented from a 15-year, retrospective, longitudinal study of the Assaulted Staff Action Program (ASAP).